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Abstract 
During sepsis and critical illness, a systemic inflammatory response can 
significantly produce reactive oxygen and nitrogen species, which can damage host 
tissues. Usually, several different antioxidant defences protect host cells from these 
reactive  species.  One  of  the  important  antioxidant  defences  is  glutathione,  a 
tripeptide  synthesised  from  the  precursor  amino  acids  cysteine,  glutamate  and 
glycine. The aim of this study was to measure glutathione synthesis in vivo, using 
deuterated glycine as a tracer.  
Firstly, a new method for analysis of glutathione and glycine using both 
gas chromatography-mass spectrometry (GC-MS) and gas chromatography-isotope 
ratio  mass  spectrometry  (GC-IRMS)  was  developed.  The  derivatives  of  both 
compounds were measured in a single chromatographic analysis, and the method 
was compatible with both GC-MS and GC-IRMS, and capable of measuring low 
carbon-13 or deuterium enrichment of glutathione in 50μl of erythrocytes. 
Erythrocyte  glutathione  synthesis  was  measured,  using  GC-IRMS,  in 
critically ill infants and children who had been infused with deuterated glycine. 
Glutathione fractional synthesis rate (FSR) was not statistically different between 
septic and non-septic patients.  
In order to determine whether glutamine is able to increase GSH synthesis 
by acting as a glutamate precursor, erythrocyte GSH synthesis was measured using 
GC-IRMS in septic infants and children randomised to receive glutamine dipeptide 
or placebo. There was no significant difference in glutathione FSR between those 
given glutamine and those given placebo.   ii 
Intestinal  glutathione  depletion  is  known  to  occur  following  intestinal 
ischaemia-reperfusion injury. I measured glutathione synthesis in a rat model of 
intestinal  ischaemia-reperfusion  injury,  and  found  that  hypothermic  rats  with 
ischaemia-reperfusion  injury  had  a  higher  intestinal  glutathione  synthesis  than 
normothermic rats, providing a potential mechanism by which hypothermia may 
maintain intestinal glutathione levels. 
In conclusion, the newly developed method of glutathione analysis using 
GC-IRMS was useful for compound specific isotope analysis of biological samples.    iii 
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Abbreviation 
2D-SDS-
PAGE  Two-dimensional SDS-polyacrylamide gel electrophoresis  
ABTS  2,2'-Azinobis(3-ethylbenzothiazoline 6-sulphonate) 
Ala  Alanine 
APE  Atom percent excess 
ASR  Absolute synthesis rate 
BF3  Boron trifluoride 
CoQH2  Ubiquinol 
CSIA  Compound specific isotope analysis 
Cys  Cysteine 
DAD  Diode array detector 
DTNB  5,5'-dithiobis-(2-mitrobenzoic)-acid 
DTT  Dithiothreitol 
ECD  Electrochemical detection 
ECF  Ethyl chloroformate 
EDTA  Ethlendiaminetetraacetic acid 
EGTA  Ethyleneglycol-bis-β-aminoethylether)-N,N,N',N'-tetraacetic 
acid 
FSR  Fractional synthesis rate 
GC-C-IRMS  GC-Combustion-IRMS 
GC-MS  Gas chromatography mass spectrometry 
GC-TC-IRMS  GC-Temperature Conversion-IRMS 
Gln  Glutamine 
Glu  Glutamic acid 
Gly  Glycine   v 
GPX  Glutathione peroxidases 
GSH  Glutathione 
GSSG  Oxidised glutathione 
HCl  Hydrochloric acid 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFBTA  Heptafluorobutyric anhydride 
HPLC  High-performance liquid chromatography 
I/R  Ischaemia and Reperfusion 
IAA  Iodoacetic acid 
IL-1,-6  Interleukin-1,-6 
IRMS  Isotope ratio mass spectrometry 
KH2PO4   Potassium dihydric orthophosphate 
LC-ELSD  LC-evaporative light scattering detection 
LC-MS  Liquid chromatography-mass spectrometry 
LDL  Low-density lipoprotein 
MALDI  Matrix Assisted Laser Desorption/Ionization 
MBB  Monobromobimane 
MCF  Methyl chloroformate 
MDA  Malonaldehyde 
MeOH  Methanol 
MODS  Multiple organ dysfunction syndrome 
MOF  Multiple organ failure 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NaOH  Sodium hydroxide   vi 
NEM  N-ethylmaleimide 
NICU/PICU  Neonatal / Paediatric Intensive Care Unit 
NO  Nitric oxide 
n-PCF  n-Propyl chloroformate 
NPP  n-pivaloyl & o-isopropylate 
OPA  ortho-phthal aldehyde 
PCA  Perchloric acid 
PTV inlet  Programmed temperature vaporization inlet 
RBC  Red blood cells/erythrocytes 
RNS  Reactive nitrogen species 
ROS  Reactive oxygen species 
SBD-F  Ammonium-7-fluoro-2,1,3-benzoxadiazole-4-sulfonate 
SIM  Selected ion monitoring mode 
SIRS  Systemic inflammatory response syndrome 
SMA  Superior mesenteric artery 
SOD  Superoxide dismutase 
SSA  Sulfosalicylic acid 
TBA  Thiobarbituric acid 
TBAH  Tetrabutylammonium hydroxide 
t-BDMS  tert-Butyl-dimethylsilyl 
TBP  Tributylphosphine 
TCEP  Tris-(2-carboxylethyl)-phosphine 
TFA  Trifluoroacetic acid 
TMS  Trimethylsilyl   vii 
TNF-ʱ  Necrosis factor-alpha 
TPN  Total parenteral nutrition 
VPDB  Vienna Peedee Belemnite 
VSMOW  Vienna Standard Mean Ocean Water 
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Chapter  1 
 
Introduction  2 
Chapter 1:  Introduction 
  
1.1    Systemic inflammatory response syndrome and sepsis 
 
Systemic  inflammatory  response  syndrome  (SIRS)  is  a  leading  cause  of 
morbidity and mortality during critical illness or following severe injury (Ali et al. 
1998).  SIRS  due  to  detectable  infection  is  then  termed  sepsis.  Sepsis  is  the 
deleterious  systemic  response  to  infection  (Bone  et  al.  1992).  One  potential 
consequence  of  infection  and/or  the  deleterious  systemic  response  to  infection  is 
organ dysfunction. Failure of more than one organ is called multiple organ failure 
(MOF) or multiple organ dysfunction syndrome (MODS). MOF or MODS following 
SIRS remains the leading cause of death among critically ill patients in medical and 
surgical intensive care units (Nystrom 1998).  
   Sepsis is  the most common  cause of MODS  in  the paediatric population. 
Despite  recent  advances  in  the  care  of  critically  ill  children,  sepsis  and  MODS 
remain a major source of morbidity and mortality in paediatric patients (Upperman & 
Ford 2002). The mortality rate for paediatric patients with two or more dysfunctional 
organs remains much higher than for children without MODS (Upperman & Ford 
2002).  Most  infections  result  from  the  failure  of  the  host’s  intrinsic  defence 
mechanisms  to  combat  virulent  factors  from  invading  micro-organisms.  Children 
with impaired immune systems are particularly affected by infection. Some authors 
suggest that the pattern of organ failure in paediatric patients may differ from adult 
patients  due  to  developmental  differences  (Upperman  &  Ford  2002).  Infections   3 
represent a common inciting mechanism for the development of MODS, because 
uncontrolled  infection  can  lead  to  systemic  sepsis  and  may  ultimately  result  in 
MODS. Although sepsis is  the  most common cause of MODS,  in  many  cases  a 
specific  micro-organism  or  bacterial  by-product  responsible  for  initiating  the 
systemic inflammatory response that leads to MODS may not be detected. This is 
because the identification of the micro-organism responsible for an infection still 
relies, for the most part, on classic microbiological selective media methods, which is 
not  particularly  sensitive.  More  recently,  more  sensitive  molecular  biology 
techniques, such as detection of 16s rRNA, have been developed which are more 
effective at detecting infective agents (Qiao et al. 2009). Nevertheless, many cases of 
SIRS may in fact be due to an infection which has not been identified, and treatment 
of SIRS is by empirical antibiotics until a causative micro-organism is directed to 
enable targeted therapy to be initiated. 
In  humans,  SIRS  consists  of  a  cascade  of  events  characterised  by  an 
elevated  temperature,  cardiovascular  collapse  or  shock  and  decreased  organ 
perfusion  with  associated  dysfunction  (Bone  et  al.  1992).  Hence,  septic  patients 
usually present with fever, tachycardia and leukocytosis. 
 
1.1.1  Intestinal  ischaemia-reperfusion  injury  and  the  role  of 
hypothermic protection 
 
MODS  and  sepsis  can  be  both  a  cause  and  a  consequence  of  intestinal 
ischaemia  and  reperfusion  (I/R)  injury  (Fink  1993;Schoenberg  &  Beger  1993). 
Intestinal  I/R  injury  represents  a  major  clinical  problem  in  infants,  children  and   4 
adults.  Diseases  associated  with  this  condition  include  necrotizing  enterocolitis, 
midgut  volvulus,  acute  mesenteric  arterial  occlusion  and  haemodynamic  shock 
(Schoenberg  &  Beger  1993).  Intestinal  I/R  can  also  occur  as  a  consequence  of 
surgical  procedures  such  as  cardiopulmonary  bypass,  aortic  aneurysm  repair  and 
intestinal  transplantation  (Schoenberg  &  Beger  1993).  Reperfusion  of  ischaemic 
tissues  can  activate  endothelial  cells  to  produce  superoxide  and  consequently 
inflammatory  mediators  are  released.  The  actions  of  these  deleterious  reactive 
species  can  be  prevented  by  antioxidants,  either  given  exogenously,  or  with 
endogenous  antioxidants  such  as  glutathione  (GSH).  The  intensity  of  the 
inflammatory  reaction  in  postischaemic  tissues  can  be  also  great  that  the  injury 
response  to  reperfusion  is  also  manifested  in  distant  organs  (Neary  &  Redmond 
1999).  Thus,  intestinal  ischaemia-reperfusion  injury  can  lead  to  multiple  organ 
failure  (Neary  &  Redmond  1999).  Experimental  intestinal  ischaemia  reperfusion 
injury has been shown to lead to damage to the liver (Vejchapipat et al. 2001), lungs 
(Iglesias et al. 1998), heart (Stefanutti et al. 2004) and kidneys (LaNoue, Jr. et al. 
1996) and can thus be considered a useful model of SIRS and MODS.  
  Some studies suggested that hypothermia may protect the gut in intestinal I/R 
injury by induction of heme oxygenase-1 above the levels observed at normothermia 
(Attuwaybi et al. 2003) and prevents an increase in nuclear factor Kappa-B (NF-
kappaB) and inducible nitric oxide synthase (iNOS) expression (Hassoun et al. 2002). 
Hypothermia  has  been  shown  to  prevent  liver  bioenergetic  failure  and  mortality 
during experimental intestinal I/R injury (Vejchapipat et al. 2001). The protective 
effect  of hypothermia is associated not  only  with  a reduction in  intestinal  injury 
(Attuwaybi et al. 2003;Vejchapipat et al. 2002), but also with prevention of hepatic   5 
bioenergetic failure (Vejchapipat et al. 2001), preservation of myocardial metabolism 
(Stefanutti et al. 2004), reduced lung neutrophil infiltration (Vinardi et al. 2003), and 
decreased  oxidative  stress  in  plasma,  lungs  and  kidneys  (Stefanutti  et  al.  2005). 
Interestingly, in a study of the effects of moderate hypothermia on oxidative stress 
following intestinal ischaemia-reperfusion injury, it has been shown that GSH levels 
were  maintained  by  moderate  hypothermia,  and  were  even  higher  than  control 
normothermic animals in control hypothermic animals (Stefanutti et al. 2005). Hence, 
during hypothermic intestinal  ischaemia-reperfusion, GSH synthesis may  even be 
increased above the rate observed under normal conditions, whereas decreased rates 
of glutathione synthesis during normothermic intestinal ischaemia-reperfusion may 
explain the depletion of GSH in liver (Turnage et al. 1991) and intestine (Bhaskar et 
al. 1995;Gibson et al. 1993) following intestinal I/R.    6 
1.2  Inflammation, infection and free radical production  
 
Inflammation  is  controlled  by  white  blood  cells,  macrophages  and 
endothelial  cells,  and  by  the  cytokines  they  produce.  Infections  may  activate 
macrophages,  which  causes  enhanced  production  of  pro-inflammatory  cytokines, 
including interleukin-1 (IL-1), IL-6 and tumour necrosis factor-alpha (TNF-ʱ). These 
cytokines induce the production of secondary mediators like nitric oxide, arachidonic 
acid metabolites, bradykinin, and histamine. Then, in turn, these may further activate 
macrophages, leukocytes and endothelial cells to perpetuate the process (Despond et 
al. 2001). During sepsis, oxygen radicals and nitric oxide (NO) are released at the 
same  time  (Goode  et  al.  1995);(Tanjoh  et  al.  1995).  Release  of  both  factors  by 
macrophages may be a normal response to bacterial infection, but the regulation of 
release  of  oxygen  radicals  and  NO  varies  and  interacts  among  these  substances 
(Groeneveld  &  Sipkema  2000).  Another  potential  source  of  reactive  oxygen  and 
nitrogen species is activated neutrophils. These cells kill pathogens by producing a 
variety of cytotoxic chemicals, including hydrogen peroxide and the hypochlorite ion. 
NADPH oxidase of neutrophils and macrophages is an enzyme whose main function 
is generation of superoxide for bacterial killing. It catalyses the reaction: 
    NADPH + 2O2    NADP
+ + H
+
 + 2O2
●- 
However, excessive superoxide produced in this cascade is harmful to host 
tissues  and  affects  cell  structures  which  may  trigger  organ  dysfunction.  Another 
important source of oxygen free radicals in the cell is mitochondria. The organelle 
consumes more than 90% of the inhaled oxygen. Normally only about 1 ~ 2% of 
total  oxygen  reduced  in  mitochondria  is  converted  to  superoxide  (Thomas  &   7 
Balasubramanian 2004). Mitochondrial function is affected after sepsis (Taylor et al. 
1998). Once mitochondrial dysfunction occurs, the amount of superoxide generation 
can  increase  considerably  making  this  organelle  an  important  cellular  source  of 
reactive oxygen species (ROS) (Thomas & Balasubramanian 2004). Reactive oxygen 
and nitrogen species can also react together and produce further recative species. An 
example of this is peroxynitrite, OONO
●-, which is produced by the reaction of nitric 
oxide  with  superoxide  (Beckman  &  Koppenol  1996).  Peroxynitrite  is  extremely 
recative and can damage many proteins by nitration (MacMillan-Crow et al. 1998). 
Its production is greatly increased during sepsis, and this results in an increase in 
protein nitration (Fukumoto et al. 2004;Marcondes et al. 2001). 
In general, oxidative stress, such as production of ROS and reactive nitrogen 
species (RNS), can cause damage to proteins, membrane lipids, carbohydrates and 
DNA. These, in turn, can trigger further chemical, biochemical, cell signalling and 
immunological reactions which ultimately result in organ failure. In order to protect 
against  these  effects  and  to  prevent  oragn  damage,  antioxidant  defences  are 
extremely important. 
   8 
1.3  Antioxidant defences 
    
Antioxidant  defences  can  often  be  induced  by  exposure  of  organisms  to 
ROS/RNS and to cellular signal molecules such as cytokines. Antioxidant defences 
can be  enzymatic, where an enzyme has a specific function in reacting with reactive 
oxygen or nitrogen species (Mates et al. 1999). Examples of antioxidant enzymes are 
superoxide  dismutase,  catalase  and  glutathione  peroxidase  (Mates  et  al.  1999). 
Alternatively, antioxidants can be chemical anti-oxidants, where a chemical interacts 
directly with reactive oxygen or nitrogen species (Eaton 2006). These chemicals may 
require  the  action  of  enzymes  to  reconvert  them  to  active  forms.  In  addition  to 
chemicals whose main function is to provide an antioxidant defence, such as vitamin 
E and vitamin C, many other chemicals within the body can act as antioxidants even 
though they have another main function (Roche et al. 2008;Sedlak et al. 2009). I will 
provide a brief overview of the  main antioxidant  defence systems,  and will then 
consider the glutathione system in greater detail, as it is the main focus of this thesis. 
 
1.3.1  Superoxide dismutase 
One  of  the  most  important  antioxidant  defence  enzymes  is  superoxide 
dismutase (SOD), which exists in both cytosol and mitochondria. SOD (CuZn-SOD, 
Mn-SOD and Fe-SOD) was discovered at the same time as the discovery of toxicity 
of ROS/RNS (Fridovich 1995). The metal atoms form the active site of the enzyme, 
and so an adequate supply of copper, zinc and manganese is necessary for adequate 
mammalian  anti-oxidant  defences  (Fe-SOD  is  found  only  in  plants  and  bacteria 
(Fridovich  1995)).  Mn-SOD  is  found  exclusively  within  mitochondria  (so  is  not   9 
found in erythrocytes) whereas CuZn-SOD is found in the cytosol, lysosomes, the 
nucleus and in the mitochondrial intermembrane space (Fridovich 1995). Another 
isoform  of  CuZn-SOD  is  found  extracellularly.  Mutations  in  the  human  gene 
encoding  the  cytosolic  CuZn-SOD  cause  amyotrophic  lateral  sclerosis  (a 
neurodegenerative disease). The biological role of SOD is to scavenge superoxide, 
with the catalytic activity: 
O2
●- + O2
●- + 2H
+     H2O2 + O2 
It  is  important  to  note  that  this  reaction  therefore  scavenges  2  mol 
superoxide, but in turn produces 1 mol hydrogen peroxide, which is itself reactive 
and can damage enzymes and membranes (Halliwell & Gutteridge 2004d). 
 
1.3.2  Catalases   
Two  different  classes  of  enzymes  have  specific  roles  in  detoxifying 
hydrogen  peroxide;  catalase  and  peroxidases.  Hydrogen  peroxide  is  not  only 
produced by the activity of superoxide dismutases, but can also be produced by the 
action of several oxidases, including urate oxidase, D-amino acid oxidases and acyl-
CoA oxidase. These oxidases are mostly found within the peroxisome, which is the 
main subcellular location for catalase. Importantly, mitochondria contain little or no 
catalase, so that hydrogen peroxide generated by the mitochondria Mn-SOD must be 
disposed  of  via  another  mechanism  (Kirkman  &  Gaetani  2007).  The  reaction  of 
catalase is as follows: 
    2H2O2      2H2O + O2   10 
Mutations  in  the  human  gene  encoding  catalase  cause  the  disease 
acatalasaemia, which is a relatively benign disorder leading to mouth ulcers (Goth, 
Rass, & Pay 2004). 
 
1.3.3  Glutathione peroxidase 
As  mitochondria  completely  lack  catalase,  hydrogen  peroxide  must  be 
detoxified  via  another  route.  The  enzyme  glutathione  peroxidase  catalayses  the 
reaction  of  reduced  glutathione  (GSH)  with  hydrogen  peroxide  to  form  oxidised 
glutathione: 
    2GSH + H2O2      GSSG + H2O 
However,  glutathione  peroxidase  (Gpx)  is  also  active  towards  lipid  peroxides, 
catalysing the general reaction to the corresponding alcohol: 
    2GSH + LOOH        GSSG + LOH. 
In mammalian tissues, there are four major GPx isozymes: (a) GPx1, which 
is found in erythrocytes, liver, lung and kidney; (b) gastrointestinal GPx (GPx2); (c) 
plasma  GPx  (GPx3),  also  found  in  kidney,  lung,  heart  and  muscle,  and  (d) 
phospholipid  GPx  (GPx4),  which  is  also  broadly  distributed  in  different  tissues. 
GPx1 is found in the cytosol, nucleus and mitochondria; GPx2 in the cytosol and 
nucleus; GPx3 is a secreted protein also found in the cytosol and GPx4 is present in 
the nucleus, cytosol, mitochondria and bound to membranes (Margis et al. 2008). 
These GPx isoforms all contain selenocysteine at the active site, and so an adequate 
dietary selenium supply is essential for adequate GPx activity. As the British diet is 
lower in selenium than it was, glutathione peroxidase activity is submaximal in many   11 
individuals (Rayman 2008). Glutathione, the essential co-substrate for GPx activity, 
will be considered in more detail in section 1.4 below. 
 
1.3.4  Chemical anti-oxidants 
In  addition  to  enzymatic  methods  for  detoxifying  reactive  oxygen  and 
nitrogen species, direct chemical antioxidants are also important within the body. A 
huge range of compounds, many of which are dietary constituents or can be taken as 
dietary supplements, has been suggested to have anti-oxidant activity (Halliwell & 
Gutteridge 2004a). However, whether many of these compounds have relevant in 
vivo  antioxidant activity is  uncertain.  I will not aim to  provide  a comprehensive 
review of chemical anti-oxidants, but instead will briefly consider systems of known 
biological importance. 
 
1.3.4.1  Vitamin E 
Vitamin E, a fat soluble vitamin, is essential in the diets of animals (Clarke 
et al. 2008).  It consists of several related tocopherols and tocotrienols, the most 
common of which is dl-ʱ-tocopherol (Clarke et al. 2008). Its role is the protection of 
biological  membranes,  which  it  does  by  interruption  of  the  chain  of  lipid 
peroxidation (Traber & Atkinson 2007). After small molecule reactive oxygen and 
nitrogen species attack lipids in membranes, they produce lipid peroxides, which 
react with other unsaturated lipid in membranes to produce further lipid peroxides, 
thus  amplifying  damage  (Traber  &  Atkinson  2007).  These  peroxides  can  be 
scavenged  by  glutathione  peroxidase  (see  above),  or  by  tocopherols,  which  are 
within the lipid membranes themselves. Vitamin E has a hydrophobic chain, which   12 
allows  it  to  insert  into  biological  membranes,  and  a  hydrophilic  chromanol  ring 
which is  responsible for reacting with  lipid  peroxides  (Traber & Atkinson  2007) 
(Figure 1.1). Vitamin E cannot be synthesised by animals, but is present in many 
dietary sources and so human deficiency is rare.   
 
 
1.3.4.2  Vitamin C   
Vitamin C (Ascorbic acid), the other major chemical antioxidant within the 
body, can be synthesised from glucose in plants and most animals but not in humans 
in  whom the enzyme of the terminal  step, gulonolactone oxidase, is  not  present. 
Therefore, humans require vitamin C to be present in the diet, and scurvy is a well 
known disease in humans with lack of vitamin C. Vitamin C is one of the water-
soluble  vitamins,  and  so  is  present  in  both  extracellular  and  intracellular  fluids, 
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whereas  vitamin  E  is  in  membranes.  Ascorbate,  upon  scavenging  radicals,  is 
converted to the ascorbyl radical and then to dehydroascorbate (Figure 1.1). Ascorbic 
acid will tend to reduce more-reactive species such as hydroxyl radicals, oxygen 
free-radicals and urate radicals and is able to scavenge a wide variety of both recative 
oxygen and recative nitrogen species. In addition to its activity as an anti-oxidant, 
ascorbate is also an essential co-factor for some enzymes, such as some hydroxylases. 
As ascorbate and the glutathione systems have overlapping functions, glutathione can 
replace some of the roles of ascorbate  in vivo and vice versa (Meister 1994). In 
addition,  glutathione  appears  to  be  also  able  to  influence  the  recycling  of 
dehydroascorbate to ascorbate (Meister 1994), although whether reduced glutathione 
is  a  substrate  of  a  specific  enzyme  whose  sole  function  is  to  recycle 
dehydroascorbate  to  ascorbate  is  unclear  (Linster  &  Van  Schaftingen  2007). 
Nevertheless,  young rats given inhibitors of glutathione synthesis show markedly 
decreased levels of ascorbate and increased levels of dehydroascorbate, as well as the 
expected glutathione deficiency (Martensson & Meister 1991). 
 
1.3.4.3  Other chemical anti-oxidants 
In addition to these two well-defined anti-oxidant chemicals, several other 
biological compounds have anti-oxidant activity and may be relevant in vivo. Some 
of these other antioxidant compounds, such as bilirubin and hormones are shown in 
Figure 1.2. 
Bilirubin  is  an  end-product  of  haem  degradation  in  mammals.  In  vitro, 
bilirubin is a powerful scavenger of peroxy radicals and singlet oxygen. Bilirubin 
bound to albumin can protect both albumin itself, and albumin-bound fatty acids   14 
against  free-radical  damage,  although  the  mechanism  for  the  apparent  protective 
effects of elevated bilirubin levels are unknown (Sedlak & Snyder 2004).  
The female sex hormones oestrandiol, oestrone and oestriol can inhibit lipid 
peroxidation  (including  low-density  lipoprotein  (LDL)  peroxidation)  in  vitro  at 
micromolar concentration (Keaney, Jr. et al. 1994). They can act as chain-breaking 
antioxidants  in  a  way  similar  to  that  of  vitamin  E  (Keaney,  Jr.,  Shwaery,  Xu, 
Nicolosi, Loscalzo, Foxall, & Vita 1994), but the levels if these hormones in vivo 
may be too low to exert significant anti-oxidant activity  (Halliwell & Gutteridge 
2004e). 
The hormone melatonin is mainly produced by the pineal gland at the base 
of the brain to help regulate circadian rhythms. Melatonin shows antioxidant activity 
in vitro (probably by donation of hydrogen by the NH group), and may show anti-
oxidant effects through upregulation of synthesis of antioxidant defence enzymes 
rather than via any direct anti-oxidant effect in vivo (Anisimov et al. 2006). 
  Lipoic  acid,  thioctic  acid  (1,2-dithiolane-3-pentanoic  acid)  is  an  essential 
cofactor  as  its  amide  form  (lipoamide)  in  the  multi-enzyme  complexes.  The 
complexes  catalyse  the  decarboxylation  of  ʱ-keto  acid  such  as  pyruvate  and  ʱ-
ketoglutarate in the citric acid cycle. Both the oxidised and reduced forms of lipoic 
acid show antioxidant properties in vitro (Packer, Witt, & Tritschler 1995) and some 
authors have also suggested an in vivo anti-oxidant role in combination with acetyl-
carnitine (Hagen et al. 2002). 
Coenzyme  Q  (ubiquinone)  plays  an  essential  role  in  the  mitochondrial 
electron-transport chain, undergoing simultaneous oxidation and reduction via a free-
radical  intermediate,  ubisemiquinone.  In  vivo,  ubiquinol  (CoQH2)  can  scavenge   15 
organic radicals and thereby inhibit lipid peroxidation. Like vitamin E, coenzyme Q 
is found within biological membranes, and thus protects lipids and   low-density 
lipoprotein (LDL) from lipid peroxidation  (Bentinger et al. 2007). Ubiquinol can 
regenerate ʱ-tocopherol (vitamin E) from its radical in lipoproteins and membranes, 
so  coenzyme  Q  may  be  synergistic  with  vitamin  E  in  vivo  (Quinn  et  al. 
1999;Stoyanovsky et al. 1995).   16 
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1.4   Glutathione  
 
Glutathione  (L-γ-glutamyl-L-cysteinylglycine,  GSH),  a  tripeptide,  is 
synthesized  de  novo  within  many  cells  from  the  precursor  amino  acids  cysteine, 
glutamate and glycine, and is a major low molecular weight thiol in mammalian cells 
(Figure 1.3).  
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   The  intracellular  level  of  GSH  in  mammalian  cells  is  in  the  millimolar 
range (0.5 – 10 mM), whereas micromolar concentrations are typically found in 
blood plasma (Meister & Anderson 1983). A small proportion of the total cellular 
GSH pool (10–15%) is found in mitochondria, where it reaches a concentration 
similar to that found in the cytosol (Griffith & Meister 1985). GSH plays a major 
role  in  cellular  defenses  against  oxidative  stress.  It  takes  part  in  the  reductive 
detoxification  of  hydrogen  peroxide,  although  hydrogen  peroxide  can  also  be 
reduced  by  catalase,  which  is  present  only  in  the  peroxisome.  GSH  in  the 
mitchondria  is  particularly  important  because  there  is  no  catalase  (Fernandez-
Checa et al. 1997). The biosynthesis of GSH (Figure 1.4) is also associated with 
transport of extracellular amino acids intracellularly (Meister & Anderson 1983). 
The glutamyl group of GSH is readily transferred by γ-glutamyl transpeptidase to 
form the γ-glutamyl derivatives of free amino acid in the first reaction of the γ-
glutamyl cycle. Since γ-glutamyl transpeptidase is usually membrane bound, it has 
been suggested that this reaction might serve to capture amino acids from one side 
of the membrane (Beutler 1989;Meister 1973).  Synthesis of GSH requires two 
steps: firstly the formation of -glutamyl-cysteine from L-glutamate and L-cysteine, 
catalysed by -glutamyl-cysteine ligase, an ATP-requiring enzyme; and secondly 
the formation of GSH from -glutamyl-cysteine plus L-glycine, catalysed by GSH 
synthetase, also requiring ATP. The first of these enzymes is inhibited by GSH and 
is thought to be responsible for much of the control of GSH synthesis (Lu 1998). 
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1.4.1 Glutamine as a GSH Precursor 
 
Although  glutamate  is  the  immediate  precursor  for  GSH  synthesis, 
glutamine has a role, particularly important in critical illness, as a GSH precursor. 
For  most  cell  types,  extracellular  glutamine  is  a  better  source  of  intracellular 
glutamate than extracellular glutamate, so that synthesis of GSH is supported by 
extracellular glutamine during increased oxidative stress such as that which occurs 
during  critical  illness  (Babu  et  al.  2001).  Glutamine  is  a  better  precursor  than 
glutamate  for  GSH  synthesis  because:  (i)  the  extracellular  concentration  of 
glutamine  is  much  higher  than  that  of  glutamate;  (ii)  some  cells,  such  as 
erythrocytes, do not have a specific glutamate transporter and so glutamate uptake 
is extremely low (Ellory et al. 1983), so that extracellular glutamine, taken up by 
the Na
+-dependent system N, is a better source of intracellular glutamate. Various 
groups have shown depletion of muscle GSH during critical illness and/or surgical 
trauma (Brealey et al. 2002;Hammarqvist et al. 1997;Luo et al. 1996), and this 
depletion  can  be  counteracted  by  provision  of  glutamine  (Flaring  et  al.  2003). 
Hepatic GSH can also be replenished by provision of glutamine after depletion in 
experimental  animals  (Hong  et  al.  1992),  and  plasma  GSH  depletion  can  be 
prevented by glutamine, both experimentally  (Denno et al. 1996) and clinically 
(Luo et al. 2008), but the metabolic and clinical significance of plasma GSH is 
uncertain. 
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1.4.2.  Antioxidant function of GSH 
 
As described in section 1.3.3 above, the major anti-oxidant role of GSH is 
as a substrate of GSH peroxidases to enable detoxification of hydrogen peroxide 
and lipid hydroperoxides. In this reaction (Figure 1.5), GSH is oxidised to GSH 
disulfide (GSSG). GSSG is then reduced intracellularly to GSH by GSH reductase 
at the expense of NADPH (Beutler 1989;Meister & Anderson 1983). The GSH 
reduction/oxidation  (redox)  state  reflects  the  balance  between  the  levels  of 
oxidation and reduction in the GSH buffer system. At normal levels of oxidative 
stress, intracellular GSSG levels are extremely low, and GSH makes up over 99% 
of  total  GSH  levels  (Akerboom  et  al.  1982;Griffith  1999;Meister  &  Anderson 
1983). However, GSSG can be lost from cells rapidly, leading to a decrease in 
cellular  total  GSH  during  oxidative  stress,  when  GSSG  levels  are  increased 
(Rahman et al. 1995;Srivastava & Beutler 1969). Additionally, GSH may become 
depleted during oxidative stress by reaction with hypochlorous acid produced as 
part of the bacterial killing process (Pullar et al. 2001).   22 
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As well as its role in the GSH peroxidase reaction, GSH can also act in 
other important ways to protect against oxidative stress. GSH S-transferases act as 
detoxification  enzymes  defending  cells  against  peroxides  induced  by  toxic 
chemicals. Hence, for example 4-hydroxynonenal can be conjugated to GSH by 
GSH S-transferases and excreted in bile (Alin et al. 1985;Warnke et al. 2008) . 
Many lipid peroxides can therefore by detoxified either by conjugation to GSH by 
GSH S-transferase or reduced by GSH peroxidase (Chandan 1997;Shelly 1999). 
GSH  is  also  extremely  important  for maintaining intracellular thiol  groups  (for 
example free thiol groups of proteins) in the reduced state. Cysteine thiol groups of 
proteins  are  vulnerable  to  oxidative  damage  during  inflammation  and  oxidative 
stress. Glutathionylation of these cysteine residues provides a reversible protection 
mechanism, as well as a redox-sensing mechanism by means of which transcription 
factors can be triggered by oxidative stress (Gianazza et al. 2009;le-Donne et al. 
2009).  The  metabolism  of  intracellular  thiols  is  complex,  with  thioredoxin  and 
glutaredoxin  both  playing  crucial  roles  in  addition  to  GSH  (Johansson  et  al. 
2004;Jung & Thomas 1996). 
In addition to protecting against peroxides and hypochlorous acid, GSH 
can act to decrease high levels of nitric oxide and thereby protect against potent 
nitrating chemicals, such as peroxynitrite, generated when nitric oxide levels are 
high, as in sepsis and other inflammatory conditions. Reaction of GSH with nitric 
oxide generates S-nitrosoglutathione (Foster et al. 2009;Zhang & Hogg 2005). S-
nitrosation  of  proteins  can  alter  function,  and  GSH  can  be  nitrosated  to  S-
nitrosoglutathione by nitrosated proteins (Foster et al. 2009;Zhang & Hogg 2005). 
S-nitrosoglutathione  can  subsequently  be  de-nitrosated  by  nitrosoglutathione   24 
reductase (a recently discovered function of formaldehyde dehydrogenase); thus, 
GSH  appears  to  have  an  important  role  as  an  intermediate  in  de-nitrosation 
pathways (Haqqani et al. 2003;Liu et al. 2004;Steffen et al. 2001). It can also act as 
a  nitric  oxide  carrier  between  tissues,  so  has  nitrosating  properties  too.  The 
function of GSH in modulation of cellular S-nitrosation is an area of great current 
interest.  Peroxynitrite  is  produced  during  sepsis,  partially  by  the  reaction  of 
superoxide with nitric oxide, and is potentially very damaging to host tissues as it is 
highly  reactive  towards  tyrosines,  tryptophans  and  other  residues  in  proteins. 
Whether GSH reacts directly with peroxynitrite or decreases peroxynitrite damage 
by scavenging nitric oxide is uncertain, as the reaction of GSH with peroxynitrite 
in vitro is rather slow (Schrammel et al. 2003). 
These functions of GSH are very important as defence factors of critically 
ill patients. Adequate GSH levels prevent excessive oxidative stress induced by 
infections or an inflammatory response, to prevent further organ dysfunction. It is 
also  strongly  associated  with  the  immune  system  to  protect  neutrophils  and 
macrophages against the bactericidal compounds that they produce. Cells of the 
immune system, when stimulated, produce huge quantities of reactive species for 
bacterial killing, and GSH is essential to protect these cells from the deleterious 
effects  of  these  reactive  species  on  host  cells,  for  example  by  reaction  with 
hypochlorous acid (Pullar et al. 2001). The redox state of GSH (i.e. the ratio of 
cytosolic GSH to GSSG) is a key component of the signalling system influencing 
the translocation of the transcription factor NFκB which regulates the synthesis of 
cytokines  and  adhesion  molecules.  Thus  GSH  can  be  regarded  as  anti-
inflammatory (Peristeris et al. 1992;Saccani et al. 2000;Sato et al. 1996) but is   25 
necessary    for  cytotoxic  T-cell  activity  and  neutrophil  function  (Droge  & 
Breitkreutz 2000;Staal et al. 1992;Villa et al. 2002) hence regulation of GSH levels 
within cells of the immune system is an important part of host defence during 
infection and sepsis.  
  The deficiencies of GSH and GSH related enzymes can be  lethal if the 
disorder occurs from either congenital or acquired diseases. Inherited deficiencies 
of  γ-glutamylcysteine  synthetase  (very  rare),  GSH  synthetase  (less  rare),  GSH 
reductase,  γ-glutamyltranspeptidase,  and  5-oxoprolinase  have  been  reported 
(Kamerbeek  et  al.  2007;Ristoff  &  Larsson  2007).  In  addition,  congenital  GSH 
peroxidase deficiency can be caused by lack of dietary selenium during pregnancy 
(Perona et al. 1979), as selenocysteine is essential for the active site of the enzyme, 
and GSH peroxidase activity can be affected both by selenium status and gene 
polymorphisms (Hesketh 2008). As erythrocytes are very dependent on the pentose 
phosphate pathway to supply NADPH to recycle GSSG to GSH, invididuals with 
glucose-6-phosphate  dehydrogenase  deficiency  (common  in  Medinterranean 
populations) can also suffer from lack of reduced GSH and a functional decrease in 
erythrocyte GSH peroxidase activity (Kurata et al. 2000)  
Newborn  mice  with  GSH  reductase  deficiency  show  early  cataracts 
(Meister 1995). Glutathionemia (excess GSH in the blood) occurs with aberrant 
expression  of  γ-glutamyltranspeptidase.  Transgenic  mice  with  lack  of  γ-
glutamyltranspeptidase showed elevated plasma GSH but decreased tissue levels, 
suffered growth retardation and developed cataracts, and most died between 10 and 
18 weeks of age (Lieberman et al. 1996).  γ-Glutamyltranspeptidase deficiency  can 
lead to an imbalance in glutamic acid homeostasis, so the disease is sometimes   26 
classed as an inherited disorder of dicarboxylic acid catabolism. (Townsend et al. 
2003) A severe GSH synthetase deficiency (5-oxoprolinuria) results in an increase 
in γ-glutamylcysteine synthetase activity through a feedback mechanism, leading to 
an  accumulation  and  excretion  of  5-oxoproline  (Meister  &  Larsson  1989).  In 
humans,  γ-glutamylcysteine  synthetase  activity  is  diminished  in  patients  with 
haemolytic anaemia (Beutler et al. 1999). 
 
1.4.3  GSH metabolism in infants and children. 
 
There is limited knowledge on GSH metabolism specific to infants and children. 
Birth itself is marked by a period of relative hypoxia, followed by oxygenation, and 
thus can be considered analogous to ischaemia-reperfusion. In term infants, anti-
oxidant  defences,  including  GSH,  are  adequate  to  counteract  this  challenge, 
because of the increases in anti-oxidant defences in late gestation (Friel et al. 2004). 
However, anti-oxidant defences on preterm infants may be less effective because of 
immaturity of anti-oxidant enzymes and decreased concentration of anti-oxidants 
and their precursors (Thibeault 2000).  
Although preterm infants show diminished availability of other components of 
the antioxidant defense systems, the GSH concentrations in cord blood of preterm 
infants  at  birth  exceed  those  of  term  infants  (Ahola  et  al.  2004;Jain  et  al. 
1995;Jean-Baptiste & Rudolph 2003).  GSH concentrations, however, fall rapidly 
after birth in preterm infants (Ahola et al. 2004;Jain et al. 1995;Jean-Baptiste & 
Rudolph  2003),  despite  the  presence  of  significant  hepatic  gamma-glutamyl 
cysteine synthetase activity from the second trimester of pregnancy (Levonen et al.   27 
2000).  This  appears  to  be  due  to  lack  of  early  amino  acid  supply,  as  earlier 
intervention  with  amino  acids  increases  GSH  concentration  in  preterm  infants 
(Braake et al. 2008). Paradoxically, although it would be expected that amino acid 
administration, especially cysteine, would increase GSH fractional synthesis rate, 
the effect of amino acid mixtures on GSH concentration appears to be mediated via 
a decrease in GSH consumption rather than an effect on GSH synthesis (Braake et 
al. 2009;Rook et al. 2010;te Braake et al. 2008). After the neonatal period, there is 
little available literature on alterations in GSH metabolism in later infancy and in 
childhood.  The  little  available  data  suggests  that  there  may  be  a  lower  GSH 
concentration in plasma in infants than in adults (Ono et al. 2001), although other 
authors have found no evidence for any age-related differences (Pastore et al. 1998). 
In septic infants and children, GSH concentration and synthesis rates are decreased 
compared with controls (Lyons et al. 2001), and this did not appear to be due to 
decreased  cysteine  availability.  In  contrast,  in  children  with  protein  energy-
malnutrition, the decreased rates of GSH synthesis do appear to be related to lack 
of availability of cysteine (Badaloo et al. 2002;Reid et al. 2000).   28 
1.5   Methods to study antioxidant defences 
 
In order to understand how anti-oxidant defences are useful and oxidative 
stress is important, a very wide variety of methods have been established. As free 
radical themselves are very reactive and short lived, they are rarely measured in 
body fluids or tissues, although they can be measured in vivo using specialised 
equipment  and  techniques.  Most  studies  on  anti-oxidants  and  oxidative  stress 
therefore  measure  either  end  products  (“footprints”)  of  oxidative  damage,  or 
measure  changes  in  concentration  of  anti-oxidants.  I  do  not  aim  to  provide  a 
comprehensive review of these methods, but a very brief introduction to areas of 
methodology relevant to this thesis. 
The thiobarbituric acid  reactive substances  (TBARS) test  is  one of the 
most frequently used measured of lipid peroxidation. It measures mainly (but not 
exclusively)  malondialdehyde  (MDA;  malonaldehyde).  In  fact,  MDA  is  formed 
only  in  small  amounts  during  the  peroxidation  of  most  lipids,  although  larger 
amounts are produced during the peroxidation of liver microsomes in the presence 
of iron salts (Esterbauer et al. 1991). Other aldehydic lipids (e.g. 4-hydroxynonenal) 
are  also  products  of  lipid  peroxidation  which  can  be  measured.  Another  major 
group of lipid peroxidation products is the isoprostanes. Isoprostanes are formed by 
peroxidation of phospholipids containing arachidonic acid. During conditions of 
oxidative stress, levels are increased. F2-isoprostanes are useful markers in human 
blood plasma and urine, and 8-epi-PGF2ʱ which is a powerful renal vasoconstrictor 
is also measured (Roberts & Morrow 1997). These can be measured with highly   29 
specific assays by HPLC, GC-MS and antibody-based determination (Halliwell & 
Gutteridge 2004b).  
  During oxidative stress in vivo, one or more antioxidants, such as ascorbate 
and GSH, can become depleted. Loss of individual antioxidants and generation of 
oxidation  products from  them can be measured as  an index of oxidative stress 
(Halliwell & Gutteridge 2004c). In addition, various assays have been developed as 
estimates of “total antioxidant activity” of body fluids (Miller et al. 1993;Wayner et 
al. 1987). An example of this is the ABTS (2,2'-Azinobis(3-ethylbenzothiazoline 6-
sulphonate)) assay, which has been used in plasma. The contribution of various 
plasma  components  to  this  “total  antioxidant  capacity”  can  also  be  calculated 
(Table 1.1.; adapted from Miller et al. 1993).  
Table 1.1  Antioxidant hierarchy in the plasma water.  
 
Concn. (μmol/l)  Antioxidant activity 
(% of total plasma 
activity) 
Range  Mid-point 
Albumin  535 - 760  640  43 
Urate  180 - 420  300  33 
Ascorbate  34 - 111  73  9 
ʱ-Tocopherol  14 - 44  29  3 
Bilirubin  < 20  10  2 
Unmeasured 
antioxidants 
    10 
The remaining 10% of the total plasma antioxidant activity is accounted 
for by substances such as cysteine, GSH, β-carotene, dihydrolipoate and ubiqinone 
(Miller et al. 1993). 
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1.6   Analysis of Glutathione 
   
Many different methods have been used for assessing GSH metabolism. 
The choice of method depends on what is required to be studied. As GSH exists in 
both  oxidised  and  reduced  forms,  it  is  also  importamt  to  decide  whether  it  is 
necessary to know the concentration or metabolism of both oxidised and reduced 
forms, or whether measurement of the total GSH pool is adequate.   
   Intracellular GSH and GSSG constitute the free GSH forms. Proteins can 
become glutathionylated, and proteomics methods such 2D-SDS-PAGE followed 
by MALDI-TOF analysis (Cotgreave & Gerdes 1998),(Fratelli et al. 2002) have 
been used to determine which proteins GSH is bound to. As GSH and GSSG have 
a low molecular weight, they are soluble in strong mineral acids, and the first step 
of GSH analysis is usually de-proteinization (protein precipitation) by acidification 
(e.g.  trichloroacetic  acid,  perchloric  acid  or  sulfosalicylic  acid).  However,  care 
must be taken at this stage if it is necessary to preserve the GSH/GSSG redox state 
in  a physiological  condition, as  GSH can be oxidised to  GSSG in strong acid, 
especially in the absence of metal chelators (Rossi et al. 2002). Deproteinization 
and centrifugation usually yields a clear, protein-free supernatant containing GSH 
and GSSG. As further manipulations in sample preparation lead to further thiol 
oxidation, at this stage the samples are usually subjected to either: 
  (i) where it is necessary to measure GSH and GSSG independently, the free 
thiol group of GSH is blocked by various agents (e.g. N-ethylmaleimide, iodoacetic 
acid, iodoacetamide or 2-vinyl pyridine), and then GSH (with blocked thiol) and 
GSSG are measured by the analytical method of choice   31 
  (ii) where it is more of interest to measure the total GSH pool, the sample is 
reduced by an excess of reducing agent, which can be performed with a variety of 
reducing compounds, such as sodium borohydride (Ivanov et al. 2001;Ivanov et al. 
2000a;Ivanov et al. 2000b;Senft et al. 2000), dithiothreitol (DTT) (Cereser et al. 
2001;Chung-Shi  et  al.  1995;Luo  et  al.  1995;Parmentier  et  al.  1998),  2-
mercaptoethanol and trialkylphosphines: tributylphosphine (TBP) (Tang et al. 2000) 
and tris-(2-carboxyethyl)-phosphine (TCEP) (Abukhalaf et al. 2002;Anderson et al. 
1999;Han & Han 1994), and the total GSH pool measured as GSH. More rarely, 
the entire GSH pool is oxidised, and measured as GSSG (Schierbeek et al. 2007).  
   The spectrophotometric assay for GSH, based on an enzymatic recycling 
reaction was first detected by Owens and Belcher (Owens & Belcher 1965) and 
then developed by Tietze (Tietze 1969). This method uses Ellman’s reagent (5,5΄-
dithiobis-(2-nitrobenzoic)-acid, DTNB), yeast GSH reductase and NADPH and to 
measure the absorbance at 412nm. The mixture results in an excess colour yield, 
and  GSH  is  detectable  at  concentrations  as  low  as  10ng/ml  (Chung  et  al. 
2005),(Pastore et al. 2003). As the assay recycles oxidised to reduced GSH, which 
then reacts with DTNB, it measures total GSH status. Where it is necessary to 
measure GSH and GSSG independently using this method, GSH is first blocked, 
e.g. with 2-vinyl-pyridine. Then, only GSSG is able to react with DTNB, after 
conversion to GSH, thus obtaining the concentration of GSSG. Another assay is 
then carried out in the absence of 2-vinyl-pyridine, to obtain total GSH, and GSH 
calculated as the difference between total GSH and GSSG. 
   High-performance liquid chromatography (HPLC) for many years has been 
the  major  method  of  measuring  GSH  and  related  thiols  in  biological  samples.   32 
HPLC  methods  in  determination  of  GSH  and  related  compounds  use  several 
different detection methods.  
   HPLC with electrochemical detection (ECD) has been used for the analysis 
of redox-reactive compounds, such as thiols and disulfides  (Richie, Jr. & Lang 
1987). In this preparation, samples after protein precipitation with metaphosphoric 
acid are diluted with mobile phase. Thiol elution from the column is detected by 
dual electrochemical detector of two gold-mercury electrodes. This method has the 
advantage of speed and simplicity, and has also been used for analysis of related 
thiol  compunds,  such  as  gamma-glutamyl-cysteine  (Gegg  et  al.  2002).  One 
potential disadvantage is that as GSSG is not electrochemically active, GSH and 
GSSG cannot both be analysed in a single run. 
   HPLC with photometric detection, such as UV-Visible absorbance detectors, 
or diode array detectors (DAD), is simple and applicable to determination of GSH 
and GSSG. GSH and GSSG are both lacking in chromophores so derivatization 
with  a  suitable  chromophore,  e.g.  DTNB  or  Sanger’s  reagent  (2,4-
dinitrofluorobenzene), is necessary. GSH and GSSG can be analysed in a single 
run  together  with  other  related  thiols  (Reed  et  al.  1980),  but  these  methods 
generally  have  low  sensitivity  and  specificity  in  comparison  with  ECD, 
fluorometric and MS determination (Camera & Picardo 2002).  
   HPLC with fluorometric detection of GSH was first described by Imai et al., 
using  ammonium-7-fluoro-2,1,3-benzoxadiazole-4-slufonate  (SBD-F)  for 
determination of GSH and other thiols (Imai et al. 1983). This method has been 
improved and modified by Toyo’oka and Oe et al. (Oe et al. 1998;Toyo'oka & Imai 
1983). GSH and other low-molecular-mass thiols are derivatised with SBD-F and   33 
quantified after elution from a reverse-phase column. The methods based on SBD-
F are sensitive and specific, and there are no particular interfering peaks in the 
chromatogram. However, it requires high temperature (60°C) and a long reaction 
time (Pastore et al. 2003). Monobromobimane (MBB) rapidly reacts with thiols at 
room temperature to produce a highly fluorescent thio-ether (Fahey et al. 1981). 
The method requires pH adjustment following derivatization, and MBB derivatives 
are usually separated from other thiols by gradient elution. MBB has been used for 
determining reduced, oxidised and protein-bound GSH in whole blood (Svardal et 
al. 1990),(Pastore et al. 2001). NaBH4 is also used as a reduction reagent and total 
recovery  of  oxidised  GSH  can  be  obtained.  ortho-phthalaldehyde  (OPA) 
derivatization pre-column is another method of HPLC with fluorescence detection. 
OPA reacts widely with GSH and related amino thiols. However, derivatization of 
GSH with OPA is pH-dependent (Parmentier et al. 1998) and GSSG cannot react 
with OPA to form a fluorescent derivatives due to alkaline hydrolysis at pH 12 to 
produce  GSH  (Yan  &  Huxtable  1995).  Improvement  of  chromatographic 
separation in several amino thiols derivatives is based on aqueous-polar organic 
mixtures  with  ion  pairing  reagents,  such  as  tetrabutylammonium  hydroxide 
(TBAH), trifluoroacetic acid (TFA) and sodium n-decysulfate (Chung-Shi et al. 
1995;Ivanov et al. 2000b;Parmentier et al. 1998;Tang et al. 2000). 
   HPLC has been combined with mass spectrometry (MS), either as LC-MS 
or LC-MS-MS and (tandem mass spectrometry), and these methods have expanded 
the potential for high-throughput analysis of GSH and other low-molecular-mass 
thiols  in  biological  samples.  The  advantages  of  LC-MS-MS  methods  are  (i) 
derivatization  is  not  usually  necessary  and  (ii)  the  analysis  time  is  very  short   34 
because chromatographic resolution of different components from each other is not 
important.  Norris et  al.  described the assay  of  GSH and GSSG in  mouse liver 
samples by using tandem MS (Norris et al. 2001). Petritis et al. tried the analysis of 
underivatised  small  peptides  by  using  ion-pair  LC-ELSD  (LC  coupled  with 
evaporative light scattering detection) and tandem MS (Petritis et al. 2002). Guan 
et al. used LC-MS for analysis of biological samples in rats, and quantified GSH, 
GSSG, cysteine, homocysteine and homocystine (Guan et al. 2003). 
   Gas chromatography mass spectrometry (GC-MS) methods for analysis of 
GSH and other thiols have also been reported. GC-MS methods can analyse very 
low  amount  of  samples  for  identification  and  quantification.  GC-MS  detection 
system requires volatile condition of compounds consequent to evaporation in a 
high  temperature  inlet  port.  Then,  the  eluants  from  the  column  reach  the  MS 
detector where they are ionized and detected (Eiceman et al. 2000). Derivatization 
in GC-MS is very important and is needed to lower the boiling point of the analyte. 
Only a few gas chromatographic methods for GSH have been described, as GSH 
itself is non-volatile, and derivatization yields bulky derivatives which are difficult 
to elute from GC columns. Kataoka and co-workers first used chloroformates as 
derivatizing  agents  for  GSH,  although  they  used  flame  photometric  detection 
(Kataoka et al. 1995;Takagi et al. 1996). These derivatives have been subsequently 
exploited for GC-MS analysis of GSH (Capitan et al. 1999;Humbert et al. 2001), as 
described  in  more  detail  in  Chapter  2.  Other  groups  have  used  alternative 
derivatization  methods  such  as  derivatization  to  a  complex  bicycloglutarimide 
(Lyons et al. 2000), or methyl ester trifluoroacetyl derivatives (Faber et al. 2002). 
Although GC-MS analysis of GSH has been used to measure concentration, it is   35 
more frequently used to measure isotopic enrichment. Another alternative approach 
applicable to measurement of GSH enrichment, has been to isolate GSH by HPLC, 
then to hydrolyse the collected peak and measure enrichment in glycine by GC-MS 
(Jahoor et al. 1999). 
The methods for analysis of GSH are summarised on Table 1.2 below.  
 
Table 1.2  Glutathione analysis 
Method of analysis  Analyte  Comments  References 
Proteomics 
(MALDI-TOF) 
glutathionylated 
proteins 
Includes 2D-SDS-
PAGE 
Cotgreave et al. 
1998 
Fratelli et al. 
2002 
Spectrophotometric 
assay 
(412nm 
absorbance) 
GSH/GSSG  Enzymatic recycling 
Ellman’s reagent 
(5,5΄-dithiobis-(2-
nitrobenzoic)-acid, 
DTNB) 
Owens & 
Belcher 1965, 
Tietze 1969, 
Chung et al. 
2005, Pastore et 
al. 2003 
HPLC 
(electrochemical 
detection) 
either GSH or 
GSSG 
GSH and GSSG 
cannot both be 
analysed in a single 
run  
Richie, Jr. et al. 
1987, 
Gegg, Clark, & 
Heales 2002 
HPLC  
(photometric 
detection) 
GSH/GSSG   DTNB or Sanger’s 
reagent (2,4-
dinitrofluorobenzene) 
analysis in a single 
run 
Reed et al. 
1980, 
 
HPLC 
(fluorometric 
detection) 
GSH/GSSG and 
protein bound 
GSH 
Ammonium-7-fluoro-
2,1,3-benzoxadiazole-
4-slufonate (SBD-F) 
 
Derivatives: 
Monobromobimane 
(MBB) 
Ortho-Phthalaldehyde 
(OPA) 
Tetrabutylammonium 
hydroxide (TBAH) 
Trifluoroacetic acid 
(TFA)  
Sodium n-decysulfate 
Imai et al.1983 
Oe et al. 1998 
 
 
 
 
Fahey et al. 
1981 
 
Parmentier et al. 
1998 
Chung-Shi et al. 
1995,  
Ivanov,   36 
Nazimov, & 
Baratova 2000, 
Parmentier et al. 
1998, Tang, 
Wen, & 
Santschi 2000 
Tandem Mass 
Spectrometry  
(LC-MS-MS) 
GSH/GSSG  Derivatisation is not 
usually necessary 
Norris et al. 
2001 
LC-ELSD  
(LC coupled with 
evaporative light 
scattering 
detection) 
 
Small peptides  Underivatisation 
 
Petritis et al. 
2002 
LC-MS  GSH/GSSG, 
CysSH, 
HCysSH and 
homocystine 
Ellman’s reagent  Guan et al. 2003 
GC-MS  GSH (total)  Chloroformates 
 
 
N-pivaloyl & O-
isopropylates (NPP) 
Bicycloglutarimide 
Methyl ester 
+Trifluoroacetylate 
Kataoka et 
al.1995, Husek 
1998, Eiceman 
et al. 2000 
Metges et 
al.1996 
 
 
Lyons et al. 
2000 
Faber et al. 
2002 
GC-IRMS  GSH  Chloroformates 
13C-/
2H-GSH 
13C-GSH 
Kimura et al. 
(SIMSUG), 
2007 
Tea et al. 2007 
LC-IRMS  GSH/GSSG 
13C-GSH  Schierbeek et al. 
2007 
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1.7  Isotope ratio mass spectrometry in metabolic research 
    
Stable  isotope  tracer  methodologies  are  well  characterised  for 
measurement of metabolism in vivo. However, these methods mostly use GC-MS 
for measurement of tracer or product enrichment; some other methods use liquid-
chromatography-mass  spectrometry  (LC-MS)  or  nuclear  magnetic  resonance 
(NMR). However, these techniques are only sensitive to fairly large changes in 
enrichment,  for example down to 0.5% atom percent excess (Meier-Augenstein 
1999a). Gas isotope ratio mass spectrometry (IRMS), based on magnetic sector 
instruments,  has  been  a  standard  tool  in  archaeology,  geochemistry  and 
environmental science for analysis of isotopic enrichment of gases, water, or bulk 
samples (via an elemental analyser). However, the IRMS instruments have been 
used with GC via a combustion interface, for compound-specific isotope analysis 
of 
13C/
12C, since 1990. These instruments are now commercially available. More 
recently,  compound-specific  analysis  of 
2H/
1H, 
18O/
16O  and 
15N/
14N  has  also 
become possible using appropriate high-temperature reactions. 
 Since  then,  GC-C-IRMS  has  been  applied  to  other  areas  of  analytical 
chemistry  in  where  GC-MS  and  LC-MS  are  commonly  used  for  analysis  in 
complex matrix or variety concentrations of substances. GC-C-IRMS is coupled a 
dual collector mass spectrometer to a GC via combustion interface for recording of 
(m + 1)/m isotope ratio by detecting two successive masses simultaneously (Meier-
Augenstein 1999a;Wolfe 1992). GC-C-IRMS can measure isotope composition at 
very low enrichment and natural abundance level. It means that minute variations 
in small amount of heavier isotope are detected in comparison with large amount of   38 
lighter  isotope  (Meier-Augenstein  2004).  Isotopic  differences  which  cannot  be 
detected by GC-MS can be detected by GC-IRMS. GC-C-IRMS enables the more 
precise  analysis  of  compound-specific  isotope  especially  at  natural  isotopic 
abundance level. Compound-specific isotope analysis at natural abundance level 
can provide information on the biogenic relation and origin of a given organic 
compound. Minute differences in the isotopic abundance of 
2H, 
13C, 
15N or 
18O can 
be useful in testing adulteration of foodstuff, or doping of sport players or race 
hoses in comparison with reference data. Compound-specific isotope analysis in 
tracer studies is of increasing interest. This approach is concerned with quantitative 
studies of biochemical processes. This isotope tracer studies is for assimilation or 
incorporation of nutrients, turnover rates of biologically important molecules, and 
quantification of protein synthesis (Meier-Augenstein 1999a).  
   IRMS  instruments  achieve  highly  precise  measurement  of  isotopic 
abundance  at  the  expense  of  the  flexibility  of  scanning  MS.  For  isotope  ratio 
measurement, the analyte must be converted into a simple gas which is isotopically 
representative of the original sample. Isotope ratio measurements of 
2H/
1H, 
15N/
14N, 
13C/
12C, 
18O/
16O and 
34S/
32S use continuous flow of gases of H2, N2, CO2, CO and 
SO2,  respectively.  IRMS  determines  the  difference  in  isotope  ratio  with  great 
precision  and  accuracy  rather  than  the  absolute  isotope  ratio.  It  provides  the 
information  of  isotopic  abundance  of  the  analyte  gas  relative  to  the  measured 
isotope ratio of a standard or reference gas (Meier-Augenstein 1999a).  
   In  measurement  of 
15N/
14N  as  N2  gas,  Metges,  C.  et  al.  measured 
15N 
isotopic abundances of N-acetyl-n-propyl (NAP)- and N-pivaloyl-i-propyl (NPP)-
amino acid esters in physiological samples by using GC-C-IRMS (Metges, Petzke,   39 
& Hennig 1996). This was a pilot study of amino acid synthesis in minipigs. The 
same group had analyzed individual plasma free amino acids of human adults at 
natural  abundance  to  measurement  of 
15N/
14N  isotopic  composition  (Metges  & 
Petzke 1997). 
   In measurement of 
13C/
12C as CO2 gas, the data comprise three different 
isotope combinations of 
12C
16O2, 
13C
16O2 and 
12C
18O
16O with their corresponding 
masses  at  m/z  44,  45  and  46,  respectively.  Utility  of  GC-C-IRMS  has  been 
expanded
  in  compound  specific  isotope  analysis  (CSIA)  by  using 
13C-labelled 
compound. Infusion of 
13C-labelled glutamine tracers used for measurement of the 
rates of production, utilization and oxidation of glutamine’s carbon skeleton in vivo. 
GC-C-IRMS can allow to measure more accuracy low 
13C enrichment in plasma 
free glutamine (Menand et al. 1997). Metges, C. et al. who had analyzed 
15N/
14N 
abundances of amino acids by former pilot study in GC-C-IRMS had used 
13C-
labelled  casein  as  a 
13C-labelled  tracer  and  analysed  NPP-ester  amino  acids  in 
tissues and plasma samples (Metges & Daenzer 2000). Montigon et al. measured 
13C-  and 
15N-enrichment  of  glutamine  in  rat  plasma  and  human  plasma, 
respectively (Montigon et al. 2001).  
   Measuring  the 
2H/
1H  (D/H)  ratio  of  materials  by  using  GC-Thermal 
Conversion-IRMS  is  more  complicated.  The  first  commercial  GC-IRMS 
instrument to measure 
2H/
1H was produced in 1998 (Sessions 2006). Hydrogen in 
samples is converted to H2 via pyrolysis or coupled oxidation/reduction and flows 
into an IRMS. In all cases, mass-2 (H2) and mass-3 (HD) ion beams are monitored 
continuously, and D/H ratios are based on integration of the mass-2 and mass-3 ion 
current signals. Basically data-processing procedures are similar to those carbon   40 
isotopic analyses (Sessions et al. 2001a).  The abundance of 
2H (D) is low relative 
to that of 
1H (H). It means, at natural abundance, most organic materials contain 
less than 100 ppm D. To avoid confounding contributions from other, such as 
13C 
in  CH4,  molecular  H2  as  the  sample  gas  needs  to  get  mass  spectrometric 
determination of H2 and HD abundances for precise measurements of hydrogen 
isotopic ratios. The reaction (H2
+ + H2  H3
+ + H˙) in the ion source of the mass 
spectrometer ensues from using H2 for these measurements. In materials containing 
a natural abundance of D, H3
+ can account for as much as 5-30% of the m/z 3 
signal. Therefore, the correction for H3
+ is significant (Sessions et al. 2001b). The 
H3
+ factor is determined as the value of K which is described the formula: iHD = i3 – 
K(i2)
2,  where  i2  and  i3  are  the  raw  mass-2  and  mass-3  ion  currents,  iHD  is  the 
corrected ion current. The value of K minimizes the mean absolute error of the 9 - 
10 peaks of varying size and determined using this method are generally within 5% 
of  those  determined  conventionally.  Raw  mass-3  ion  currents  are  corrected  for 
contributions from H3
+ on a point-by-point basis (Sessions et al. 1999). When the 
H3
+  factor  has  been  corrected,  isotope  ratios  are  determined  using  the  same 
techniques as a carbon measurement in GC-C-IRMS. Thus, frequent determination 
of the H3
+ factor, and stability of the H3
+ factor within a run and between runs, is a 
key requisite for accurate compound-specific analysis of 
2H/
1H. 
    The  ability  to  measure  low  deuterium  enrichments  is  very  attractive,  as 
many metabolic processes incorporate deuterium from water and so can in theory 
be measured in vivo by administering D2O (Dufner & Previs 2003). Deuterated 
water  as  a  heavier  isotope  tracer  has  been  used  for  measurement  of  de  novo 
triacylglycerol synthesis in  humans  (Scrimgeour et  al.  1999). Scrimgeour et  al.   41 
used GC-IRMS techniques for the measurement of deuterium enrichment. Cogo et 
al.  also  measured  surfactant  palmitate  disaturated-phosphatidylchline  (DSPC) 
synthesis in human infants by using deuterated water. They used GC-IRMS for 
deuterium labelled lipid synthesis and measured deuterium enrichment of urine and 
tracheal aspirates. In this study, there were no side effects from the administration 
of D2O (Cogo et al. 2005). Deuterated water (D2O) does not cause any adverse 
physiological effects unless used in very high concentrations. As GC-C-IRMS is 
more sensitive than GC-MS, even in selected ion monitoring (SIM) mode, lower 
D2O  infusion  rates  can  be  used.  It  is  because  GC-C-IRMS  can  detect  minute 
variations of very small amount of the heavier isotope in the presence of large 
amounts of the lighter isotope. 
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1.8  Aim of this thesis 
 
The aims of the work described in this thesis were: 
(i) to establish a method for analysis of GSH enrichment and synthetic rate 
using  isotope-ratio  mass  spectrometry,  which  would  be  suitable  for  use  with 
deuterated and 
13C- labelled amino acid precursors 
(ii) to use this method to measure GSH synthesis in critically-ill infants and 
children 
(iii) to  use this  method to  measure  GSH synthesis in  septic infants  and 
children given parenteral glutamine as a potential GSH precursor 
(iv)  to  use  this  method  to  measure  GSH  synthesis  in  rats  undergoing 
intestinal ischaemia-reperfusion injury as a model of systemic inflammation. 
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Chapter  2 
 
Development of methods to measure 
enrichment of Glutathione and Glycine 
by Gas Chromatography- 
Isotope Ratio Mass Spectrometry   44 
Chapter 2:___________________________  ______ 
 
2.1  Introduction 
The use of GC-IRMS in medical biochemical research is very recent, as it 
has  been  mainly  previously  used  in  archaeology,  geology  and  environmental 
chemistry. Although the IRMS is able to detect very small (ppm) differences in 
isotopic enrichment, simple gases, such as CO2, H2, N2 and CO must be analysed, 
so that organic biochemical compounds have to be converted by a high temperature 
interface. 
 GC-Combustion/Thermal Conversion-IRMS is based on a GC and IRMS 
attached  to  GC  via  a  thermal  conversion  interface  (Figure  2.1).  A  combustion 
interface is used for analysis of carbon isotopic enrichment in organic compounds 
and high temperature conversion (“pyrolysis”) interface used for hydrogen isotopic 
analysis in organic compounds. 
Auto Sampler
GC
Combustion/
Thermal Conversion 
Reactor
Reduction 
Oven
Amplifier Array
Reference gas
Auto Sampler
GC
Combustion/
Thermal Conversion 
Reactor
Reduction 
Oven
Amplifier Array
Reference gas  
Figure 2.1  Set-up of an isotope ratio mass spectrometer to a gas chromatograph 
via a combustion interface to measure 
13C/
12C (carbon mode) or high 
temperature conversion interface to measure 
2H(D)/
1H (hydrogen mode).   45 
Gas chromatography-mass spectrometry is often used for measurement of 
stable isotope tracer enrichments in biochemistry and biomedicine but it is not an 
ideal  method.  When  GC-MS  is  used  for  tracer  studies,  either  high  tracer 
enrichments and/or selective ion monitoring (SIM) mode have to be used. As GC-
IRMS has been developed for specifically for analysis of isotopic ratios, it should 
be a much more sensitive detector than GC-MS even in SIM mode, allowing lower 
tracer infusion rate or more complex analysis in which the infusion tracer is several 
biochemical steps away from the measured compound. 
Methods of sample derivatization using GC-MS have been developed and 
studied  intensively.  Silylation  agents  (e.g.  trimethylsilyl  (TMS)  and  tert-butyl-
dimethylsilyl (tBDMS)) and fluorinating agents (e.g. trifluoroacetates (TFA) and 
boron trifluoride (BF3)) have enjoyed great popularity. However, many of these 
methods are not compatible with GC-C/TC-IRMS. Using either TMS or tBDMS 
derivatization causes a high load of carbon and which, in the case of carbon isotope 
ratio measurement, causes dilution of ʴ
13C-value of the measured compound. In 
addition,  the  life  of  the  combustion  reactor  may  be  shortened  by  silylation. 
Fluorinated derivatives have also a huge risk of damage to combustion reactor. As 
fluorine  forms  extremely  stable  fluorides  with  cupper  (Cu)  and  nickel  (Ni),  if 
CuO/Pt  is  used  as  combustion  catalyst,  this  effect  will  show  up  immediately 
(Meier-Augenstein  2004).  In  addition,  fluorine-containing  ions  produced  in  the 
source can be very corrosive to be the mass- spectrometer.   
For  analysis  of  amino  acids  using  GC-MS,  some  groups  have  used 
chloroformates (e.g. methyl chloroformate (MCF) and ethyl chloroformate (ECF)) 
(Capitan, Malmezat, Breuille, & Obled 1999;Husek 1998), and Metges et al. used   46 
N-pivaloyl & O-isopropylates (NPP) (Metges & Petzke 1997;Metges, Petzke, & 
Hennig 1996). The derivatization has the advantages that (i) it does not involve 
damaging silylation or fluorinating agents, (ii) the carbon and/or hydrogen load on 
the target compound are relatively low, and (iii) the chloroformate reaction takes 
place readily in aqueous solution. GSH is not an amino acid but it is a tripeptide. 
This derivatization method, therefore, could be used for analysis of GSH using GC-
C/TC-IRMS. 
I aimed to establish a new methodology to analyse GSH and its precursor 
amino acids simultaneously using GC-C/TC-IRMS. The new methodology is also 
compatible with GC-MS.  
 
 
2.2  Aim 
  My aims were (i) to establish a method for measurement of 
13C/
12C ratios in 
GSH and glycine using GC-MS and GC-C-IRMS and (ii) to establish validate a 
method for measurement of 
2H/
1H ratio in GSH and glycine using GC-TC-IRMS.  
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2.3  Methods 
 
2.3.1  Chemicals  
All chemicals came from the sources describe in Appendix 2 (Chemicals 
and Procedures). 
 
2.3.2  GC-MS  
GC-MS measurements were carried out with an Agilent 6890 Series Gas 
Chromatograph coupled to an Agilent 5973 Series Mass Spectrometer, in electron 
impact (70 eV) ionisation mode.  
 
2.3.3   GC-IRMS 
Isotope  ratios  of  either 
13C/
12C  or
  2H/
1H  was  measured  by  GC-IRMS, 
which  was  Thermo  Finnigan
TM  GC  Combustion  III  and  Thermo  Finnigan
TM 
DELTA
Plus XP with ISODAT software. Combustion mode (
13C/
12C) was carried 
out using a ceramic tube with a copper oxide lining, operated at 950
ºC. The copper 
oxide was periodically re-oxidised by backflushing with O2 gas. High temperature 
conversion (
2H/
1H) was carried out in a ceramic tube at 1425
ºC in the absence of 
oxygen. The inner surface of the tube was coated with elemental carbon, which acts 
as  a  catalyst  and  scavenges  residual  oxygen.  The  tube  was  periodically  re-
carbonised  (every  ~200  injections,  or  when  peak  heights  were  noticeably 
diminished) by backflushing with methane gas (0.8-1.0ml/min for 10 minutes). 
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2.3.4  Gas chromatography (GC-MS and GC-IRMS) 
Sample injections were made in splitless mode, the injector temperature 
was at 250°C and helium flow rat was 1.2 ml/min. The injection volume was 2 μl. 
Column was 10m of Phenomenex ZB-50 (ID 0.25 mm × film thickness 0.25 μm). 
Two  oven  temperature  gradients  were  programmed.  One  was  a  temperature 
programme from 70°C to 180°C at a rate of 5°C/min, then from 180°C to 280°C at 
a rate of 30°C/min and from 280°C to 320°C at a rate of 5°C/min, holding at 320°C 
for 1 min. Another was programmed temperature from 70°C to 180°C at a rate of 
14°C/min, then from 180°C to 280°C at a rate of 30°C/min and from 280°C to 
310°C at a rate of  3°C/min, holding at 310°C for 3 min. 
 
 
2.3.5  Samples 
Standard glycine (Gly) and GSH (L-γ-glutamyl-L-cysteinylglycine) were 
used in this study. Chemical structures are shown in Figure 2.2. 
 
 
 
Figure 2.2 Chemical structure of glycine and GSH 
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13C2-Glycine and Gly
13C(C2)-
15N-GSH, as stable isotope standard samples, 
were used. Chemical structures are shown in Figure 2.3.  
 
 
2.3.6  Generation of d2-Glutathione 
As  d2(GlyC2D2)-GSH  is  not  commercially  available,  I  generated 
deuterated GSH by incubating human RBC with D2-glycine in vitro.   
Red blood cells were separated from whole human blood of a healthy 
adult  volunteer  by  taking  blood  (20ml)  into  a  Li-Heparin  tube,  and 
centrifugation at 3000rpm for 15min at 4°C. 1ml aliquots of the pellet were 
stored at -80°C until analysis. 
10 mM d2-Gly (distilled water solution) was added to an aliquot of RBC to 
a final concentration of 1 mM. The RBC sample was incubated for 18h (overnight) 
at 37ºC. The reaction was stopped by addition of EDTA (ethylendiaminetetraacetic 
acid) to a final concentration of 5 mM. The deuterated-(Gly)-GSH of RBC sample 
was kept at -80ºC until analysis. Chemical structures are shown in Figure 2.4. 
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Figure 2.3 Chemical structure of 
13C labelled glycine and GSH   50 
 
This method relies on the activity of the enzyme GSH synthetase, with 
catalyses the reaction: γ-glutamyl-cysteine + glycine ↔ GSH, and requires Mg
2+ 
ions for its activity and is, therefore, inhibited by excess of chelating agents such as 
EDTA (Oppenheimer et al. 1979). 
 
 
2.3.7  Preparation of samples and standards for analysis 
Reduction of GSH and protein precipitation of erythrocyte samples 
50 ~ 200 μl of RBC sample was taken into a microcentrifuge tube and 200 
μl  of  TCEP  (tris-(2-carboxyethyl)-phosphine)  buffer  (7.5  mM  TCEP,  0.2  M 
KH2PO4, 5 mM EDTA, pH 7.5) added. The sample was mixed for 15 min at room 
temperature to reduce all oxidised GSH to GSH. 200 μl of 10% SSA (sulfosalicylic 
acid) was added into the sample and mixed vigorously. The sample was centrifuged 
at 1200g for 12 min at 4C and the supernatant immediately derivatised as below. 
Derivatization  
After  protein  precipitation,  200  μl  of  the  supernatant  (or  the  standard 
solution) was transferred into a 10 ml screw capped glass tube. The sample was 
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Figure 2.4 Chemical structure of deuterium labelled glycine and GSH   51 
made pH > 10 with 2 M NaOH. 50 μl of PCF (n-propyl chloroformate) was added 
to the sample and mixed for 5 min at room temperature. 1 M HCl was added into 
the sample to pH < 2 and then 0.5 g of NaCl added. Then, 3 ml of diethyl ether 
(peroxide  free)  was  added  for  extraction  of  the  organic  phase.  The  extracted 
organic  phase  was  transferred  to  a  new  tube  and  the  aqueous  phase  was  re-
extracted. The organic phase was dried down under nitrogen air at 60°C. 200 μl of 
1 M HCl in MeOH (340 μl of concentrated HCl (ca. 6 M) put into volumetric flask 
to make up 10 ml with MeOH (HPLC grade)) was added to the dry sample. The 
sample was incubated for 10 min at 80°C and then dried down under nitrogen at 
60°C. The sample was re-suspended with 100 μl of ethyl acetate and transferred to 
an autosampler vial for GC-MS or GC-IRMS analysis, as described in section 2.3.4.  
 
2.3.8  Statistics 
Data were compared by t-tests (two samples), one-way ANOVA (more 
than  two  samples)  or  by  linear  regression  analysis.  p<0.05  was  regarded  as 
significant.   52 
2.4 Results 
 
2.4.1   Method development 
2.4.1.1  N,S-ethoxycarbonyl methyl esters 
The initial attempts to develop a method for GC-IRMS-compatible analysis 
of GSH were based on the method of Capitan et al. (Capitan, Malmezat, Breuille, 
&  Obled  1999),  which  were  based  on  derivatization  with  ethyl  chloroformate 
followed by methanolic-HCl to yield the N,S-ethoxycarbonyl methyl ester of GSH. 
Using the reaction conditions described: standards were dissolved in 0.8 ml of 0.2 
M phosphate buffer, 5 mM EDTA, 80 mM DTT, pH 7.5. After addition of 100 μl 
ethyl chloroformate, the mixture was shaken on a tube rotator for 15 min at room 
temperature. The pH of the mixture was then adjusted to 1.5 with 2 M HCl. The 
mixture was saturated with NaCl (~0.3 g per ml) and extracted three times with 3 
ml of peroxide-free diethyl ether. The ether extracts were evaporated to dryness at 
80ﾰC,  then  200  μl  of  1  M  HCl  in  methanol  was  added,  the  vial  capped  and 
incubated at 80°C for 10 min in a heating block. The solvent was then evaporated 
to dryness at 80°C under a stream of air and the residue dissolved in 50–100 μl of 
ethyl  acetate.  These  samples  were  analysed  by  GC-MS  using  the  following 
conditions: the temperature of the GC injector was 270°C. The column used was a 
10m x 0.25 mm I.D.×0.25 μm film thickness HP5MS. Injections (1–2 μl) were 
made  in  the  split  mode  with  a  20:1  split,  with  a  column  helium  flow  rate  of 
1ml/min. 
The  GC  oven  temperatures  were:  200°C  for  0.5  min,  then  increased  to 
280°C at a rate of 30°C/min, 280°C for 0.1 min, increased to 295°C at a rate of   53 
5°C/min and 295°C for 2 min. Although this method gave the expected peaks for 
cysteine, cys-gly and gly-cys, no clear peaks were obtained for GSH (expected m/z 
479 with fragments at 363 and 216). Despite variation in reaction pH, different 
methods for producing dry methanolic HCl, and ensuring samples were completely 
dry  before  esterification  with  methanolic-HCl,  clear  GSH  peaks  could  not  be 
obtained. In addition, other stages of the sample derivatization were also altered, 
such as use of ethyl- acetate to extract the N,S-ethoxycarbonyl ester, and use of 
methanolic acetic acid for the final esterification, all without success. 
The next attempt was to use the above reaction method, but with methyl-
chloroformate followed by methanolic-HCl, with the expectation of producing the 
N,S-methoxycarbonyl  methyl  ester  of  GSH.  This  would  have  had  a  lower 
molecular  weight  than  the  N,S-ethoxycarbonyl  methyl  ester,  which  could  have 
circumvented  any  problems  due  to  GSH-derivatives  not  being  eluted  from  the 
HP5MS column. 
 
2.4.1.2  Single stage chloroformate derivatisation 
The problems regarding use of the above described method were considered 
to be due to the second esterification step, that of methanolic-HCl, in which the 
samples must be water-free. It was therefore decided to attempt to derivatize GSH 
in a single step procedure, in aqueous solution, using the methods of Husek (Husek 
1991;Husek  1998).  Initially,  to  a  200μl  aqueous  standard  were  added  164μl 
methanol, 34μl pyridine, then 2 aliquots of 20μl of methyl chloroformate, with 
vortexing after each addition. Then, products were extracted with 400μl chloroform, 
with  addition  of  400μl  50mM  NaHCO3.  The  chloroform  phase  was  dried  over   54 
anhydrous sodium sulphate and injected to the GC-MS, using a temperature profile 
from 60°C, then 15°C/min to 275°C, then 30°C/min to 300°C. Clear single peaks 
were obtained for gly, cys and cys-gly. Although a derivative was obtained for 
GSH, multiple chromatographic peaks were obtained.  
It was then attempted to optimise this method using ethyl chloroformate, n-
propyl  chloroformate,  iso-propyl  chloroformate  and  butyl  chloroformate.  In 
addition, several different solvents such as acetonitrile, piperidine, triethylamine, 
1% NaOH previously described as variants on the Husek method were attempted. 
However, none of these variants gave a single clear peak of GSH. 
 
2.4.1.3 N-pivalolyl-2-propanol derivatization 
The  next  method  attempted  was  to  use  the  N-pivalolyl-2-propanol 
derivatization  described  by  Metges  et  al.  (Metges  &  Daenzer  2000;Metges  & 
Petzke 1997;Metges, Petzke, & Hennig 1996). Although this yielded single clear 
peaks for alanine, glycine and other amino acids, GSH was either not derivatized or 
not eluted from the GC column. 
 
2.4.1.4 Use of a commercial amino acid analysis kit 
It was then decided to use a commercially available kit for GC-MS based 
amino acid analysis, EZ-Faast (Phenomenex, UK). This method also used single 
step  chloroformate  based  derivatization  (I  e.  similar  to  Husek),  but  the 
manufacturers did not disclose the alkyl chloroformate or the solvent used in their 
kit, nor was the GC column disclosed. Although the EZ-Faast kit did not derivatize 
GSH,  it  was  considered  to  be  very  promising  as  dipeptides  were  amenable  to   55 
derivatization  and  analysis.  From  the  mass  spectra  of  the  amino  acids,  the 
derivatives appeared to be n-propyl derivatives. It was therefore decided to attempt 
to use n-propyl chloroformate derivatization, followed by solvent extraction and 
methylation.  This  method,  as  described  above  in  section  2.3.7,  proved  to  be 
successful in analysis of GSH and glycine, with GC analysis on the 10m EZ-Faast 
column.  Examination  of  the  characteristics  of  the  EZ-Faast  column  led  to  the 
conclusion that the ZB-50 column (Phenomenex, UK) was very similar to the EZ-
Faast column, so a 10m ZB-50 column was used, as described in 2.3.4. for all 
future work. 
 
2.4.1.5  Internal standardisation 
In  order  to  develop  a  method  for  measuring  concentration,  as  well  as 
enrichment, of GSH, it was necessary to try to find a suitable internal standard for 
GC-IRMS analysis. Usually, for GC-MS analysis of concentration, a deuterated or 
13C- labelled internal standard would have been used, but this was not appropriate 
as it would have interfered with the isotopic analysis necessary. It was therefore 
necessary  to  attempt  to  find  an  internal  standard  with  the  characteristics  (i) 
chemically similar to GSH so losses of GSH are reflected in losses of internal 
standard; (ii) not found endogenously so no interference from biological samples 
and (iii) must appear completely separate chromatographically from all endogenous 
compounds. The last was especially difficult to achieve, as it must be remembered 
that in GC-IRMS, detection is detection of 
2H/
1H or 
13C/
12C, so that any organic 
compound would interfere.   56 
Two  different  compounds  assessed  as  internal  standards  are  shown  on 
figures 2.5. and 2.6  respectively: 
 
 
Figure  2.5  Use  of  gamma-glutamyl-glutamate  as  internal  standard.  GSH 
peak is at 30 minutes. 
 
Gamma-glutamyl-glutamate  unfortunately  yielded  a  peak  which  co-
chromatographed  with  other  biological  material  in  red  blood  cell  samples, 
appearing at several split peaks between 24 and 27 minutes (Figure 2.5). 
Homoglutathione  (gamma-L-glutamyl-L-cysteinyl-beta-alanine)  initially  showed 
promising results, as suggested by Humbert et al. (Humbert, Nguyen, Obled, Bobin, 
Vaslin, Sweeten, & Darmaun 2001) and as shown in Figure 2.6, where a clear peak 
separate  from  that  of  GSH  was  observed.  However,  there  is  significant  band 
broadening in the high-temperature conversion/ combustion ceramic tube, so that 
on  GC-IRMS,  the  homoglutathione  peak  was  not  chromatographically  separate 
from  that of GSH,  rendering it not  suitable for use  as  an internal  standard for 
concentration measurement by GC-IRMS. 
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Figure 2.6 Use of homoglutathione as internal standard. GSH peak is at 30 
minutes, homoglutathione at 31minutes. 
 
 
 
2.4.2  Glycine and GSH in GC-MS 
GC-MS was used for identification of glycine and GSH derivatives, as 
structured  information  can  not  be  obtained  by  GC-IRMS.  All  structured 
information  is  lost  after  conversion  to  CO2,  H2,  or  N2  in  GC-IRMS  analysis. 
Glycine  and  GSH  were  identified  by  these  retention  time  and  mass  spectrum 
patterns at GC-MS.  
Glycine derivative gave the fragments; m/z = 116, 88, 56, 59, 74, 90, 102, 
134. (m/z = 116 was the base peak ion.) Virtually no molecular ion was detected. 
Retention time was around 8 min using the temperature programme: from 70°C to 
180°C at 5°C/min, from 180°C to 280°C at 30°C/min and from 280°C to 320°C at 
5°C/min, holding at 320°C for 1 min. The structure of glycine n-propoxycarbonyl 
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methyl ester is shown at Figure 2.7, the chromatogram in Figure 2.8 and the mass 
spectrum is in Figure 2.9. 
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Figure 2.7  Glycine n-propoxycarbonyl methyl ester 
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Figure 2.8  Chromatogram of Glycine n-propoxycarbonyl methyl ester   59 
 
 
The GSH derivative gave the fragments; m/z = 144, 84, 162, 142, 391, 230, 
56, 331, 88, 82. Again, virtually no molecular ion was detected. Retention time was 
around 30.4min in temperature programme: from 70°C to 180°C at 5°C/min, from 
180°C to 280°C at 30°C/min and from 280°C to 320°C at 5°C/min, holding at 
320°C for 1 min.  
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Figure 2.9  Mass Spectrum of Glycine n-propoxycarbonyl methyl ester   60 
The structure of the GSH N,S-n-propoxycarbonyl methyl ester is shown in 
Figure 2.10, the chromatogram in Figure 2.11, and the mass spectrum in Figure 
2.12.  
  The  peak  shape  for  the  GSH  derivatives  was  relatively  poor,  as  the 
compound has limited volatility. A high temperature was necessary to elute GSH 
from the column, and a column longer than 10m could not be used as GSH did not 
elute at all. 
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Figure 2.10  Glutathione N,S-n-propoxycarbonyl methyl ester   61 
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Figure 2.11  Chromatogram of Glutathione N,S-n-propoxycarbonyl methyl 
ester 
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Figure 2.12  Mass Spectrum of Glutathione N,S-n-propoxycarbonyl methyl 
ester   62 
2.4.3  Methods in GC-C-IRMS 
When  GC-C-IRMS  had  been  set  up  at  using  CO2  reference  gas  for 
analysis of 
13C/
12C, the column was the same as in using GC-MS. The temperature 
gradient was also the same method in GC-MS: temperature programme from 70°C 
to 180°C at 5°C/min, from 180°C to 280°C at 30°C/min and from 280°C to 320°C 
at 5°C/min, holding at 320°C for 1 min. Injection volume was 2 μl in splitless 
mode.  
Each  eluted  peak  from  the  column  was  transferred  on-line  to  a  950°C 
ceramic  combustion  tube  containing  copper  wires  (Figure  2.13).  The  resulting 
12C
16O2, 
13C
16O2 and 
12C
18O
16O were shown as their corresponding masses at m/z 
44,  45  and  46  respectively,  by  an  on-line  magnetic  sector  isotope  ratio  mass 
spectrometer  (Thermo  Finnigan
TM DELTA
Plus XP with  ISODAT software). The 
ʴ
13C is reported against Vienna Peedee Belemnite (VPDB) (VPDB is presented by 
International  Atomic  Energy  Agency,  Vienna,  Austria).  The  copper  of  the 
combustion tube was  re-oxidised to  Cu2O every  200  - 300 injections  by back-
flashing with O2 over night.  
 
Figure 2.13  Analysis of 
13C/
12C in GC-C-IRMS; Each peak of 
12C
16O2, 
13C
16O2 and 
12C
18O
16O is eluted and the δ
13C is calculated   63 
2.4.4  Analysis of 
13C-Glycine and 
13C-GSH 
Although the 
13C-glycine stock solution was made at 10 mM in analytical 
grade  water  (HPLC  grade),  the 
13C-GSH  stock  solution  was  made  10  mM  in 
methanol because stable isotope labelled GSH was more stable in methanol than in 
water. Each standard and stable isotope labelled sample was analysed by carbon 
mode of GC-C-IRMS. RBC and RBC with 
13C-glycine were also analysed. The 
chromatograms are shown in Figure 2.14, Figure 2.15 and Figure 2.16.  
Analysis of both standards and blood samples, was successful, showing 
that the derivative could be combusted online to CO2 and detected by IRMS.  
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Figure 2.14  Chromatogram of 
13C-glycine-spiked RBC sample, GSH peak was 
from endogenous GSH in RBC.   64 
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Figure 2.16  Chromatogram of GSH standard 
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Figure 2.15  Chromatogram of unspiked RBC sample   65 
2.4.5  
13C-GSH calibration curve 
10mM 
13C,
15N-GSH  was  mixed  into  GSH  standard  solution  (10mM)  to 
make an isotopic calibration curve from 0% to 5% of 
13C-GSH (the 
15N-label is not 
relevant  to  these  studies,  and  was  present  because 
13C,
15N-GSH  was  available, 
whereas 
13C-GSH was not). The mixed 200μl of GSH samples were analysed. Each 
sample was analysed in triplicate and the result of 
13C/
12C shown per mille (i.e. 
parts per thousand, ‰) against VPDB. For this analysis of 
13C/
12C-GSH, a different 
oven  temperature  gradient  was  used:  One  was  started  from  70°C  to  180°C  at 
5°C/min, from 180°C to 280°C at 30°C/min and from 280°C to 320°C at 5°C/min, 
holding at 320°C for 1 min. Another was started from 70°C to 180°C at 14°C/min, 
from 180°C to 280°C at 30°C/min and from 280°C to 310°C at 3°C/min, holding at 
310°C for 3 min.  
The  other  programmed  temperature  gradient  was  initial  temperature  of 
110°C, and increased at a rate of 30°C/min from 110°C to 280°C, holding at 280°C 
for 0.1min, then at 5°C/min from 280°C to 320°C, holding at 320°C for 2min. It 
was only focused on analysis of 
13C/
12C-GSH, not including glycine. 
Linear regression of 
13C/
12C vs. 
13C-GSH (%) gave a good linear fit with r
2  
of 0.9981, and a Y intercept of –28.02 ± 0.58. Calibration curve of 0-5% of 
13C-
GSH in GSH standard is shown in Figure 2.17 and chromatogram of 2.5% of 
13C-
GSH in GSH standard is shown in Figure 2.18. 
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Figure 2.17  Calibration curve of 0% to 5% of 
13C-GSH in GSH standard 
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Figure 2.18  Chromatogram of 2.5% of 
13C-GSH in GSH standard; 
13C/
12C-
GSH peak was at 728 sec of the chromatogram.   67 
Samples of lower enrichment (0-1%) also showed a good linear regression 
with r
2 of 0.9779 and a Y intercept of –26.57 ± 0.4290. This calibration curve is 
shown  in  Figure  2.19.  Although  the  r
2-value  was  good,  examination  of  the 
calibration  curve  shows  a  departure  from  linearity  below  0.25% 
13C-GSH.  A 
sample chromatogram at 0.025% 
13C-GSH is shown in Figure 2.20. 
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Figure 2.19  Calibration curve of 0% to 1% of 
13C-GSH in GSH 
standard    68 
 
 
 
2.4.6  
2H/
1H analysis of glycine and GSH in GC-TC-IRMS 
As  deuterium  analysis  by  IRMS  is  less  sensitive  than 
13C/
12C,  it  was 
necessary to inject larger volumes. In order to do this, injections of 11.25 μl were 
made via a programmed temperature vaporization inlet (PTV inlet) in solvent vent 
mode.  11.25  μl  of  sample  was  injected  at  1  μl/sec  into  a  Siltek
®  treated  liner 
(volume 125μl) containing Siltek
®-treated glass wool to increase evaporation area. 
The  liner  was  held  at  37ºC  and  vented  with  helium  at  100  ml/min  to  remove 
solvent. Analytes remained in the liner until, after 0.8min, the temperature of the 
liner was  increased  to  300°C at  a rate of 150°C/min,  and held  at  300°C for 5 
minutes.  This  rapid  heating  transfers  analytes  onto  the  head  of  the  analytical 
column. The liner was purged with helium at 50 ml/min for the last 2.5 minutes of 
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Figure 2.20  Chromatogram of 0.025% of 
13C-GSH in GSH standard 
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the 300°C isothermal period. At the end of the run, the inlet was rapidly cooled to 
37°C with liquid N2. The column was 10m of Phenomenex ZB-50 (ID 0.25 mm × 
film thickness 0.25 μm), as for GC-MS analysis. The GC oven temperature was 
programmed from 70°C to 180°C at a rate of 14°C/min, from 180°C to 280°C at a 
rate of 30°C/min and from 280°C to 310°C at a rate of 3°C/min, holding at 310°C 
for 3 min. 
The eluted peaks were passed through a high temperature conversion oven 
operated at 1425°C, in the absence of oxygen, containing an Al2O3 ceramic tube 
(0.5mm i.d., 320mm long). This results in the quantitative conversion of organic 
compounds of H2. The resulting H2 and DH were shown as their corresponding 
masses at m/z 2 and 3, respectively (see Figure 2.21).  
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Figure 2.21  Analysis of 
2H/
1H in GC-TC-IRMS; each peak of 
2H
1H and 
1H2 is 
eluted and the δ
2H is shown from these H2 result.   70 
2.4.7 Analysis of D2-Glycine and D2(Gly)-GSH 
Standards  of  glycine  (5  mM;  Figure  2.22),  GSH  (10  mM;  Figure  2.23),  
d2(Gly)-GSH (generated from RBC with d2-glycine in vitro as described above; 
Figure 2.24) and RBC (Figure 2.25) were analysed by hydrogen mode of GC-TC-
IRMS.  
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Figure 2.22 Chromatogram of glycine standard    71 
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Figure 2.23 Chromatogram of GSH standard 
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Figure 2.24  Chromatogram of Deuterated RBC sample 
   72 
 
 
 
 
 
 
 
0 500 1000 1500 2000
0
250
500
750
1000
1250
-250
-150
-50
50
150
250 glycine
GSH
time (sec)
m
a
s
s
 
2
(
m
V
)
m
a
s
s
 
3
(
m
V
)
 
Figure 2.25  Chromatogram of RBC sample   73 
2.4.8  Deuterated RBC 
When  d2(Gly)-GSH  was  generated  from  GSH  by  erythrocytes  (as 
described in section 2.3.6), 28.8% of endogenous GSH in RBC was converted to 
d2(Gly)-GSH. The investigation of the yield of converted GSH was performed by 
analysis of both control RBC and RBC with d2-glycine in GC-TC-IRMS. The yield 
of converted GSH was calculated from the results of 
2H/H-GSH in GC-TC-IRMS 
by following formula: 
Converted 
2H-GSH (%) =  
(
2H/H(%) of GSH in RBCd2-Gly – 
2H/H(%) of GSH in RBCcontrol) / (2/33) 
(as 2 of the 33 hydrogens of GSH could be replaced by deuterium.  
The GSH derivative of control RBC and the d2(Gly)-GSH derivative of 
RBC with d2-glycine was analysed. The results from GC-TC-IRMS were 
2H/H of 
GSH in RBCd2-Gly = 1.77%, and 
2H/H of GSH in RBCcontrol = 0.02%. These values 
put into the formula: 1.77- 0.02 / (2/33) = 28.8 (%) 
Although excess d2-glycine was added into RBC in this GSH generated 
process, d2(Gly)-GSH and d2-glycine in the RBC were analysed by GC-TC-IRMS 
simultaneously. It was not necessary to purify the d2(Gly)-GSH from the RBC with 
d2-glycine for this study as a purpose of the study was to measure both GSH and 
glycine in a sample simultaneously by GC-TC-IRMS. 
   74 
2.4.9   D2-GSH calibration curve 
A calibration curve of deuterated GSH was made by mixing RBC with d2-
labelled RBC in proportions from 0% to 100%. 200μl of these mixed samples were 
analysed in triplicate by 
2H/H-GSH. The results of 
2H/H were shown as parts per 
mill against reference gas. This calibration curve gave a linear regression with r
2 of 
0.9892 and a Y intercept of 1669 ± 1042. The calibration curve is shown at Figure 
2.26, and the chromatogram of 100% deuterated RBC is shown in Figure 2.24 
above. 
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Figure 2.26  Calibration curve of d2-GSH in deuterated RBC   75 
corresponds to an enrichment on the two labelled hydrogen atoms of 28.8% x 0.025 
= 0.72%. An acceptable linear regression was obtained with an r
2 value of 0.965 
and a Y intercept of 885.5 ± 235.5 (Figure 2.25). The chromatogram of 2.5% of 
deuterium RBC is shown at Figure 2.28. 
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Figure 2.27  Calibration curve of 0% to 20% of d2-GSH in deuterated 
RBC   76 
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Figure 2.28 Chromatogram of 2.5% of D2-RBC in control RBC   77 
2.4.10    Stability test 
The stability of the derivatives was tested as follows. Standards of glycine 
and GSH, and control and deuterated RBC were derivatised at the same time, and 
split  into  three  aliquots.  One  was  analysed  immediately,  another  kept  at  room 
temperature for 10 days, and the other kept at 4°C for 10 days. The results were 
compared between storage these three injections. 
 
2.4.10.1  Glycine stability 
Using  150  μl  of  10  mM  glycine  standard,  after  derivatization  step  the 
glycine sample was re-suspended with 300μl of ethyl acetate and 100μl aliquot into 
3 vials. The result of glycine stability showed no significant difference between the 
sample of  day 0 and day 10,  even between in room temperature and  4°C (see 
Figure 2.29). 
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Figure 2.29  Standard glycine stability   78 
 
2.4.10.2  GSH stability 
Using 200 μl of 10 mM GSH standard, after derivatization step the GSH 
sample was re-suspended with 300 μl of ethyl acetate and 100 μl aliquot into 3 
vials. The result of GSH stability showed also no significant difference between the 
sample of day 0 and day 10,  even between in room temperature and  4°C (see 
Figure 2.30). 
 
2.4.10.3  RBC stability 
Using 200 μl of control RBC, after protein precipitation and derivatization 
the RBC sample was re-suspended with 300μl of ethyl acetate and 100 μl aliquot to 
3 vials. Glycine in RBC showed stability over the three samples (see Figure 2.31). 
However, there was a slight alteration in GSH after being kept at 4°C for 10 days. 
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Figure 2.30  Standard GSH stability   79 
 
 
 
2.4.10.4  Deuterated RBC stability 
Using  150μl  of  deuterated  RBC,  after  protein  precipitation  and 
derivatization, the deuterated RBC sample was  re-suspended in 300 μl of ethyl 
acetate and 100 μl aliquot into 3 vials. Glycine in deuterated RBC showed stability 
over the three samples (see Figure 2.32). However, GSH in the deuterated RBC 
showed a change in enrichment, both when kept at room temperature for 10 days, 
and when stored at 4°C, but the change in enrichment at 4°C was less than that at 
room temperature (see Figure 2.33). 
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Figure 2.31  RBC stability. Samples were analysed in duplicate at 
each time point, error bars are SEM   80 
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Figure 2.32  Glycine stability in deuterated RBC 
GSH in d-RBC
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Figure 2.33  GSH stability in deuterated RBC   81 
2.5   Discussion 
 
GC-C/TC-IRMS is in some ways similar to GC-MS but is up to a hundred 
times  more  sensitive  to  isotopic  differences  than  GC-MS  (Meier-Augenstein 
1999b), although it has a lower analytical sensitivity. However, GC-IRMS cannot 
be  used  for  identification  of  unknown  compounds  because  only  CO2 or  H2 are 
measured and all structural information is lost. Therefore, a combination of GC-MS 
and  GC-IRMS  can  be  important  when  it  is  necessary  to  analyse  unknown 
compounds. In that case, it is necessary to use the same column in GC-IRMS as 
GC-MS. The step of sample derivatization is also important to use both machines. 
GC-IRMS can be suitable for compound specific isotope analysis (CSIA), but the 
silylated and fluorinated derivatives which are often used in GC-MS may cause 
damage to the IRMS. 
A  new  derivatization  method  using  n-propyl  chloroformate  and 
methanolic hydrochloric acid has been developed in this study. This method was 
able  to  be  used  successfully  for  both  GSH  and  glycine.  GSH  is  a  tripeptide 
synthesized from the precursor amino acids,  cysteine, glutamate and glycine. It 
might be more difficult to make GSH derivative than to make derivatives of single 
amino  acid  such  as  glycine  and  glutamate.  The  derivative  of  GSH  should  be 
compatible for using both GC-MS and GC-IRMS. Moreover, it is desirable that 
derivatization is simple and straightforward, and yields stable derivatives. The new 
derivatization method which I developed is based on chloroformates. For analysis 
of  amino  acids  by  chloroformates,  several  derivatization  methods  had  been 
established; there are mainly four methods, acetyl/methylation, ethylchloroformates   82 
(ECF),  n-pivaloyl  and  o-isopropylates  (NPP),  and  n-acetyl  and  o-propylates 
(Capitan et al. 1999;Husek 1998;Metges & Petzke 1997;Metges et al. 1996;Wolfe 
1992). Some groups had also analysed GSH as well as other amino acids for using 
GC-MS (Capitan et al. 1999;Kataoka et al. 1995). I was especially interesting in 
using chloroformate as the derivative of GSH. 
The use of alkyl chloroformates (Husek 1998) as derivatization agents is 
attractive for GSH and related peptides as the amino and sulphydryl functions are 
simultaneously derivatised in aqueous solution, allowing subsequent alkylation of 
the carboxylic acid groups (Capitan et al. 1999;Kataoka et al. 1995;Takagi et al. 
1996). Capitan et al. used ethyl chloroformate (ECF) and methanolic hydrochloric 
acid, in two steps. Firstly, sulfhydryl groups (-SH) and amine groups (-NH2) of 
GSH or an amino acid were esterified with ECF, and then methanolic hydrochloric 
acid  reacted  with  the  carboxylic  acid  group.  I  had  difficulty  obtaining  reliable 
derivatization  using  this  method  and  therefore  explored  the  derivatization  of 
glycine and  GSH  using a range of different  alkyl  chloroformates  and  alcohols. 
However, as GSH is a tripeptide, many of the derivatives generated were difficult 
to  elute  from  a  GC  column.  Use  of  n-propyl  chloroformate  and  methanolic 
hydrochloric  acid  to  generate  the  N,S-n-propoxycarbonyl  methyl  ester  of  GSH 
allowed chromatographic separation on a 10m column, with the added advantage 
that glycine, which I intended to use as a stable isotopic label for measurement of 
GSH  synthesis,  could  be  derivatised  and  analysed  in  the  same  sample.  The 
derivatives  from  chloroformate  are  more  polar  than  other  derivatives  such  as 
trimethylsilylates  (TMS).  Polar  GC  columns  tend  not  to  be  used  at  high 
temperature  because  the  stationary  phase  decomposes.  However,  a  moderately   83 
polar column can be used at high temperature. I used a ZB-50 column, which is the 
highest polarity phenyl phase available (50% Phenyl 50% Dimethylpolysiloxane) 
and is reported by the manufacturers to be stable to 320ºC (isothermal) or 340ºC 
for short periods or grandients. It was necessary to operate the column to 320ºC to 
elute the GSH derivative. The column was reasonable stable under these conditions, 
but even so required changing every few months. 
Moreover, it was necessary to analyse stable isotope labelled GSH and 
glycine as one of precursor amino acids of GSH at once, if possible. An advantage 
of using n-propylchroloformate and methanolic hydrochloric acid is that it allowed 
analysis of glycine and GSH in a single chromatogram. This is especially important 
in hydrogen mode GC-TC-IRMS, where it was necessary to inject in excess of 10μl 
of derivatised sample in order to be able to detect GSH. Thus, detection of both 
glycine and GSH in a single injection enabled samples to be analysed by duplicate 
injections.  This  derivatization  method  can  potentially  be  used  for  many  other 
amino acids and dipeptides as well as single amino acids. The column can be used 
for both GC-MS and GC-IRMS and also the derivatised sample can be analysed by 
both machines.  
In order to able to calculate the dilution of the labels within the glycine 
and  GSH  derivatives,  it  was  important  to  characterise  the  structure  of  each 
derivative by GC-MS. The GSH derivative showed characteristic fragments of m/z 
230 and 391, and glycine derivatives also showed m/z 116. Although the molecular 
ion could be detected for the glycine derivative (m/z = 175), the GSH derivative 
was fragmented very easily and its molecular ion (m/z = 507) could not be detected. 
Glycine and GSH derivative were identified by the retention time and characteristic   84 
fragmentation in GC-MS. My initial aim was to identify a suitable internal standard 
that could  be used in  GC-IRMS, which  would have allowed calculation  of the 
amount of GSH as well as enrichment. I tested several other di- and tri-peptides for 
potential  use  as  internal  standard.  In  particular,  γ-glutamyl  glutamate  and 
homoglutathione  (γ-Glu-Cys-β-Ala)  were  tested.  However,  none  of  the  tested 
compounds  were  clearly  separated  from  other  interfering  peaks  in  GC-IRMS 
analysis, so I was unable to identify a suitable internal standard. 
For analysis of biological samples, it is necessary to reduce oxidised GSH 
(GSSG) to GSH. I chose tris-(2-carboxyethyl)-phosphine (TCEP) for reduction of 
disulfide,  although  dithiotreitol  (DTT)  is  commonly  used  for  reduction  of  thiol 
compounds.  When  I  compared  DTT  with  TCEP  to  blood  samples  in  this 
derivatization  method,  TCEP  treated  samples  gave  fewer  interfering  peaks  and 
noise than DTT (Anderson et al. 1999). It may because of the structure of TCEP 
chemical,  which  has  a  carboxyethyl  group.  The  carboxylation  of  GSH  by 
propylchroloformate was less affected from TCEP than DTT. TCEP can be a good 
reductant over a relatively wide range of pH (2 ~ 11), and thus will continue to 
reduce  thiol  groups  during  the  subsequent  steps,  in  which  the  sample  is  first 
acidified  and  then  made  alkaline,  and  then  re-acidified.  Thiol  group  of  DTT 
changes disulfide-bridge into circled chemical structure per se when DTT reduces 
other thiol compounds. In comparison, TCEP does not contain thiol group and also 
non-volatile. 
 
After establishing the temperature gradient and the derivatization method, 
I started to analyse 
13C-glycine, (glycine-
13C,
15N)-GSH (because glycine-
13C-GSH   85 
is  not  commercially  available),  and 
13C/
12C-glycine  and  GSH  in  RBC  by  GC-
Combustion-IRMS.  Calibration  curves  for 
13C-GSH  were  generated  and  were 
linear. Before I continued to analysis of 
2H/
1H in samples, I needed to analyse 
2H-
glycine-GSH. As this is not commercially available, I generated deuterated GSH 
from human blood in vitro. I found that when glycine, cysteine or glutamate were 
added to RBC collected in a Li-Heparin tube, the peak area of the GSH derivative 
increased, whereas when the RBC was collected in an EDTA tube, there was no 
change in peak area. I concluded that the enzymes of GSH synthesis are active in 
heparinised blood, but their activity can be stopped by EDTA. Thus, I used the 
method of heparinised blood incubated with 
2H-glycine, followed by stopping the 
reaction  with  5mM  EDTA,  for  generation  of 
2H-GSH  in  vitro.  Stopping  the 
reaction with EDTA is important otherwise the isotopic enrichment of GSH would 
have changed over time as the enzymes would still have been active. Analysis of in 
vitro generated 
2H-GSH showed that approximately 29% of the glycine moieties in 
GSH had been replaced by 
2H2-glycine, and thus the in vitro generated
 2H-GSH 
could be used to create a calibration curve of deuterated GSH in RBC. As 
2H/
1H 
compound  specific  isotopic  analysis  is  inherently  less  sensitive  than 
13C/
12C 
analysis (Sessions 2006), in order to increase the amount of analyte on column, it 
was  necessary  to  use  large  volume  injection  via  a  programmable  temperature 
vaporization (PTV) inlet. Using this method, it was possible to make duplicate 
injections of 11.25μl from the same sample, which allowed measurement of 
2H/
1H 
enrichment of glycine and GSH in a single chromatogram.  
Calibration curves were made by mixing deuterated with non-deuterated 
RBC in various proportions. The calibration curve was acceptable, with r
2=0.965,   86 
p<0.001. The relatively poor correlation coefficient may be due to the fact that 
programmable temperature vaporization with solvent venting is less reproducible 
than other GC injection techniques. Incomplete transfer of GSH during heating of 
the inlet from 37 to 300°C could introduce a variable fractionation. In addition, the 
chromatographic peak height for GSH sometimes fell below 1000mV, thus leading 
to inaccurate quantification of 
2H/
1H of GSH (the amplifiers of the IRMS are most 
linear in response between 1000mV and 10,000mV). Thus the method is acceptable 
for studies of enriched samples, where the fractional synthesis rate is calculated 
from the slope of the enrichment over time, but is not yet suitable for studies close 
to,  or  at,  natural  abundance  of 
2H/
1H,  or  where  an  absolute  measurement  of 
enrichment relative to VSMOW (Vienna Standard Mean Ocean Water) is required. 
In terms of stability of the new developed derivatization, chloroformate-
mediated derivatives are relatively stable (Husek 1998;Montigon et al. 2001), but 
the derivative samples would be normally analysed as soon as possible, or at least 
within 24h on an autosampler sequence. However, IRMS machines are frequently 
temperamental, so that after preparing a batch of samples for analysis, it is not 
always  possible  to  analyse  them  immediately  until  the  machine  problems  were 
solved. In order to determine whether samples that were stored could be reliably 
analysed  later,  I  carried  out  a  preliminary  assessment  of  sample  stability.  The 
results suggested that standards of both glycine and GSH, and RBC sample were 
reasonably stable, although RBC samples appeared to be less stable than standards, 
especially if kept at room temperature. Therefore, if there was a delay between 
derivatization and analysis, I stored samples at 4°C and tried to analyse as soon as   87 
possible, although the stability results suggested that the derivatives could be stable 
for a week, even at room temperature.   
Since I carried out the practical work appearing in this thesis, two further 
papers measuring GSH synthesis using labelled glycine have been published. Tea 
et al. described a determination of 
13C isotopic enrichment of GSH and glycine 
using GC-C-IRMS (Tea et al. 2007) They also used GC-MS for analysis of two 
compounds. They used  ethyl  chloroformate (ECF)/methanolic HCl  to  derivatise 
both  GSH  and  glycine,  and  an  apolar  column  (HP-5MS,  5%  phenyl 
polysilphenylene-siloxane) which Capitan group had used (Capitan et al. 1999), In 
my preliminary experiments with ECF-methanolic HCl and an HP-5MS column, 
although glycine gave a clear peak when analysed by GC/MS, GSH did not give a 
clear peak or consistent results. The paper by Tea et al. also shows a poorly-defined 
GSH peak (see Figure 2.34). 
Even  though  derivatization  with  chloroformate  plus  alcohol  blocks  the 
hydroxyl groups, GSH derivatives still retain some polarity due to the secondary 
amine functions (Figure 2.10). Hence, using a more polar column, such as the ZB-
50  column  (50%  phenyl  polysilphenylene-siloxane)  which  I  used,  GSH 
chloroformate-derivatives are eluted more clearly and reproducibly. When the polar 
column was used for analysis of GSH in GC-C-IRMS, both GSH and glycine, as a 
 
Figure 2.34  GSH peak from GC-C-IRMS using HP-5MS column (Tea et al. 2007)   88 
tracee and a tracer, could be analysed in a single chromatographic run because of a 
good peak  separation.  Tea et  al.  also  had good results  for their stability  study, 
confirming my findings that glycine and GSH chloroformate derivatives have good 
stability properties up to 10 days. 
Shierbeek,  et  al.  performed  a  study  of  GSH  kinetics  using  LC-IRMS 
(Schierbeek  et  al.  2007).  LC-IRMS  has  been  recently  developed  and  became 
commercially available in 2004 (Krummen et al. 2004). Shierbeek et al. used LC-
IRMS for analysis of GSH and GSSG in low birth weight infants who were infused 
13C-glycine intravenously for 6 hours. They were able to measure 
13C-enrichment 
of GSH by LC-IRMS without the need for derivatization, and were also able to 
measure GSH concentration by the use of two internal standards. Their method has 
two  disadvantages.  Firstly,  underivatised 
13C-glycine  was  not  clearly  separated 
from other amino acids in their LC-IRMS analysis, so that it was necessary to 
measure 
13C-glycine enrichment independently by GC-C-IRMS. This requirement 
for two separate measurements would increase the amount of sample needed for 
analysis. Secondly, LC-IRMS cannot be used for deuterated tracers, as all HPLC 
solvents contain hydrogen, which would overwhelm the IRMS signal. 
Very  recently,  another  method  for  measuring  GSH  synthesis  using 
deuterated tracers has been described (Cabral et al. 2008). In this method, animals 
are  given  deuterated  water  over  a  period  of  several  days  to  reach  a  target 
enrichment  of  5%  in  water.  Repeated  blood  samples  are  taken,  and  the 
incorporation of deuterium into GSH is measured by LC-MS after derivatisation to 
the  N-ethylmaleimade  derivative  of  GSH.  Analysis  of  the  GSH  synthesis  rate 
depends  on  a  complex  isotopomer  analysis.  Administration  of  deuterated  water   89 
over a period of several days is clearly not easily applicable to patients, although 
the derivatisation and analytical  method could  also  be applied when deuterated 
amino acids are administered. 
The method I have developed in this chapter has the advantages that it can 
be used with either 
13C or 
2H tracers, and that glycine and GSH can be analysed in 
a single sample. In theory, my method could also be used with 
15N- or 
18O- labelled 
amino acids, although I did not test this. It does, however, have the disadvantages 
that (i) I was unable to find a suitable internal standard to allow GSH concentration 
to  be  determined,  (ii)  although  linearity  is  good  at  medium-high  enrichments, 
linearity is not so good at low enrichments so cannot currently be used for analyses 
close to natural abundance, (iii) unlike the method of Shierbeek et al, GSH and 
GSSG cannot both be analysed, (iv) the derivative used adds several carbon and 
hydrogen atoms, thus diluting the enrichment of 
13C or 
2H in the IRMS analysis.  
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2.6   Conclusions 
  GC-C/TC-IRMS is suitable for compound specific isotope analysis (CSIA), 
and the derivatization method which I established is compatible with IRMS and 
does  not  chemically  attack  the  mass  spectrometer  or  the  combustion/high 
temperature conversion interfaces. The newly-developed derivatization method is 
suitable for both chemical standards and physiological samples, is simple and is 
able to derivatise tri-peptides such as GSH as well as single amino acids. Using 
either 
13C-GSH  standard,  or  in  vitro-generated 
2H-GSH,  acceptable  calibration 
curves  were  generated.  Thus, the new method  can be used for  in  vivo studies, 
although  it  has  the  disadvantage  that  GSH  concentration  is  not  simultaneously 
measured. 
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Chapter  3 
 
Measurement of glutathione synthesis 
in septic & non-septic critically ill infants   92 
Chapter 3:___________________________________ 
 
3.1  Introduction 
Despite  recent  advances  in  the  care  of  critically  ill  children,  systemic 
inflammatory response syndrome (SIRS) and sepsis, which cause multiple organ 
dysfunction syndrome (MODS), remain a major source of morbidity and mortality 
(Edited by: Deitch et al. 2002). Systemic inflammatory response syndrome (SIRS), 
sepsis and MODS are major issues in the paediatric intensive care unit (Despond, 
Proulx, Carcillo, & Lacroix 2001). Until now there has been no definitive treatment 
of MODS patients, therefore, control of infections, conventional treatments and 
total  parenteral  nutrition  (TPN)  support  is  necessary.  A  systemic  inflammatory 
response  induces  cytokines,  which  includes  pro-inflammatory  and  anti-
inflammatory mediators, and these activated cytokines also induce production of 
reactive oxygen (ROS) and nitrogen species (RNS). ROS and RNS damage cellular 
structures  and  can  be  a  trigger  of  organ  dysfunction  (Goode,  Cowley,  Walker, 
Howdle, & Webster 1995;Tanjoh, Shima, Aida, Tomita, & Kurosu 1995;Thomas & 
Balasubramanian 2004).  
Antioxidant defences play a key role in critical illness as they can protect 
tissues  and  cells  from  reactive  oxygen  free-radicals  which  are  induced  from 
inflammation. One of the major important antioxidant functions is GSH. GSH, a 
tripeptide, is synthesized de novo within many cells from the precursor amino acids 
cysteine,  glutamate  and  glycine,  and  is  a  major  low  molecular  weight  thiol  in 
mammalian cells (Meister & Anderson 1983). The study of antioxidant defences,   93 
especially GSH, in critically ill paediatric patients can help understanding of the 
involved pathophysiology and potential therapies. When patients are critically ill, 
GSH must be continually synthesised and the oxidised form re-converted to the 
reduced form to protect cells from ROS and RNS.  
 
 
3.2  Aim 
 
The  aim  of  this  study  was  to  measure  erythrocyte  GSH  synthesis,  using 
deuterated  glycine as  a  tracer, in  septic  and non-septic  infants  and  children, to 
determine the GSH synthesis rate in both groups.  
I hypothesised that GSH synthesis rate would be decreased in septic patients 
compared with non-septic patients. 
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3.3  Methods 
 
This study was approved by Great Ormond Street Hospital and Institute of 
Child Health joined ethics committee.  
 
3.3.1  Study groups 
All patients in this study were in neonatal and paediatric intensive care 
units (NICU and PICU). There were two groups, one group with evidence of sepsis 
and the other group (control) was in the ICU but had no evidence of infection or 
inflammation at the time of the study. Patients were defined as septic on the basis 
of a clinical diagnosis based on two or more of the following conditions being 
present: (1) Hyperthermia (> 38
°C) and/ or hypothermia (< 36
°C); (2) Age-related 
tachycardia (Heart rate higher than the normal range for age: beats/min); (3) Age-
related  tachypnoea  (Respiratory  rate  higher  than  the  normal  range  for  age: 
breaths/min); (4) White blood-cell count (x 10
9 cells/l) higher or lower than the 
normal range for age; (5) Platelet count less than 150 x 10
9 cells/l. (American & 
Society 1992;Turi et al. 2001) 
Infants and children requiring ventilation for airway management but with 
no clinical signs of sepsis were used as controls as there is no reason to suspect that 
they  might  have  a  reduced  rate  of  GSH  synthesis.  (Table  3.1  shows  clinical 
characteristics of patients in this study.)   95 
Table 3.1 Clinical characteristics of patients 
PRVC: pressure regulated volume control; SIMV: Synchronized Intermittent Mandatory Ventilation; HFOV: high frequency oscillatory 
ventilatio
 
Age  at  study 
(months)  Gender  Weight 
(kg)  Clinical Diagnosis  Nutrition  Ventilation 
Control   1  M  4.2  Head injury  saline/dextrose  PRVC 
  6  M  5  Stable post-surgery  saline/dextrose  Pressure support 
  8  M  7  Subglottic stenosis  saline/dextrose  SIMV 
  8  M  4.5  Subglottic stenosis  100% EN (formula)  CPAP 
  9  F  7  Stable post-surgery  80% PN, 20% EN  Y 
  11  F  10  Seizures  saline/dextrose  SIMV-extubated 
  15  F  8  Stable post-surgery  saline/dextrose  SIMV 
  20  M  12  Head injury  EN/saline/dextrose  PRVC 
  23  M  14  Head injury  EN  PRVC 
  32  M  12  Stable post-surgery  saline/dextrose  Y 
  73  M  20  Head injury  EN/saline  Y 
  108  M  25  Head injury  EN  Y 
  108  M  43  Asthma  saline/dextrose  Y 
Sepsis  0.25  F  3  Bilateral pneumonia  EN  HFOV 
  1  M  5  Meningitis/ Enterovirus encephalitis  EN  SIMV 
  2  M  5  Bronchiolitis  EN  SIMV 
  4  M  5.3  Bronchiolitis  EN  Y 
  5  M  6.5  Septicaemia  saline/dextrose  SIMV 
  6  M  6  RSV Bronchiolitis and pulmonary pseudomonas  TPN/EN  PRVC 
  7  F  7.3  RSV Bronchiolitis   EN  SIMV 
  11  F  10  Meningitis   saline/dextrose  PRVC 
  18  M  11  Epiglotitis  EN  Y 
  51  M  16  Asthmatic exacerbation with suspected sepsis  EN  Mask O2 
  99  M  33  Severe chest infection  EN  PRVC   96 
 
3.3.2  Infusion and sampling protocol 
Administrated  d2-glycine was sterile and pyrogen-free, and prepared to 
pack  in  ampoules  by  Department  of  Pharmacy  at  Northwick  Park  Hospital  in 
Harrow and Department of Pharmacy at Royal Victoria Infirmary in Newcastle. 
D2-glycine infusion was intravenously given at 15 μmol/kg/h after a priming dose 
of 15 μmol/kg to all patients. All patients were given d2-glycine for 8 hours. 0.2 - 1 
ml of blood samples were taken into EDTA tubes from at baseline and then both of 
groups every 2 hours until 8 hours. Blood samples were centrifuged and separated 
erythrocyte was kept at -80°C until analysis.    
 
 
3.3.3  Sample preparation, derivatization and analysis 
Glycine  analysis  in  preliminary  study  using  GC-MS  was  used 
heptafluorobutyric anhydride (HFBTA) for derivatization; 300 μl of H2O and 600 
μl of 1M perchloric acid (PCA) was added into 100 μl of erythrocytes, and mixed 
vigorously.  The  mixed  sample  was  centrifuged  at  13000  rpm  for  15  min. 
Supernatant added through AG-50W-X8 column H
+ form. Pellet was washed with 
400 μl of H2O and 600 μl of 1M PCA, and the supernatant was also added through 
the column. The column was washed by 2 ml acetic acid and 6 ml of water until 
elution was pH >4. The retaining sample was eluted with 3 ml of 30% ammonia 
water (NH4OH), and the eluted sample was evaporated to dryness under N2. 0.5 ml 
of esterification agent (freshly mixed by propanol:acetyl chloride = 5:1) was added 
and heated for 1h at 110
°C. Excess agent was evaporated under N2, and 100 μl of   97 
HFBTA was added and heated at 60
°C for 20 min. Excess derivatization agent was 
dried  under  N2.  200  μl  of  ethylacetate  was  added  to  the  dry  sample  and  well 
resolved, and the sample was transferred to an autosampler vial. 2 μl of injection 
volume was on split/splitless injector in splitless mode, and initial temperature of 
injector was at 200
°C. GC-MS temperature was from 80
°C to 280
°C at the rate of 
10
°C/min  and  helium  flow  rate  was  2  ml/min.  HP-5MS  column  (Agilent 
Technologies) was used. Samples were monitored in selected ion monitoring (SIM) 
mode for the derivative of glycine (272 for unlabelled and 274 for d2-labelled). 
50  μl  of  erythrocytes  form  each  sample  was  reduced,  derivatised  and 
analysed as described in section 2.3.7. Duplicate injections were made from each 
sample. 
 
 
3.3.4  Data analysis 
2H/
1H-glycine and 
2H/
1H-GSH in RBC patient samples were analysed by 
GC-TC-IRMS.  The atom  percent  excess  (APE) of  both  glycine and GSH were 
calculated using the baseline, RBC sample as time zero (to).  
Using the following formula: 
 
Where rta is observed 
2H/
1H at time a. (Wolfe 1992) 
 
 
APE = 100 x 
(rta – rt0) 
(rta – rt0 + 1)    98 
The fractional synthesis rate (FSR) of GSH was calculated from the steady 
state enrichment of glycine and the rate of increase of GSH enrichment in both 
groups. The FSR (%/h) of GSH was calculated following formula:  
Glyss = APE of glycine of steady state from 4 to 8 hr. 
 
The FSR of GSH between groups was also statistically analysed by Student 
t-test.  Values  were  means  ±  SE.  The  calculated  method  of  FSR  was  based  on 
(Wolfe 1992;Wolfe & Chinkes 2004).  
 
3.3.5  Statistics 
Data were compared by t-tests (two samples), one-way ANOVA (more than 
two samples) or by linear regression analysis. p<0.05 was regarded as significant.
  (GSHAPE t8 – GSHAPE t4) 
Glyss  x 4h 
FSR (%/h) of GSH = 100 x 
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3.4   Results 
 
3.4.1  Preliminary study 
In a preliminary study to determine whether plasma glycine enrichment 
and erythrocyte glycine enrichment are equivalent, a healthy adult male volunteer 
was infused with deuterated glycine for 6 hours. Blood samples were separated to 
plasma and erythrocytes immediately, and then both  samples  were analysed by 
GC-MS.  
 
The result showed that the enrichment of deuterated glycine in plasma was 
higher  than  in  erythrocytes.  Therefore,  in  order  to  calculate  the  erythrocyte 
synthesis rate of GSH, it is necessary to measure erythrocyte glycine enrichment, 
0 1 2 3 4 5 6 7
0.000
0.025
0.050
0.075
0.100
Time of infusion (hours)
D
2
-
G
l
y
/
G
l
y
 
r
a
t
i
o
 
 
Figure 3.1  The ratio of d2-glycine to glycine in plasma and erythrocyte 
The dotted line (□) is plasma and the straight line (▲) is erythrocytes.   100 
as this is the true precursor for erythrocyte GSH synthesis and is lower than the 
enrichment in plasma (Figure 3.1). Therefore, in all further experiments, I analysed 
only erythrocyte glycine enrichment. 
 
 
3.4.2  A sample graph of enrichment of glycine and GSH 
One  septic  patient  sample  showed  a  typical  graph  of  enrichment  of 
erythrocyte both glycine and GSH by GC-TC-IRMS analysis. On the figure 3.2, the 
glycine enrichment achieved steady state at 4 to 8 hours, and the GSH enrichment 
was linearly increased during the steady state of glycine at 4 to 8 hours.  
Calculation of APE of glycine and GSH, and FSR of GSH was described 
using this septic patient; APE of glycine and GSH was calculated from the baseline 
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Figure 3.2  A sample graph of enrichment of both glycine and GSH of a septic 
patient   101 
at time 0 to each time point. For example, glycine and GSH APE at time 4 h was 
calculated the following formula.  
Glycine APE (at time 4h)  
= 100 x (0.0008069t4 – 0.0002090t0) / (0.0008069t4 – 0.0002090t0 + 1)  
GSH APE (at time 4h)  
= 100 x (0.0002326t4 – 0.0001947t0) / (0.0002326t4 – 0.0001947t0 + 1) 
During glycine steady state of 4 to 8 hours, GSH FSR was calculated from glycine 
and GSH APE at time 4 h and 8 h. 
GSH FSR (%/h)  
= 100 x (0.009369GSHt8 – 0.003795GSHt4) / (0.06119 x 4h) 
Glyss: 0.06119 = (0.062621Glyt8 + 0.059759Glyt4) / 2 
GSH FSR = 2.28 %/h: This is GSH FSR of this septic patient. 
 
 
3.4.3  Glycine enrichment between control and septic group 
Glycine enrichment in erythrocytes increased to steady state in both septic 
and control patients. Between 4 and 8 hours, There was no significant difference in 
glycine enrichment in either group. There was no significant difference between 
control and septic patients at any time point. These data are shown as enrichment 
(see Figure 3.3) and as atom percent excess (APE) (see Figure 3.4).    102 
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Figure 3.3  Glycine enrichment of control and septic group for 8 hours 
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Figure 3.4  Glycine APE in two groups for 8 hours: The dotted line is 
septic group and the straight line is control.   103 
3.4.4  GSH enrichment between control and septic group 
 
  During steady state of glycine enrichment at 4 to 8 hours, there was a 
linear increase in GSH enrichment in both control and sepsis, but there was a big 
variation of GSH enrichment in septic group. Although the septic group showed a 
higher  enrichment,  there  was,  however,  no  statistically  significant  difference 
between control and septic patients at any time point. The results are shown in 
figure 3.5 as enrichment, and in figure 3.6 as APE. 
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Figure 3.5  GSH enrichment of control and septic group for 8 hours: The 
dotted line is septic group and the straight line is control.   104 
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Figure 3.6  GSH APE for 8 hours in two groups: The dotted line is septic 
group and the straight line is control.   105 
3.4.5  The FSR of GSH between control and septic group 
 
  The FSR (%/h) of GSH was calculated from APE of both glycine and 
GSH during steady state of glycine enrichment. The FSR of GSH in control group 
was higher than septic group, but this difference was not significant. The FSR of 
GSH in control group was 1.096 ± 1.173 %/h and the FSR of GSH in septic group 
was 0.246 ± 0.618 %/h (see Figure 3.7). There was, however, a very wide variation 
in FSR in each group.  
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Figure 3.7  The FSR (%/h) of GSH between control and septic group: 
The blank column is control and the cross line column is septic group.   106 
3.5  Discussion 
 
In the study of GSH synthesis in critically ill patients, I used the method of 
GC-TC-IRMS analysis which I had developed. Using this method, it was possible 
use a single 50 μl erythrocyte sample for measurement of 
2H/
1H enrichment of both 
glycine and GSH. This was an important consideration for performing in vivo GSH 
synthesis studies in infants, where blood samples must be as small a volume as 
practical. Erythrocyte GSH was analysed in this study, rather than plasma, because 
erythrocyte GSH is a much bigger GSH pool than plasma (Meister & Anderson 
1983), and has been thought of as representative of other tissues (Humbert et al.  
2001;Lyons et al. 2001;Reid et al. 2000). 
  The  enrichment  of  deuterated  glycine  in  plasma  was  higher  than  in 
erythrocytes. Therefore, in order to calculate the erythrocyte synthesis rate of GSH, 
it  is  necessary  to  measure  erythrocyte  glycine  enrichment,  as  this  is  the  true 
precursor  for  erythrocyte  GSH  synthesis  and  is  lower  than  the  enrichment  in 
plasma. Enrichments of both erythrocyte glycine and GSH were measured in this 
study.  Lyons,  et  al.  commented  that  the  enrichment  of  the  “true”  intercellular 
precursor pool is correspondingly lower than that which can be determined from 
the apparent cysteine plateau (Lyons et al. 2000). My preliminary study showed 
that the erythrocyte enrichment was lower than plasma. When erythrocyte GSH 
synthesis  rate  from  a  precursor  amino  acid  would  be  calculated,  erythrocytes 
precursor enrichment must be measured.  
The GSH enrichment between both groups was not significantly different, 
although the GSH enrichment of the septic group was higher than control group.   107 
The APE of GSH in septic group seemed to show a delayed response compared to 
the control group. During steady state of glycine, the GSH APE in control group 
showed a linear increase, whereas GSH APE in the septic group started to increase 
only after 6 hours. The wide variation in the GSH FSR in the septic group suggests 
that GSH re-synthesis might be subject to other variables, such as ventilation or 
inotropic support, or whether patients have acute sepsis or are in the recovery phase. 
Interestingly,  in  children  with  severe  protein-energy  malnutrition,  concentration 
and  fractional  synthesis  rate  (FSR)  of  erythrocyte  GSH  was  different  between 
groups of each stage (admission: Study 1, postadmission: Study 2 and recovery: 
tudy 3, see Figure 3.8) (Reid et al. 2000).  
The fractional synthesis rate (FSR) of GSH between the two groups was 
not significantly different, although the FSR of the control group was higher than 
the  septic  group.  Although  11  septic  patients  and  13  non-septic  patients  were 
analysed  in  this  study,  a  larger  study  group  may  have  shown  a  significant 
difference.  
 
 
 
   108 
Using 
13C-cysteine,  Lyons,  et  al.  showed  that  septic  children  have  a 
significantly lower FSR of GSH than control (see Figure 3.9) (Lyons et al. 2001).  
As well as the fact that Lyons, et al. used 
13C-cysteine as a tracer, there are 
other differences between their study and mine. Firstly, whole blood measurement 
 
Figure 3.8 from Reid, et al.: Erythrocyte GSH concentration. †P < 0.05 vs. Study 2, 
#P < 0.01 vs. Study 3 and *P < 0.01 oedematous vs. non-oedematous. 
 
Figure 3.9 from Lyons, et al., 2001: Whole blood glutathione fractional synthesis 
rate (day
-1) in septic patients and control (*p < 0.02)    109 
of cysteine and GSH enrichment were made in their study. This may give incorrect 
estimates  of  FSR,  as  the  true  precursor  for  erythrocytes  GSH  synthesis  is 
intracellular cysteine, which may have a different enrichment from plasma cysteine 
as was measured in their study (Lyons et al. 2001). Indeed, the authors comment on 
this in a previous paper (Lyons et al. 2000). Secondly, the clinical status of the 
patients may have been different between the two studies: in Lyons et al., many of 
the patients were in septic shock, whereas in my study, they  were more stable. 
Additionally, the control group were different, as Lyons et al. studied apparently 
healthy patients admitted for elective procedures, whereas in my study, patients 
were critically ill but with no evidence of inflammation (Lyons et al. 2001). These 
differences could also have contributed to the differences between our results and 
theirs. 
There was  no significant  difference in  glycine  enrichment  between the 
control and septic groups.  The APE of glycine was also not different between the 
two groups. This could suggest that glycine turnover of erythrocytes in both groups 
as a probe of GSH synthesis is independent of sepsis. The control group in this 
study was not septic, but did consist of critically ill infants and children. The uptake 
of glycine into erythrocytes might be also depend on the stage of sepsis. Glycine is 
one of precursor amino acids of GSH, however it is not though to be the rate-
limited factor as much as cysteine in the pathway of GSH synthesis (Griffith & 
Meister 1979).   
Although ideally, a healthy control group should have been studied, it was 
not  possible  to  submit  healthy  age-matched  children  to  an  infusion  protocol, 
cannulation and multiple blood sampling.  A non-inflammatory control group was   110 
therefore studied. Although this group can be criticised as they were also receiving 
intensive  care,  they  were  not  in  an  inflammatory  state,  as  evidenced  by  the 
significantly lower cytokine profile in the control group (Figure 3.10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Pro- and anti- inflammatory cytokine profile of control and septic 
patients from the current study  (Data of Mr Moti Chowdhury) 
 
Unfortunately,  absolute  synthesis  rate  (ASR)  of  GSH  could  not  be 
measured  in  my  study  as  there  was  insufficient  volume  of  erythrocytes  for  a 
separate  measurement  of  GSH  concentration,  and  I  had  been  unable  to  find  a 
suitable  internal  standard  for  GC-IRMS  to  allow  measurement  of  GSH 
concentration as well as enrichment. 
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3.6  Conclusion 
 
GSH synthesis, as fractional synthesis rate, in septic children was lower 
but not significantly so, compared to non-septic critically ill children. However, the 
results in each group showed very wide variability, suggesting that the septic and 
control groups may not have been homogeneous in terms of GSH synthesis. It is 
possible that a study either on more homogeneous patient groups, or on a lager 
number of patients, may have shown a difference.   112 
 
 
 
 
Chapter  4 
 
Effect of glutamine infusion on 
erythrocyte glutathione synthesis in 
septic infants and children 
   113 
Chapter4:___________________________________ 
 
4.1  Introduction 
  Glutamine is the most abundant amino acid in the body (Neu et al. 2002). 
It is particularly important in cells of the immune system (Ardawi & Newsholme 
1990;Newsholme 2001) and in enterocytes (Kimura 1996). In some cell types, such 
as  erythrocytes,  extracellular  glutamine  is  used  as  a  source  of  glutamate,  as 
glutamate  uptake  by  human  erythrocytes  is  extremely  low  and  inadequate  to 
maintain  erythrocyte  GSH  levels  (Ellory  et  al.  1983).  The  major  source  of 
glutamate for GSH synthesis by erythrocytes is thought to be glutamine (Ellory et 
al. 1983), taken up largely by the Na
+-dependent system N.  
  Although  glutamine  is  a  non-essential  amino  acid,  the  nutritional 
requirement for this amino acid in catabolic illness may differ greatly from normal 
healthy condition (Neu et al. 2002). During starvation or stress, the concentration 
of free glutamine in the intracellular amino acid pool of skeletal muscle rapidly 
decrease (Roth 2007). Thus, some people consider glutamine to be a “conditionally 
essential” amino acid during sepsis, trauma or after surgery. Historically, glutamine 
has not been included in parenteral nutrition, firstly because it was thought to be 
non-essential, and secondly because glutamine is not stable in aqueous solution and 
changes the formation to pyroglutamic acid and ammonia during heat sterilisation. 
In  addition,  glutamine  is  not  very  water  soluble  so  a  large  infusion  volume  is 
needed.  Recently,  however,  glutamine  containing  dipeptides,  such  as  alanyl-
glutamine, have become available, which have the advantages that they are much   114 
more water soluble than free glutamine, and can be heat sterilised and thus are 
stable when added to parenteral nutrition (Furst et al. 1997).  
  As  GSH  is  very  important  during  oxidative  stress,  it  is  possible  that 
glutamine supply for GSH synthesis also becomes very important during oxidative 
stress. Thus, provision of glutamine can maintain intracellular GSH levels in vitro 
(Babu et al. 2001) and in several in vivo studies where oxidative stress and/or GSH 
depletion takes place (Denno et al. 1996;Flaring  et al. 2003;Hong et al. 1992). 
Glutamine  supplemented  total  parenteral  nutrition  (TPN)  has  been  shown  to 
prevent intestinal atrophy and necrosis in critically ill adult patients (Jian et al. 
1999),  and  to  improve  gut  immune  function  in  animal  models  (Calder  1994). 
Studies have also shown the clinical benefits of glutamine supplemented TPN in 
adult  patients  undergoing  bone  marrow  transplantation  (Furst  &  Stehle 
1993;Schloerb & Amare 1993;Young et al. 1993;Ziegler et al. 1992).  
Although it is classified as a “non-essential” amino acid, in states of critical 
illness  or  trauma  it  has  been  described  as  by  some  authors  as  “conditionally 
essential”  (Lacey & Wilmore 1990), and it  has even been described as “a life 
saving nutrient” in critically ill patients (Preiser & Wernerman 2003). However, 
critically  ill  patients  do  not  routinely  receive  glutamine,  and  although  there  is 
evidence that glutamine supplementation may be beneficial during critical illness, 
there is also evidence that glutamine may have no effect. 
Glutamine  is  able  to  participate  in  many  biological  activities  which  are 
crucial  to  maintenance  of  homeostasis  during  critical  illness:  scavenging  of 
ammonia, acid-base regulation, nitrogen transport between tissues and organs, as a 
fuel and nucleic acid precursor for rapidly dividing cells such as enterocytes and   115 
cells of the immune system, and as a precursor for GSH. Proliferating cells, such as 
enterocytes and cells of the immune system, which are particularly important in 
critical illness, require a continual supply of purines and pyrimidines, dependent on 
glutamine,  for  DNA  and  RNA  synthesis.  Supply  of  amino  sugars  for  mucin 
synthesis, together with other components of the extracellular matrix, also seems to 
be crucially dependent on glutamine for maintenance of intestinal integrity (Khan 
et al. 1999;Panigrahi et al. 1997). Oxidation of glutamine as a fuel is thought to be 
particularly important for enterocytes (Kimura 1987;Windmueller & Spaeth 1974), 
and glutamine can also be used as a respiratory substrate by cells of the immune 
system, although the rate of glutamine oxidation is low compared to the total rate 
of glutamine utilisation (Newsholme et al. 2003). Although, circulating glutamine 
levels  decrease  during  critical  illness,  it  is  not  known  whether  this  is  due  to 
increased  oxidation  of  glutamine  as  a  fuel,  or  due  to  increased  utilisation  of 
glutamine in other pathways.  There is very little information available on whether 
critical illness increases the utilization of glutamine as a fuel. 
Heat shock proteins (HSPs) are essential to cellular survival under a variety 
of  conditions  not  limited  to  heat  shock.  There  are  many  different  heat  shock 
proteins  with  differing  functions  and  subcellular  localisation,  but  HSP70  is  of 
particular interest both during critical illness and glutamine supplementation. HSPs 
frequently  act  as  chaperones,  protecting  misfolded  proteins  from  degradation. 
During  critical  illness,  HSP70 expression is  impaired in  a variety of  cell types 
(Durand et al. 2000;Schroeder et al. 1999;Weingartmann et al. 1999) and serum 
levels are lower in those patients who do not survive trauma, suggesting that the 
ability to up-regulate HSP70 is associated with improved ability to withstand stress   116 
(Pittet et al. 2002). Interestingly, in vitro and animal studies (reviewed in (Roth 
2008)) have suggested that glutamine increases HSP70 expression, and it has been 
shown  that  parenteral  glutamine  enhances  plasma  HSP70  levels  in  critically  ill 
patients  (Ziegler  et  al.  2005).  In  this  study,  the  increases  in  HSP70  inversely 
correlated with length of ICU stay. It has been suggested that increased HSP70 
expression  by  glutamine  renders  monocytes  better  able  to  withstand  high 
temperatures induced by fever (Pollheimer et al. 2005). 
  Glutamine  can  potentially  act  as  a  gluconeogenic  substrate,  so  it  is 
important  to  know,  in  the  era  of  tight  glucose  control  in  the  ICU,  whether 
glutamine supplementation is likely to cause hyperglycaemia or worsen glucose 
control.  In  fact,  the  available  evidence  suggests  that  the  converse  is  true;  i.e. 
incidence of hyperglycaemia and insulin requirement are decreased by glutamine in 
critically-ill patients (Dechelotte et al. 2006), and insulin sensitivity is improved in 
multiple trauma patients (Bakalar et al. 2006).  
  Glutamine  has  a  great  number  of  effects  within  the  immune  system. 
Although many of these are directly related to metabolism and proliferation of cells 
of the immune system, glutamine also appears to directly influence cell signalling 
and cytokine production. Of particular interest is the ability of glutamine to affect 
expression of monocyte HLA-DR, a cell-surface molecule thought to reflect global 
immune function, which is usually expressed on more than 90% of monocytes. 
HLA-DR expression falls following surgery or other trauma, and expression on 
less than about 60% of monocytes is predictive of ICU patients getting infections 
(Allen  et  al.  2002;Cheadle  et  al.  1991;Hershman  et  al.  1990).  This  immune 
hyporesponsiveness  (termed  “immunoparalysis”)  is  also  reflected  in  a  reduced   117 
ability  of  whole  blood  to  produce  TNF-  in  response  to  lipopolysaccharide. 
Glutamine is able to prevent this immunoparalysis in surgical patients (Exner et al. 
2003;Spittler et al. 2001) and trauma patients (Boelens et al. 2002).  The effects of 
glutamine on cytokine production are complex, and different studies have yielded 
different results.  
During critical illness, whole body glutamine economy is altered, such that 
glutamine release from muscle and lung is increased due to increased proteolysis, 
and  utilization  by  other  organs,  such  as  kidney,  liver  and  gut  may  increase; 
ultimately  consumption  exceeds  production  and  glutamine  may  become 
“conditionally essential” (Jackson et al. 1999;Souba & Austgen 1990). Glutamine 
rapidly becomes depleted in muscle following surgery, sepsis or trauma (Blomqvist 
et al. 1995;Hammarqvist et al. 1989;POWELL et al. 1994;Roth et al. 1982;Stehle 
et  al.  1989;Vinnars,  Bergstom, & Furst  1975),  and of all the amino acids,  low 
muscle glutamine concentration was found to be most predictive of mortality in 
patients with abdominal sepsis (Roth et al. 1982). Muscle glutamine deficiency also  
results in depletion of muscle GSH (Hammarqvist et al. 1997), which has also been 
shown  to  a  prognostic  marker  for  poor  outcome  (Brealey  et  al.  2002).  Muscle 
glutamine  deficiency  is  prolonged,  even  in  patients  undergoing  uncomplicated 
elective  liver  surgery  (Petersson  et  al.  1992),  but  can  be  prevented  by 
supplementation  with  glutamine  (Hammarqvist  et  al.  1989),  alanyl-glutamine 
(Hammarqvist et al. 1990;Stehle et al. 1989), or even by alpha-ketoglutarate, which 
forms  the  carbon  skeleton  of  glutamine  (Hammarqvist  et  al.  1991).  Glutamine 
supplementation  also  prevents  the  fall  in  muscle  GSH  (Flaring  et  al.  2003). 
Depletion of muscle glutamine appears to be due to increased glutamine efflux   118 
from muscle in critical illness, possibly due to a decreased ability of glutamine 
transporters  to  maintain  the  normal  25-30:1  ratio  of  intracellular:extracellular 
glutamine (Biolo et al. 2005). This also explains why muscle glutamine is only 
slowly  repleted  by  exogenous  supplementation.  The  hypothesis  that  glutamine 
efflux  from  muscle  during  critical  illness  is  due  to  dysregulation  of  transport 
mechanisms is supported by the finding that patients with elevated creatine kinase 
levels  in  plasma,  suggestive  of  muscle  damage,  also  have  elevated  plasma 
glutamine (Oudemans-van Straaten et al. 2001).  Despite the increases in glutamine 
efflux  from  muscle,  increased  utilization  of  glutamine  in  plasma  results  in 
glutamine depletion, which is characteristic of plasma amino acid changes during 
critical  illness  (Jackson  et  al. 1999). Decreases  in  plasma  glutamine have been 
observed  following  burns  (Parry-Billings  et  al.  1990),  major  surgery  (Parry-
Billings et al. 1992;POWELL et al. 1994), sepsis (Planas et al. 1993;Roth et al. 
1982), pancreatitis (Roth et al. 1985) and in nutritional depletion due to cancer 
(vanderHulst et al. 1997). Plasma glutamine at ICU admission has also been found 
to  be  a  prognostic  indicator  for  mortality  in  emergency  admissions;  having  a 
plasma glutamine of <0.42mM at admission carried a relative risk of mortality of 
1.2 compared to patients having a plasma glutamine of >0.42mM (Oudemans-van 
Straaten et al. 2001). Given the importance of glutamine for the gastrointestinal 
system, limited data are available on glutamine content of intestinal mucosa during 
critical  illness.  Mucosal  glutamine levels  are decreased by chronic malnutrition 
and/or  inflammation  (Hulsewe  et  al.  2004;vanderHulst  et  al.  1994),  but  other 
studies have indicated that glutamine content is increased during critical illness or 
following abdominal surgery (Ahlman et al. 1995a;Ahlman et al. 1995b).    119 
If glutamine is administered parenterally, it is usually given as a dipeptide, 
either  alanyl-glutamine  or  glycyl-glutamine.  These  dipeptides  are  rapidly 
hydrolysed to constituent amino acids and do not accumulate to any great extent, 
even in critically-ill patients (Berg et al. 2005). In order not to increase total fluid 
administered, or the amount of nitrogen administered, the amount given of other 
parenteral amino acids is usually decreased. This limits the amount of glutamine 
that can be given parenterally, as sufficient of the other amino acids has to be given 
in order to prevent deficiency of those amino acids occurring during the period of 
parenteral feeding.  
 
4.1.1   Supplementation in critical illness 
  Several studies have been conducted with glutamine-supplementation of 
either  enteral  or  parenteral  nutrition  (EN  or  PN)  in  critical  illness.  The  most 
recently available systematic reviews and meta-analyses both suggest that there is 
no  significant  effect  of  glutamine-supplemented  EN  on  mortality,  infection  or 
organ  failure  when  all  studies  on  critical  illness  are  aggregated  (Avenell 
2009;Heyland et al. 2009a). Thus, the European Society for Parenteral and Enteral 
Nutrition (ESPEN) guidelines for EN state that there is insufficient evidence to 
recommend routine is of glutamine supplementation in EN for critically-ill adults 
(Kreymann et al. 2006). However, both the Canadian Clinical Practice Guidelines, 
the  ESPEN  guidelines  and  the  American  Society  for  Parenteral  and  Enteral 
Nutrition (ASPEN) guidelines all recommend the use of glutamine-supplemented 
EN  for  patients  with  trauma  and  burns  (Heyland  et  al.  2009b;Kreymann  et  al. 
2006;McClave et al. 2009), where the evidence for the use of glutamine is stronger,   120 
as  highlighted  by  previous  systematic  reviews  (Windle  2006).  Glutamine 
supplementation of PN, on the other hand, may be associated with benefit, although 
there is a discrepancy between the two recent meta-analyses on whether this effect 
is significant: Avenell’s meta-analysis suggests that there is no significant benefit 
of  glutamine  supplemented  PN  on  mortality,  although  she  found  a    significant 
decrease in  infection rate and organ failure  (Avenell 2009), whereas  Heyland’s 
meta-analysis found a significant benefit for glutamine in decreasing mortality as 
well as infectious complications and length of hospital stay (Heyland et al. 2009c). 
These differences appear to be due to the studies included in the meta-analyses. 
The  Canadian  Clinical  Practice  Guidelines,  the  ESPEN  PN  guidelines  and  the 
ASPEN guidelines all recommend glutamine supplementation of PN for critically-
ill adults, but with differing grades of evidence (Heyland et al. 2009d;McClave et 
al. 2009;Singer et al. 2009). 
  Small  studies  in  premature  infants  showed  that  intravenous  or  enteral 
glutamine  supplementation  decreased  duration  of  ventilation  and  decreased 
incidence  of  sepsis  (Lacey  et  al.  1996;Neu  et  al.  1997;Thompson  et  al.  2003). 
Despite these promising results from small studies, larger scale studies of enteral 
(Vaughn  et  al.  2003)  or  parenteral  (Poindexter  et  al.  2004)  glutamine 
supplementation  showed  no  effect  on  the  incidence  of  sepsis.  One  randomised 
controlled trial in surgical infants found that parenteral glutamine supplementation 
had no significant effect on intestinal permeability or nitrogen balance, although 
this  study  was  not  powered  to  detect  differences  in  clinical  endpoints  such  as 
incidence of sepsis or duration of parenteral nutrition (Albers et al. 2005). Despite 
these studies on glutamine supplementation in parenteral nutrition of infants, there   121 
have been no studies on the effect of glutamine supplementation in septic infants 
and children, and no studies on the effect of glutamine on GSH synthesis in septic 
infants and children.  
 
 
 
4.2  Aim 
 The aim of this study was to measure erythrocyte GSH synthesis, using 
deuterated glycine as a tracer, in septic infants and children who were randomly 
allocated to receive either glutamine dipeptide or placebo, to determine the GSH 
synthesis rate in both glutamine and placebo groups.  
  I  hypothesised  that  intravenous  glutamine  supplementation  would 
increase GSH synthesis rate in septic patients compared to placebo. 
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4.3  Methods 
 
4.3.1  Study groups 
All patients in this study were in neonatal or paediatric intensive care units 
(NICU and PICU) and were aged from 3 days to 9 years. All patients were defined 
as septic on the basis of a clinical diagnosis based on two or more of the following 
conditions being present: (1) Hyperthermia (> 38
°C) and/ or hypothermia (< 36
°C); 
(2)  Age-related  tachycardia  (Heart  rate  higher  than  the  normal  range  for  age: 
beats/min); (3) Age-related tachypnoea (Respiratory rate higher than the normal 
range for age: breaths/min); (4) White blood-cell count (x 10
9 cells/l) higher or 
lower than the normal range for age; (5) Platelet count less than 150 x 10
9 cells/l. 
(American & Society 1992;Turi, Petros, Eaton, Fasoli, Powis, Basu, Spitz, & Pierro 
2001).  
 
4.3.2  Study design and interventions 
Patients were randomly allocated to receive either glutamine or placebo 
for  76h.  L-alanyl-L-glutamine  (Dipeptiven®;  0.6  g/kg/day),  equivalent  to  0.4 
g/kg/day  of  glutamine,  was  given  to  9  septic  patients,  and  Vaminolact®  as 
isonitrogenous placebo which did not contain glutamine (See Table 4.1) was given 
to 7 septic patients. The clinician administering the study intervention was blinded 
to which arm the patients were assigned to, and I was likewise not aware of the 
group allocation whilst performing the analyses. The only people who knew the 
group allocations were (i) Dr Eaton who performed the randomisation and (ii) the 
study pharmacist who prepared the glutamine/placebo infusions in identical bags   123 
marked only with the patient name and the nitrogen content. These supplements 
were  intravenously  infused.  GSH  synthesis  was  measured  twice  in  all  patients, 
using a deuterated glycine infusion from 0 to 8 hours and again from 20 to 28 hours 
(Figure 4.1). D2-glycine infusion was given intravenously at 15 μmol/kg/h after a 
priming dose of 15 μmol/kg. 
 
Table 4.1 Composition of placebo infusion (Vaminolact) 
Vaminolact  Composition  g/l 
Alanine  6.3 
Arginine  4.1 
Aspartic acid  4.1 
Cysteine  1 
Glutamic acid  7.1 
Glycine  2.1 
Histidine  2.1 
Isoleucine  3.1 
Leucine  7 
Lysine  5.6 
L-methionine  1.3 
Phenylalanine  2.7 
Proline  5.6 
Serine  3.8 
Taurine  0.3 
Threonine  3.6 
Tryptophan  1.4 
Tyrosine  0.5 
Valine  3.6 
Total amino acid   65.3 g/l 
Nitrogen  9.3 g/l 
Osmolality  510 mOsmol/kg 
Energy  240 kCal 
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4.3.3  Blood samples 
Blood samples of the two septic groups were taken every 2 hours during 
the first 8 hours (i.e. during the first d2-glycine infusion) and then at 20, 24, 28 
hours  (second  d2-glycine  infusion)  and  at  52  and  76  hours  (See  Figure  4.1). 
Erythrocytes (RBC) were immediately separated and kept at -80°C until analysis.    
 
4.3.4  Sample preparation and derivatization 
Blood  samples  were  prepared,  derivatised  and  analysed  by  the  same 
procedures as described in Chapter 3 (section 3.3.3). 
 
4.3.5  Data analysis 
2H/
1H-glycine and 
2H/
1H-GSH in RBC patient samples were analysed by 
GC-TC-IRMS. Each time point of 
2H/
1H-glycine and 
2H/
1H-GSH was statistically 
analysed by Student t-test. Values were means ± SEM. 
The atom percent excess (APE) of both glycine and GSH were calculated from 
time at 0 (base line) to 8 hours and 20 (2
nd base line) to 28 hours. Each APE was 
calculated using the following formula (Wolfe 1992): 
 
0      8      20      28      4  0      52      72      76     
h  ours     
G lutamine     or Placebo    
[D2]-glycine 
Blood 
samples 
 
Figure 4.1  Infusion protocol of glycine and either glutamine or placebo  
and sample taking   125 
 
 
Where rt0 and rtx are the observed hydrogen ratios (
2H/
1H) at baseline (t0) and time x 
(tx) respectively.  
Each time point of APE of both glycine and GSH was statistically analysed by 
Student t-test. Values were mean ± SEM.  
The fractional synthesis rate (FSR) of GSH was calculated from the steady state 
enrichment of glycine and the rate of increase of GSH enrichment in both groups. 
The  FSR  (%/h)  of  GSH  was  calculated  following  formula  (based  on  (Wolfe 
1992;Wolfe & Chinkes 2004)):  
FSR (%/h) of GSH: 
 
 
 
Where: GlyAPEt1 and GlyAPEt2 are the glycine atom percent excess values at t1 and 
t2, GSHAPEt1 and GSHAPEt2 are the GSH atom percent excess values at t1 and t2, 
and Δt is the difference in time in hours between t1 and t2. The FSR of GSH 
between  groups  was  also  statistically  analysed  by  Student  t-test.  Values  were 
means ± SEM.  
(GlyAPEt1 + GlyAPEt2)/2
(GSHAPEt2 – GSHAPE t1)
Δt FSR (%/hr) = 100 x
(GlyAPEt1 + GlyAPEt2)/2
(GSHAPEt2 – GSHAPE t1)
Δt FSR (%/hr) = 100 x
 
APE = 100 x 
(r  tx -  r  t0  )     
(  r  tx -  r  t0 ) + 1   126 
 4.4   Results 
 
 4.4.1   Study groups  
 
Patients were allocated by weighted minimisation, balancing groups for age, 
inotropic support, ventilation, and whether immunosupressed. The allocations were 
well matched, as shown in Table 4.2. 
Table 4.2  Patient allocations 
  Vaminolact  Dipeptiven 
Age     
   0-6 months  2  3 
   6 months – 3 years  3  4 
   over 3 years  3  3 
Ventilated?     
   Yes  8  8 
   No  0  2 
Inotropes?     
   Yes  4  5 
   No  4  5 
Immunosupression?     
  Yes  0  1 
   No  8  9 
TOTAL  8  9 
One patient in each group subsequently dropped out. 
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4.4.2  Glycine enrichment and APE in two septic groups 
   
  D2-glycine  was  infused  twice  in  the  two  groups  during  76  hours. 
Erythrocyte  glycine  enrichment  declined  between  the  two  d2-glycine  infusions. 
There was a significant difference in erythrocyte glycine enrichment between the 
glutamine group and the placebo group at 8 hours (p = 0.013), but enrichment was 
similar at all other time points (see Figure 4.2). 
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Figure  4.2    Glycine  enrichment  (
2H/
1H)  in  glutamine  and  placebo 
groups over 76 hours * p=0.013 between glutamine and placebo   128 
The  same  data,  expressed  as  APE,  are  shown  for  the  first  8  hours  in 
Figure  4.3.  After  4  hours,  glycine  APE  achieved  steady  state.  There  was  a 
significant difference in glycine APE only time at 8 hours (P = 0.012).  
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Figure 4.3  Glycine APE in glutamine and placebo groups during the first 
8 hours; * p=0.012 between the two groups   129 
  The glycine enrichment declined to near normal level at 20 hours (Figure 
4.4)  and  then  the  second  d2-glycine  infusion  was  given.  Figure  4.4  shows  the 
glycine  enrichment  in  the  two  groups  between  20  and  76  hours.  The  glycine 
enrichment achieved the second steady state during 24 to 28 hours. The glycine 
enrichment started to decrease after 28 hours, and at 52 hours it was back to the 
same level as at 20 hours. There was no significant different at any time point after 
the second d2-glycine infusion. 
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Figure 4.4  Glycine enrichment in glutamine and placebo groups during 20 
to 76 hours after the second d2-glycine infusion. There were no significant 
differences at any time point   130 
  During  20  to  28  hours,  glycine  APE  in  two  septic  groups  was  also 
calculated. It was thought to be more appropriate to use the glycine enrichment at t0 
as  the baseline for the  APE  calculations,  so  there is  an APE  of approximately 
0.02%  at  t20,  when  the  second  d2-glycine  infusion  was  started.  There  was  no 
significant difference between two groups at any time point (see Figure 4.5).  
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Figure 4.5  Glycine APE in two septic groups during 20 to 28 hours   131 
4.4.3  GSH enrichment and APE in two septic groups 
 
The  enrichment  of  GSH  in  the  two  septic  groups  showed  no  change 
between the two d2-glycine infusions (see Figure 4.6). 
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Figure 4.6  GSH enrichment in two septic groups for 76 hours   132 
GSHAPE was calculated during the first 8 hours. GSHAPE linearly increased 
during 4 to 8 hours and was no difference between two groups at any time point. 
Placebo group was increased but not as much as glutamine group during that time 
(see Figure 4.7). 
 
 
The  enrichment  of  GSH  was  maintained  until  the  second  d2-glycine 
infusion. After the second d2-glycine infusion, GSH enrichment was increased and 
well maintained in both groups by 76 hours. Although the enrichment was always 
higher in glutamine group, this difference was not statistically significant at any 
time point (see Figure 4.8). 
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Figure 4.7  GSH APE in two septic groups for the first 8 hours   133 
 
  During 20 to 28 hours, GSHAPE was also calculated, again using t0 as the 
baseline. GSHAPE in both septic groups linearly increased from 24 to 28 hours. 
Glutamine  group  was  slightly  higher  than  placebo  group  but  there  was  no 
significant difference at any time point in two groups (see Figure 4.9).  
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Figure 4.8  GSH enrichment in two septic groups during 20 to 76 hours 
after the second d2-glycine infusion   134 
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Figure 4.9  GSH APE in the two septic groups during 20 to 28 hours   135 
4.4.4  The FSR of GSH in the two septic groups 
 
During steady state of glycine enrichment at 4 to 8 hours and 24 to 28 
hours, The fractional synthesis rate (FSR) (%/h) of GSH in the two septic groups 
was calculated from APE of both glycine and GSH, respectively.  
The FSR (%/h) of GSH for the first 8 hours in two groups showed the 
glutamine  group  was  slightly  higher  than  placebo  group  but  there  was  no 
significant difference between two groups (p = 0.61; Figure 4.10).  
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Figure 4.10  The FSR (%/h) of GSH in two septic groups for the first  
8 hours   136 
  After the second d2-glycine infusion, the FSR (%/h) of GSH during the 24 
to 28 hours in two groups showed the glutamine group was still slightly higher than 
placebo group but again, there was no significant difference between two groups (p 
= 0.39; Figure 4.11) 
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Figure 4.11  The FSR (%/h) of GSH in two septic groups during 24 to 
28 hours   137 
4.4.5  Comparison between the non-supplementation groups 
and supplementation groups 
 
I also compared the glutamine and placebo septic groups (this Chapter) 
with  the  two  groups  studied  with  the  same  infusion  and  sampling  protocol  as 
Chapter 3 (i.e. control and sepsis).   
The glycine APE of all groups for the 8 hours showed that the glutamine 
group and placebo group achieved a higher steady state at 4 hours than the control 
and septic group, but the placebo group was gradually decreased at 8 hours to the 
similar  level  to  the  control  and  septic  group  (see  Figure  4.12).  There  was  no 
significant difference at any time point between the 4 groups, except between the 
glutamine and placebo group at 8 hours (discussed previously in section 4.4.2). 
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Figure 4.12  The glycine enrichment between all groups for the first 8 hours; 
There was a significant difference between glutamine and placebo time at 8 
hours. (#p < 0.05)   138 
The  GSHAPE  in  the  4  groups  showed  that  all  groups  increased  during 
steady state of glycine at 4 to 8 hours. The glutamine and placebo groups both 
linearly increased and had a higher GSHAPE than control and septic group during 4 
to 8 hours (see Figure 4.13). There were significant differences in GSHAPE between 
sepsis and both the glutamine and placebo groups (p < 0.05) at 6 hours.  
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Figure 4.13  GSHAPE in all groups for the first 8 hours; 
At 6 hours, the sepsis group had a significantly lower GSHAPE than both the 
placebo and glutamine groups (* p < 0.05).   139 
The FSR (%/h) of GSH was also compared between all four groups during 
4 to 8 hours. There was a lower FSR in the septic group than all three others, but 
this difference was not significantly different. The FSR of GSH of both glutamine 
and placebo groups was slightly higher than control group, but again there was not 
a statistically significant difference (see Figure. 4.14). 
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Figure 4.14  FSR (%/h) of GSH in all four groups during 4 to 8 hours 
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4.5   Discussion 
 
I  hypothesised  that  glutamine  infusion  during  sepsis  in  infants  and 
children  would  increase  erythrocyte  GSH  synthesis.  My  data  presented  in  this 
chapter suggest that, on the contrary, glutamine infusion has no effect on GSH 
synthesis.  
Free glutamine is not usually added to parenteral nutrition, for reasons of 
stability, as it forms either free glutamate or pyroglutamic acid. With the advent of 
stable glutamine dipeptides, it is possible to add glutamine into parenteral nutrition 
as either alanyl-glutamine or as glycyl-glutamine. However, in this study, a stand-
alone infusion of either alanyl-glutamine or Vaminolact (isonitrogenous placebo) 
was used. The reason for this is that when identified as being septic, infants and 
children  may  be  receiving  some  enteral  nutrition,  may  already  be  receiving 
parenteral  nutrition,  or  may  be  receiving  only  intravenous  glucose  whilst 
intravenous nutrition is initiated. Thus, in order to maximise patient recruitment, 
and to make the results more widely generalisable, it was decided to give alanyl-
glutamine  or  Vaminolact  as  a  separate  infusion,  in  addition  to  whatever  other 
nutrition was being received by the patient. 
GSH synthesis was measured on two occasions during the intervention 
with glutamine or placebo. Thus, I was able to test whether glutamine was able to 
increase  erythrocyte  GSH  synthesis  under  two  conditions:  (i)  initiation  of 
glutamine/placebo infusion and (ii) after 20 hours of glutamine/placebo infusion.   141 
Plasma glutamine concentration in glutamine and placebo groups, and the control 
group previously referred to in chapter 3, are shown below: 
 
Figure  4.15, Plasma  glutamine concentration in  the glutamine and placebo 
groups studied in this chapter, and the control group studied in chapter 3 (data 
of Mr Moti Chowdhury). 
 
As  seen  in  this  graph,  there  was  no  significant  difference  in  plasma 
glutamine concentration between the glutamine group and the placebo group at the 
time  of  the  second  d2-glycine  infusion  (GSH  synthesis  measurement).  Thus,  it 
could be argued that there might be a difference in GSH synthesis when measured 
after  at  least  48  hours  of  infusion.  However,  it  is  also  possible  that  plasma 
glutamine levels are not increased during the first 24 hours of infusion because 
utilisation of glutamine could be increased. This is indeed a possibility, as cells of 
the immune system are known to be major consumers of glutamine during sepsis 
(Newsholme  2001).  In  order  to  determine  whether  glutamine  utilisation  is 
increased during sepsis, it would be necessary to undertake a glutamine turnover 
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study, using labelled glutamine. Interestingly, although a d2-glycine infusion was 
not  performed  during  the  48-76  hours  during  which  we  know  that  plasma 
glutamine is elevated, I did measure the enrichment of deuterated GSH at 52 and 
76 hours. If GSH turnover was increased during this time period due to elevated 
plasma  glutamine  levels,  one  would  expect  the  enrichment  of  deuterium  in 
erythrocyte GSH to decrease more rapidly than that of the placebo, because glycine 
incorporated into newly-synthesised GSH would be unlabelled. If the decrease in 
GSH enrichment between 52 and 76 hours is compared between the glutamine and 
placebo  groups  (Figure  4.6),  it  appears  that  the  decrease  in  the  glutamine-
supplemented group is indeed more rapid than that of the placebo group. However, 
this possible difference would require further study to be confirmed. Unfortunately, 
in my study due to lack of sample, and lack of an internal standard to measure GSH 
concentration in the same sample as GSH enrichment, I was unable to measure 
erythrocyte GSH concentration. 
  To  my  knowledge,  there  are  no  studied  that  have  studied  the  effect  of 
glutamine  supplementation  on  GSH  synthesis  in  humans.  In  a  study  of  adult 
intensive care unit patients, Flaring et al. showed that glutamine supplementation 
attenuates  the  fall  in  muscle  GSH  concentration  which  is  induced  by  surgery. 
However,  in  this  study,  GSH  synthesis  was  not  measured,  and  the  effects  of 
glutamine were demonstrated in muscle rather than in erythrocytes (Flaring et al. 
2003).  Using 
15N-glutamic  acid  to  measure  GSH  synthesis  adult  beagle  dogs, 
Humbert et al. showed that erythrocyte GSH synthesis was not affected by enteral 
glutamine  supplementation  (Humbert  et  al.  2007).  However,  in  their  study,  the 
dogs  were  not  septic  but  instead  had  been  starved  for  3  days  to  mimic  the   143 
malnutrition frequently observed in intensive care unit patients. Interestingly, in 
their  study  glutamine  supplementation  caused  a  decrease  in  intestinal  GSH 
synthesis, which they speculated could be due to glutamine utilisation to provide 
NADPH, thus allowing reconversion of oxidised GSH back to the reduced form, 
and thus a decreased need for de novo GSH synthesis.   
It is possible that at the rates of GSH synthesis taking place in erythrocytes, 
factors other than glutamate supply are limiting. For instance, some authors have 
considered  cysteine  supply  to  be  rate  limiting  for  erythrocyte  GSH  synthesis 
(Badaloo et al. 2002). However, in the current study, the placebo group received 
cysteine supplementation (at 4.3μmol/kg/h as a component of Vaminolact), so that 
if cysteine were rate-limiting for GSH synthesis in these patients, one would expect 
to  see  an  increase  in  GSH  synthesis  in  the  placebo  group  compared  to  the 
glutamine supplemented group. This is not the case, so cysteine is probably not 
rate-limiting. In addition, erythrocyte GSH concentration may have been adequate 
in these children, so that GSH synthesis rate was limited by feedback inhibition of 
the  pathway,  rather  than  substrate  limitation.  Indeed,  there  appears  to  be  no 
difference in GSH fractional synthetic rate between any of the four patient groups 
studied  (i.e.  control  non-septic,  sepsis  without  supplementation,  sepsis  plus 
glutamine  and  sepsis  plus  placebo).  Despite  this  lack  of  difference  in  GSH 
synthesis, sepsis and glutamine supplementation had marked effects on immune 
function in these patients in the same timescale over which GSH synthesis was 
measured (Chowdhury et al. unpublished). As glutamine is a very important fuel 
for cells of the immune system, and GSH is also important as an anti-oxidant for 
cells of the immune system during infection, where it protects against cytotoxic   144 
reactive oxygen species produced in the bacterial killing process, it is possible that 
glutamine  may  have  increased  GSH  synthesis  in  leukocytes  in  this  study,  but 
unfortunately I did not measure GSH synthesis in this cell type. Another tissue 
where  it  would  be  of  great  interest  to  measure  the  effect  of  glutamine 
supplementation during sepsis would be muscle. During sepsis and other critically-
ill states, amino acids are released from muscle in order to provide amino acids to 
the  liver.  As  a  consequence,  muscle  GSH  becomes  depleted  (Brealey  et  al. 
2002;Flaring  et  al.  2003)  and  levels  may  be  relatively  preserved  by  glutamine 
supplementation in adults (Flaring et al. 2003). Ethically, I was of course unable to 
obtain muscle biopsies from the infants and children in this study. 
Deuterated glycine was used in this study as a probe of GSH synthesis. 
Glycine  is  also  one  of  the  precursor  amino  acids  of  GSH,  but  in  this  study 
deuterated  glycine  infusion  was  given  at  tracer  amounts  (15μmol/kg/h  after  a 
priming  dose  of  15μmol/kg).  This  can  be  compared  with  the  glutamine 
supplementation rate of 114μmol/kg/h (in the glutamine supplemented group), and 
14.5μmol/kg/h  glycine  plus  4.3μmol/kg/h  cysteine  and  25μmol/kg/h  glutamate 
received  as  a  component  of  Vaminolact  in  the  placebo  group;  however  the 
glutamine/Vaminolact infusion was in addition to whichever nutrition was being 
administered to the patients. One advantage of using glycine as a precursor in these 
studies is that glycine is incorporated at the final step of GSH synthesis, so the 
contribution of recycling of γ-glutamyl cysteine is included in the measurement, 
whereas this would not be included if labelled glutamate or cysteine were to be 
used as the precursor.   145 
One possibility for the negative results observed is that an inadequate dose 
of glutamine was given (0.6k/kg/d dipeptide, equivalent to 0.4g/kg/d glutamine). 
This  dose  was  chosen  on  the  basis  of  previous  experience  of  glutamine 
supplementation (Allen et al. 1993) and is comparable to that used in other studies 
in  infants  and  children  (Albers  et  al.  2005;Lacey  et  al.  1996;Ong  et  al. 
2007;Scheltinga  et  al.  1991;Ziegler  et  al.  1992).  Although  a  similar  dose  of 
glutamine is frequently used in adult studies (e.g. (Heyland et al. 2007)), some 
studies  in  adults  have suggested that 0.4g/kg/d  is  in  the middle of the  a dose-
response  curve  and  that  higher  doses  are  well  tolerated  (Tjader  et  al.  2004). 
Although glutamine supplementation in parenteral nutrition is theoretically limited 
because the amounts of other amino acids  given are decreased and amino acid 
deficiency  must  be  avoided,  in  the  current  study  glutamine  was  given  as  an 
standalone infusion so was independent from any parenteral amino acids given. 
The enrichment of GSH in each group was maintained at an elevated level 
between the two glycine infusions, whereas that of glycine fell rapidly between the 
two infusions, as would be expected as the turnover of intracellular glycine is much 
faster than that of GSH. The fractional synthesis rates (FSR) for GSH which I 
measured in this study, approximately 1.5% per hour, are lower, but comparable to, 
the rates obtained by Lyons et al. and Reid et al. in children (Lyons et al. 2001;Reid 
et  al.  2000)  and  Humbert  et  al.  in  dogs  (Humbert  et  al.  2007),  whereas  the 
fractional synthesis rate (FSR) of GSH in the rat is much higher, approximately 
20% per hour (Lauterburg & Mitchell 1981). The FSR which I obtained equates to 
36% per day, so one would potentially expect the enrichment of GSH to fall by 
18% during the 12 hours between the end of the first glycine infusion and the start   146 
of  the  second.  However,  the  enrichment  of  glycine  does  not  fall  to  0  APE 
immediately after stopping the infusion, so presumably the continued incorporation 
of glycine at a gradually lower enrichment is  enough to prevent a fall in GSH 
enrichment  over  these  12  hours.  The  estimated  curves  of  GSH  and  glycine 
enrichments are shown in Figure 4.16.  
 
  The finding that the FSR over the first 8 hours was different between the 
placebo group in this study and the sepsis group in chapter 3 is surprising, as these 
groups should be comparable. Possible explanation for this discrepancy are: (i) the 
small numbers of patients in each study meant tat there was a clinical difference 
between the two groups, resulting in a difference in FSR; (ii) there was an effect of 
acute infusion of placebo; (iii) there was a systematic difference in the analyses 
(samples  were  analysed  in  different  batches,  and  differences  small  in  analysis 
between the two studies could have accounted for the apparent difference in FSR). 
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Figure 4.16  Estimated curves of enrichment glycine and GSH   147 
  Other work on these patients (performed by Mr Moti Chowdhury) indicated 
that glutamine attenuated the immune response to sepsis by decreasing pro- and 
anti- inflammatory cytokines and decreasing the fall in HLA-DR expression. In 
addition, glutamine seemed to improve organ failure scores compared to placebo, 
although the number of patients was small. 
 
 
4.6   Conclusion 
 
Glutamine supplementation did not significantly enhance erythrocyte GSH 
synthesis in septic paediatric patients in comparison to placebo. This could be due 
to several factors: 
(i) not enough patients were studied  
(ii) other amino acids were rate-limiting  
(iii) GSH synthesis is already maintained at adequate levels, even during 
sepsis,  
(iv) there could be differences in absolute synthesis rates which it was not 
possible to determine in this study 
(v) there may be differences in other tissues. 
(vi) the dose of glutamine may have been inadequate 
Despite  this  negative  finding,  my  results  show  the  utility  of  my  method  for 
measuring GSH synthesis in vivo in paediatric patients where sampling of large 
blood volumes is a problem.   148 
 
 
 
Chapter  5 
 
Glutathione synthesis in a rat model of 
Intestinal Ischaemia-Reperfusion 
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Chapter 5:___________________________________ 
 
5.1  Introduction 
    
Intestinal  ischaemia  and  reperfusion  (I/R)  injury  represents  a  major 
clinical  problem  in  infants,  children  and  adults.  Diseases  associated  with  this 
condition  include  necrotizing  enterocolitis,  midgut  volvulus  acute  mesenteric 
arterial occlusion and haemodynamic shock (Schoenberg & Beger 1993). Intestinal 
I/R  can  also  occur  as  a  consequence  of  surgical  procedures  such  as 
cardiopulmonary  bypass,  aortic  aneurysm  repair  and  intestinal  transplantation 
(Schoenberg & Beger 1993). Sepsis can be both a cause and a consequence of 
intestinal  I/R  injury  (Fink  1993;Schoenberg  &  Beger  1993).  The  intestinal 
ischaemia  and  reperfusion  rat  model,  consisting  of  superior  mesenteric  artery 
occlusion (ischaemia) followed by de-occlusion (reperfusion) is a widely-used and 
reproducible model of intestinal I/R  (Iglesias, LaNoue, Rogers, Inman, & Turnage 
1998;Poggetti  et  al.  1992;Stefanutti,  Vejchapipat,  Williams,  Pierro,  &  Eaton 
2004;Stefanutti, Pierro, Vinardi, Spitz, & Eaton 2005).  
During ischaemia and subsequent reperfusion, there is a great increase in 
production of reactive oxygen and nitrogen species, such as hydrogen peroxide 
(H2O2) and the superoxide radical anion (O2
●–), which reacts with the nitric oxide 
radical (NO
●) to produce the potentially cytotoxic peroxynitrite anion (ONOO
–) 
(Edited by: Halliwell & Gutteridge 1999;Granger & Kubes 1994). This production 
of reactive oxygen and nitrogen species is thought to be important in causing tissue   150 
damage after I/R of several tissues, such as heart (Stefanutti et al. 2004) kidney 
(LaNoue, Jr. et al. 1996), and the intestine (Stefanutti et al. 2005). The actions of 
these deleterious reactive species can be prevented by antioxidants, either given 
exogenously,  or  with  endogenous  antioxidants  such  as  GSH.  GSH  levels  are 
depleted in liver (Turnage et al. 1991) and intestine (Bhaskar et al. 1995;Gibson et 
al. 1993) following intestinal I/R. 
Our group has shown that hypothermia prevents liver bioenergetic failure 
and mortality during experimental intestinal I/R injury (Vejchapipat et al. 2001). 
Hypothermia  is  beneficial  not  only  in  reducing  local  damage  (Hassoun  et  al.  
2002;Kalia  et  al.  2002;Vejchapipat  et  al.  2002)  but  also  in  decreasing  lung 
neutrophil  infiltration  (Vinardi  et  al.  2003),  alterations  in  heart  mitochondrial 
function (Stefanutti et al. 2004) and the effect on mortality has been confirmed 
(Kalia et al. 2001). Some studies suggested that hypothermia may protect the gut in 
intestinal I/R injury by induction of heme oxygenase-1 above the levels observed at 
normothermia (Attuwaybi et al. 2003) and prevents an increase in nuclear factor 
Kappa-B  (NF-kappaB)  and  inducible  nitric  oxide  synthase  (iNOS)  expression 
(Hassoun  et  al.  2002).  Interestingly,  in  a  study  of  the  effects  of  moderate 
hypothermia on oxidative stress following intestinal ischaemia-reperfusion injury, 
it has been shown that GSH levels were maintained by moderate hypothermia, and 
were  even  higher  than  control  normothermic  animals  in  control  hypothermic 
animals (Stefanutti et al. 2005) (Figure 5.1). 
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This could be due to decreased export/destruction of GSH in hypothermic 
animals, or even due to increased GSH synthesis due to hypothermia.  
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Figure 5.1 Concentration of total glutathione in rats undergoing sham (C) 
operation or intestinal ischaemia reperfusion injury (I/R) at normothermia 
(Normo) or hypothermia (Hypo), from (Stefanutti et al. 2005).   152 
5.2  Aim 
 
The aim of this study was to investigate the consequences of intestinal 
ischaemia  and  reperfusion  (I/R)  and  the  effects  of  whole-body  moderate 
hypothermia  on  systemic  oxidative  stress  in  the  rat,  by  measuring  the  GSH 
synthesis rate with deuterated glycine intravenous infusion. The hypothesis was 
that GSH synthesis in hypothermia I/R could increase more than normothermia I/R, 
and could be maintained the same as control (sham operation). 
 
 
5.3  Methods  
 
5.3.1  Experimental animals 
This  study  was  approved  under  the  United  Kingdom  Home  Office 
regulations  for  Animals  (Scientific  Procedures)  Act  1986,  after  obtaining 
appropriate project and personal licenses. Adult male Sprague-Dawley rats (210 to 
340g) were used. The following five experimental groups (n = 8 per group) were 
studied: 
(1) baseline for harvesting samples without operative procedure; 
(2) sham operation for 150 minutes at normothermia; 
(3) intestinal ischaemia for 60 minutes, followed by reperfusion for 90 minutes 
at normothermia; 
(4) sham operation for 150 minutes at hypothermia;   153 
(5) intestinal ischaemia for 60 minutes, followed by reperfusion for 90 minutes 
at hypothermia. 
 
5.3.2  Anaesthesia and body temperature 
Anaesthesia  was  induced  with  ~3%  isoflurane,  following  which 
spontaneously  breathing  animals  were  maintained  under  anaesthesia  with 
oxygen/nitrous oxide (1:1) and 2.0% to 2.5% isoflurane inhalation, delivered via a 
nose cone, as described in previous studies (Stefanutti et al. 2004;Stefanutti et al. 
2005;Vejchapipat et al. 2001;Vinardi et al. 2003). Baseline samples were taken 
immediately after induction of anaesthesia. 
Normothermia (rectal temperature between 36 and 38°C) was maintained by 
use  of  a  heating  blanket  and  lamp.  Moderate  hypothermia  (rectal  temperature 
between 30 and 32°C) was induced at the beginning of the experiment by exposing 
the rats to an environmental temperature of 22 to 23°C, with warming by a heating 
blanket  and  lamp  to  prevent  excessive  cooling.  Anaesthetised  rats  lose  body 
temperature rapidly if not kept with a heating blanket, so active cooling was not 
required.  All  animals  were  allowed  to  stabilise  for  period  of  30  minutes  after 
anaesthesia and monitoring had been established, in order to achieve the desired 
rectal temperature. During this time, a cannula was placed in the femoral vein, and 
an  intravenous  infusion  of  d2-glycine  (0.592μmol/kg/h)  initiated,  as  a  tracer  of 
GSH synthesis, until the experiment was terminated. 
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5.3.3  Operative procedure 
In sham groups (group (2) and (4)), laparotomy was performed and the 
origin of the superior mesenteric artery (SMA) identified and dissected only, the 
abdominal  wound  was  sutured  and  the  animal  monitored  until  the  end  of  the 
experiment. Intestinal ischaemia (group (3) and (5)) was induced by occluding the 
SMA by a vessel clip (8 × 1.5mm jaws vessel clip, World Precision Instruments, 
UK),  and  the  abdomen  sutured.  After  60  minutes  the  clip  was  removed  and 
reperfusion was confirmed by visualization of pulsation in the vascular arcades of 
the mesentery, and the abdomen sutured. Reperfusion was continued for a further 
90 minutes when the experiment was terminated. 
 
5.3.4  Sample collection 
Rats from all groups were killed by exsanguination, and liver and terminal 
ileum (5 to 10cm from the ileocecal valve) were removed. Blood was taken via 
cardiac puncture into an EDTA tube, and erythrocytes were immediately separated 
from whole blood by centrifugation at 3000rpm for 15 min at 4°C, following which 
samples were stored at -80°C. One lobe of liver was immediately stored at -80°C, 
and the rest of the liver used to prepare mitochondrial and cytosolic fractions (see 
below). Intestine sample was gently washed with saline and then stored at -80°C 
until analysis. 
 
5.3.5  Hepatic mitochondria and cytosol 
Liver was placed in a Teflon-on-glass Potter-Elvejheim hand homogenizer 
with ice cold Medium B (250mM sucrose, 2mM HEPES (4-(2-hydroxyethyl)-1-  155 
piperazineethanesulfonic  acid),  0.1mM  EGTA  (ethyleneglycol-bis-β-
aminoethylether)-N,N,N',N'-tetraacetic acid), pH 7.4), and hand-homogenized by 
10 strokes. The homogenate was transferred into centrifuge tubes (Round-bottom 
plastic tubes) and centrifuged at 1500g for 10 minutes at 4°C. The supernatant was 
gently transferred into fresh tubes. Medium B was added into the residue, which 
was hand-homogenized again and re-centrifuged. The supernatant was combined 
with  the  first  supernatant,  which  were  then  centrifuged  at  13500  rpm  for  10 
minutes  at  4°C,  to  obtain  a  primary  mitochondrial  pellet,  and  a  cytosolic 
supernatant, which was transferred into a capped tube and stored at -80°C until 
analysis.  The  primary  mitochondrial  pellet  was  re-homogenised  with  2-3ml  of 
Medium B using a plastic disposable pipette. The resuspended mitochondria were 
combined into microcentrifuge tubes, and samples centrifuged at 13500 rpm for 10 
minutes  at  4°C.  The  supernatant  was  discarded.  The  pellets  were  washed  with 
Medium  B  again  and  centrifuged  at  13500rpm  for  5  minutes  at  4°C.  The 
supernatant was discarded with care and the pellets stored at -80°C until analysis.  
 
5.3.6  Sample preparation and derivatization 
Erythrocytes  (50μl)  were  extracted  and  derivatised  with  n-Propyl 
chloroformate and methanolic hydrochloric acid as described earlier in this thesis 
(section 2.3.7). Whole liver (~60mg) and ileum (~100mg) were homogenised with 
200μl  TCEP  buffer  (7.5mM  TCEP  (tris-(2-carboxyethyl)-phosphine),  0.2M 
KH2PO4,  5mM  EDTA,  pH  7.5)  in  a  hand-held  glass-glass  homogeniser.  The 
homogenate was transferred to a microcentrifuge tube and the homogeniser tube 
and pestle washed with 200μl TCEP buffer, which was combined with the first   156 
homogenate. The homogenate was mixed for 15 minutes at room temperature, and 
the samples then protein precipitated and derivatised as for erythrocyte samples. 
Cytosol (500μl) and mitochondria (200μl) were mixed with 400μl of TCEP buffer, 
protein precipitated with 400μl of 10% sulphosalicylic acid. The samples were then 
centrifuged and derivatised as for erythrocytes. After derivatisations, all samples 
were resuspended in 100μl of ethyl acetate and analysed by GC-TC-IRMS. 
 
5.3.7  GC-TC-IRMS analysis 
11.25μl of sample was analysed by GC-TC-IRMS using a Programmable 
Temperature Vaporization (PTV) inlet, as described in section 2.4.5. Each sample 
was injected twice, and 
2H/
1H isotope ratios of glycine (Rt. 6.8 min) and GSH (Rt. 
20.5 min) were measured by isotope ratio mass spectrometry. H3
+ factor calculation 
was performed before each batch of samples. 
 
5.3.8   Data analysis 
2H/
1H-glycine and 
2H/
1H-GSH in all rat samples were analysed by GC-
TC-IRMS. The each atom percent excess (APE) of both glycine and GSH were 
calculated  from  the  average  of  base  line  group  (rB)  to  the  end  point  of  the 
experiment  (rtΔ),  as  described  in  section  4.3.5.  Glycine  and  GSH  APE  of  each 
group  was  compared  using  one-way  analysis  of  variance  (ANOVA);  data  are 
shown as mean±SEM. Fractional synthesis rate could  not be calculated, as this 
relies on samples from multiple time points, which was not possible using this 
model. In order to make an estimation of GSH synthesis, data were expressed as a 
ratio of GSH APE: glycine APE according to the formula:   157 
 
The factors of 33 and 13 are because 2/13 hydrogen atoms in the glycine derivative 
are labelled, whereas only 2/33 hydrogen atoms in the GSH derivative can become 
labelled by incorporation of d2-glycine. GSH/Glycine of each group was compared 
using one-way analysis of variance (ANOVA); data are shown as mean±SEM.  
 
 
 
   
APE x 33/2 
APE x 13/2 
GSH/ Gly = 
GSH  x 33/2 
Gly  x 13/2     158 
5.4  Results 
 
5.4.1  Erythrocytes 
Glycine APE was similar in all groups (Figure 5.2).  
 
 
 
 
 
 
 
Sham N Sham H I/R N I/R H
0.00
0.25
0.50
0.75
1.00
1.25
(n=8) (n=8) (n=8) (n=8)
A
t
o
m
 
%
 
e
x
c
e
s
s
 
 
Figure 5.2  Erythrocyte glycine APE 
Sham N: sham normothermia; sham H: sham hypothermia; I/R N: 
ischaemia-reperfusion normothermia; I/R H: ischaemia-reperfusion 
hypothermia   159 
 
GSH APE was significantly different between normothermia I/R group 
and hypothermia I/R group (p< 0.05; Figure 5.3). 
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Figure 5.3  Erythrocyte GSH APE  
Sham N: sham normothermia; sham H: sham hypothermia; I/R N: ischaemia-
reperfusion normothermia; I/R H: ischaemia-reperfusion hypothermia. p<0.05: 
Normothermia I/R group significantly higher than hypothermia I/R group    160 
 
The GSH to glycine APE ratio was also significantly different between 
normothermic I/R and hypothermic I/R (p< 0.05), and between the hypothermic 
sham group and normothermic I/R group (p < 0.05; Figure 5.4).  
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Figure 5.4  Erythrocyte GSHAPE/GlycineAPE  
Sham N: sham normothermia; sham H: sham hypothermia; I/R N: ischaemia-reperfusion 
normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.  p<0.05  normothermia  I/R 
group significantly higher than hypothermia I/R group and hypothermia sham group   161 
5.4.2  Whole liver 
 
Glycine APE was significantly higher in hypothermia sham group the than 
both the normothermia sham group (p<0.01) and the normothermic intestinal I/R 
group (p<0.05, Figure 5.5).  
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Figure 5.5  Glycine APE of whole liver  
Sham N: sham normothermia; sham H: sham hypothermia; I/R N: ischaemia-
reperfusion  normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.  
Hypothermia  sham  group  significantly  higher  than  normothermia  sham 
(p<0.01) and normothermia I/R group (p<0.05)   162 
The  APE  of  GSH  was  not  significantly  different  between  the  groups, 
although there was a non-significant  trend to  higher enrichment values  in  both 
hypothermic groups (Figure 5.6).  
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Figure 5.6  GSH APE of whole liver 
Sham N: sham normothermia; sham H: sham hypothermia; I/R N: ischaemia-
reperfusion  normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.  No 
significant differences between the groups   163 
The ratio of GSH APE to glycine APE was significantly different between 
hypothermia sham group and normothermia I/R group (p<0.05, Figure 5.7).  
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Figure 5.7  GSHAPE/glycineAPE of whole liver 
Sham N: sham normothermia; sham H: sham hypothermia; I/R N: ischaemia-
reperfusion normothermia;  I/R H: ischaemia-reperfusion hypothermia. p<0.05 
normothermia I/R group significantly higher than  hypothermia sham group    164 
5.4.3  Hepatic cytosol 
 
Glycine APE was significantly higher in the hypothermia sham group than 
in the normothermic sham group (p < 0.05; Figure 5.8). This significant difference, 
and values of glycine APE in the cytosolic fraction was similar to that of whole 
liver (section 5.4.2, Figure 5.5).  
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Figure 5.8  Glycine APE of hepatic cytosol  
Sham  N:  sham  normothermia;  sham  H:  sham  hypothermia;  I/R  N:  ischaemia-
reperfusion  normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.  
Hypothermia sham group significantly higher than normothermia sham (p<0.05)   165 
 
The APE of GSH was significantly different between normothermia sham 
and hypothermia sham groups (p<0.001), hypothermia sham and normothermia I/R 
groups (p< 0.01), and normothermia sham and hypothermia I/R groups (p< 0.05; 
Figure 5.9).  
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Figure 5.9  GSH APE of hepatic cytosol 
Sham  N:  sham  normothermia;  sham  H:  sham  hypothermia;  I/R  N:  ischaemia-
reperfusion  normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.  
Hypothermia sham significantly higher than normothermia sham (p < 0.001) and 
normothermia I/R group (p<0.01). Hypothermia I/R group was significantly higher 
than normothermia sham group (p< 0.01)   166 
 
The ratio of GSHAPE to glycineAPE was similar in all groups (Figure 5.10). 
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Figure 5.10  GSHAPE / glycineAPE of hepatic cytosol 
Sham N: sham normothermia; sham H: sham hypothermia;  I/R N: ischaemia-
reperfusion  normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.    No 
significant differences between the groups   167 
5.4.4  Hepatic mitochondria 
 
Glycine  APE  of  liver  mitochondria  was  significantly  different  between 
normothermia sham and hypothermia sham (p<0.05; Figure 5.11).  
 
GSH was only detectable in a few of the mitochondrial samples. There 
was no significant difference between any of the groups in those samples where 
GSH enrichment was measurable (Figure 5.12). 
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Figure 5.11  Glycine APE of hepatic mitochondria  
Sham N: sham normothermia; sham H: sham hypothermia; I/R N: ischaemia-
reperfusion  normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.  
Hypothermia sham group significantly higher than normothermia sham (p<0.05)    168 
The ratio of GSHAPE to glycineAPE was also calculated from these samples and 
there was no significant difference between the groups (Figure 5.12). However, as 
discussed below, mitochondrial GSH is probably entirely synthesised within the 
cytosol  and  then  transported  to  the  mitochondria,  so  the  true  precursor  for  the 
mitochondrial GSH pool is cytosolic glycine. The GSHAPE / glycineAPE  data were 
therefore recalculated using cytosolic glycineAPE; the results are shown in figure 
5.13. 
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Figure 5.12  GSH APE of hepatic mitochondria  
Sham N: sham normothermia; sham H: sham hypothermia; I/R N: ischaemia-
reperfusion normothermia; I/R H: ischaemia-reperfusion hypothermia     169 
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Figure 5.13  GSHAPE / glycineAPE of hepatic mitochondria, using cytosolic 
glycineAPE 
Sham N: sham normothermia; sham H: sham hypothermia;  I/R N: ischaemia-
reperfusion  normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.  No 
significant differences between the groups   170 
5.4.5  Small intestine (ileum) 
 
Glycine  enrichment  of  the  normothermia  intestinal  I/R  group  was 
significantly  higher  than  that  of  all  the  other  groups,  and  the  glycine  APE  of 
hypothermia  intestinal  I/R  group  was  significantly  higher  than  that  of  both  the 
hypothermia sham group and the normothermia sham group (Figure 5.14).  
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Figure 5.14  Glycine APE of ileum 
Sham  N:  sham  normothermia;  sham  H:  sham  hypothermia;  I/R  N:  ischaemia-
reperfusion normothermia; I/R H: ischaemia-reperfusion hypothermia. Normothermia 
I/R group was significantly (p<0.001) higher than all the other groups. Hypothermia 
I/R  group  was  significantly  higher  than  hypothermia  sham  group  p<0.001  and 
normothermia sham group (p < 0.05)   171 
For  GSH  APE  in  ileum,  there  was  an  overall  significant  difference 
between the groups (one-way ANOVA p<0.05). However, the post-tests did not 
show any significant differences between the groups. GSH APE showed a non-
significant trend to be lower in the sham hypothermic group compared to both the 
sham normothermic and the I/R hypothermic groups (Figure 5.15). 
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Figure 5.15  GSH APE of ileum 
Sham  N: sham normothermia;  sham H: sham hypothermia;  I/R N: ischaemia-
reperfusion normothermia; I/R H: ischaemia-reperfusion hypothermia. Although 
there was an overall significance on one-way ANOVA, there were no individually 
significant differences between the groups   172 
The  ratio  of  GSH  to  glycine  was  significantly  different  between 
normothermia  sham  and  normothermia  I/R  (p<0.001),  hypothermia  sham  and 
normothermia I/R (p<0.01), and normothermia I/R and hypothermia I/R (p<0.05; 
Figure 5.16). 
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Figure 5.16  GSHAPE / glycineAPE of ileum 
Sham  N:  sham  normothermia;  sham  H:  sham  hypothermia;  I/R  N:  ischaemia-
reperfusion  normothermia;  I/R  H:  ischaemia-reperfusion  hypothermia.  Ischaemia-
reperfusion  normothermia  significantly  lower  than  normothermia  sham  (p<0.001), 
hypothermia sham (p<0.01) and ischaemia-reperfusion at hypothermia (p<0.05)    173 
5.5  Discussion 
 
When the local tissue injury associated with ischaemia-reperfusion (I/R), 
distant organs can also be affected, particularly if the intensity of the inflammatory 
reaction in post-ischaemic tissue, for example intestine, is great (Carden & Granger 
2000). The remote effects of I/R are mostly frequently observed in the lung and 
cardiovascular system, and can result in the development of systemic inflammatory 
response syndrome (SIRS) and MODS, both of which account for 30 to 40% of the 
mortality  in  tertiary  referral  intensive  care  units  (Neary  &  Redmond  1999).  
Reperfusion of ischaemic tissues can induce reactive oxygen (ROS) and nitrogen 
species  (RNS)  as  consequences  of  inflammatory  reaction.  GSH  is  the  most 
important  factor  of  antioxidant  defences  during  I/R  injury.  In  this  study,  GSH 
synthesis during I/R was analysed using a rat intestinal I/R model, in which failure 
of liver, lungs and heart occurs secondary to I/R of the intestine. In this model, 
moderate hypothermia has been shown to have a beneficial effect, and this appears 
to be associated with a better preservation of intestinal GSH levels (Stefanutti et al.  
2005). 
In  erythrocytes,  the  ratio  of  GSHAPE  to  glycineAPE  was  higher  in  the 
normothermia I/R group than in both hypothermia sham and I/R groups, suggesting 
that  GSH  synthesis  is  faster  in  this  condition.  Although  reactive  oxygen  and 
nitrogen species were not  measured in  the current  study, previous studies  have 
shown that lipid peroxidation (measured as plasma malondialdehyde) and reactive 
nitrogen  species  (measured  as  nitric  oxide  products)  are  significantly  higher  in 
normothermic ischaemia reperfusion than in sham animals, and are also decreased   174 
by hypothermia (Stefanutti et al. 2005). Hence, my data suggest that GSH synthesis 
could be stimulated by reactive oxygen and nitrogen species, possibly originating 
from endothelial dysfunction (Banda et al. 1997). There are three possibilities for 
an  increase  in  GSH  synthesis:  (i)  an  increase  in  supply  of  precursors  (glycine, 
glutamate,  cysteine  or  -glu-cys);  (ii)  an  increase  in  erythrocyte  activity  of  -
glutamyl  cysteine  ligase,  the  rate-limiting  step  of  GSH  synthesis,  and  (iii)  an 
increase in erythrocyte activity of GSH synthetase. Although activity of -glutamyl 
cysteine ligase has been reported to be increased by various reactive oxygen and 
nitrogen species (Wild & Mulcahy 2000), and that of GSH synthetase has been 
reported to be increased in vitamin E and folate deficiency (Tchantchou et al. 2004) 
and  by  tert-butylhydroquinone  (Huang  et  al.  2000),  these  changes  are 
transcriptional changes mediated by increased expression of enzyme protein and so 
cannot account for the changes observed in erythrocytes. The pathway of  GSH 
synthesis is mediated by feedback control:  -glutamyl cysteine ligase is strongly 
inhibited by GSH (Griffith & Mulcahy 1999;Wild & Mulcahy 2000), so it is much 
more likely that in erythrocytes during intestinal I/R injury, there is utilisation of 
GSH  (e.g.  detoxification  of  hydroperoxides)  or  conversion  to  oxidised  GSH 
(GSSG). This would, by decreasing intracellular GSH amount, relieve the product 
inhibition of -glutamyl cysteine ligase and therefore cause an increase in the rate 
of GSH synthesis.  
In erythrocyte, the ratio of GSHAPE to glycineAPE in hypothermia I/R group 
was  decreased  to  similar  levels  to  the  sham  hypothermia  group  and  the  sham 
normothermia  group.  This  finding  supports  the  hypothesis  that  the  increase  in 
normothermic  I/R  is  due  to  reactive  oxygen  and  nitrogen  species  causing  a   175 
decrease in GSH and thus relieving the product inhibition on -glutamyl cysteine 
ligase, as these have been shown to be decreased by hypothermia after intestinal 
I/R. To confirm this, it would be necessary to make parallel measurements of GSH 
and  GSSG  concentration,  measure  reactive  oxygen  and  nitrogen  species  and 
determine GSH synthesis. It is also important to note that in my analyses, glycine 
incorporation into the total GSH pool (i.e. GSH plus GSSG) was measured because 
of the TCEP reduction step before derivatization. Further experiments could be 
designed  to  try  to  measure  the  rate  of  GSH  oxidation  by  measuring  glycine 
incorporation into the GSH and GSSG pools differentially, although it is difficult to 
measure GSSG accurately in erythrocytes because of the high artefactual oxidation 
of GSH during sample preparation procedures (Rossi et al. 2006). 
GlycineAPE  of  erythrocytes  was  similar  between  all  groups.  Our  Home 
Office  license  did  not  allow  repeated  blood  sampling,  so  we  were  not  able  to 
establish  glycine steady state in  these  animals.  The similar results  obtained for 
glycineAPE between the experimental groups, suggests, however, that steady state 
was obtained. 
 GlycineAPE  in  whole  liver  was  similar  in  sham  normothermia,  I/R 
normothermia  and  I/R  hypothermia  groups,  but  was  significantly  higher  in  the 
sham hypothermia group. This suggests that either the endogenous production rate 
of glycine was significantly lower in the hypothermic group, or an alteration in the 
routes of glycine utilisation. Glycine metabolism is based on two enzymes; serine 
hydroxymethyltransferase  reversible  interconverts  serine  and  glycine,  whereas 
glycine is catabolised by the mitochondrial glycine cleavage enzyme system (GCS). 
In mammalian liver, this reaction is reversible, so that glycine can be synthesised   176 
from CO2 + ammonia + N
5,N
10-methylene-tetrahydrofolate. However, in addition, 
glycine is used for several synthetic purposes: GSH, protein, nucleotide and bile 
acid  synthesis.  It  can  also  provide  a  gluconeogenic  precursor  via  serine  and 
pyruvate.  In order to investigate the biochemical basis for the increased glycine 
APE in hypothermia, it would be interesting to measure each of these processes. 
Interestingly,  glycine  has  recently  been  shown  to  have  hepatoprotective  effects 
during inflammation and hepatic I/R injury, although the mechanism of this is not 
known (Habib et al. 2006;Schemmer et al. 1999). 
The ratio of GSHAPE to glycineAPE in whole liver was significantly higher 
in the normothermia I/R group compared to hypothermia sham group, but that there 
was no differences between the other groups. This isolated difference is difficult to 
interpret, as there was no difference with the corresponding normothermic sham 
group.  It  is  possible  that  there  were  differences  in  the  production  of  reactive 
oxygen and nitrogen species between the groups, but this difference was only of 
sufficient  magnitude  to  cause  an  difference  in  GSH  synthesis  rate  between 
normothermic I/R (assumed to be the highest oxidative stress of all 4 groups) and 
hypothermic  sham  (assumed  to  be  the lowest  oxidative  stress  of  all  4 groups). 
However, this would need further experiments to verify. In addition, for all the 
hepatic samples (whole liver, cytosol and mitochondria), GSHAPE/glycineAPE values 
in excess of 1 were obtained, which does not make sense for a product precursor 
relationship. The reason for this is unknown, but means that the hepatic results 
must be interpreted with caution. 
 In  order  to  increase  understanding  of  hepatic  GSH  synthesis  inI/R,  I 
studied hepatic mitochondria and cytosol separately. Unfortunately, mitochondria   177 
samples, however, had severe protein interferences, and GSH could not be detected 
by  GC-IRMS  in  many  samples,  although  the  concentration  of  GSH  in  hepatic 
mitochondria was approximately 3.5 nmol/mg protein by HPLC analysis.  
GlycineAPE in hepatic cytosol, unsurprisingly, showed a similar pattern to 
that  of  whole  liver,  in  that  hypothermic  sham  animals  had  higher  glycine 
enrichment than normothermic sham animals. The magnitude of the glycineAPE  
measurements was also similar to that of whole liver, as most of the hepatic glycine 
pool  is  probably  cytosolic.  Despite  the  finding  that  there  was  a  significant 
difference  in  GSHAPE/glycineAPE  on  whole  liver,  there  were  no  significant 
differences between any of the groups in this ratio in liver cytosol. This observation 
is a little unexpected, as cytosol is thought to contain ~90% of hepatic GSH, and 
mitochondria only about 10% (Fernandez-Checa et al. 1998;Jocelyn & Kamminga 
1974;Meredith & Reed 1982). However, this lack of difference between the groups 
may  be  related  to  distribution  of  GSH  between  different  compartments:  if  the 
GSHAPE  values  are  compared  between  cytosol  and  whole  liver,  they  are  very 
similar numerically between the normothermic groups (~ 0.03%). However, there 
is a large difference between the numeric values for GSHAPE for the hypothermic 
groups between cytosol and whole liver (~0.04% for whole liver hypothermic sham, 
~0.06 % for cytosol hypothermic sham). The reason for this discrepancy is unclear, 
but could possibly reflect a higher concentration of slowly turning over GSH in the 
mitochondria of the hypothermic animals, which would have the effect of lowering 
GSHAPE in whole liver. To understand the basis of this difference would require 
further experiments, including precise measurements of GSH concentration in each 
compartment.   178 
The GSHAPE/glycineAPE ratio of hepatic cytosol was similar between all 
the groups. This is despite there being markedly significant differences in both 
glycineAPE and GSHAPE between the groups; however as all differences were of a 
similar  magnitude  between  groups  (compare  Figures  5.8  and  5.9),  there  is  no 
difference in the GSHAPE/glycineAPE ratio. This is also, unexpectedly, in contrast to 
the results of whole liver, in which there was a significantly lower ratio in the 
hypothermic sham group. The reason for this discrepancy is unknown but could be 
connected  to  different  subcellular  compartments  and/or  cell  types:  whole  liver 
contains Kupffer cells, erythrocytes, stellate cells and other cell types in addition to 
hepatocytes. It is not known whether all these cell types are equally represented in 
the “cytosolic fraction”; certainly erythrocytes are not present as they are removed 
in the low speed centrifugation step. 
Hepatic  mitochondrial  glycineAPE  was  significantly  higher  in  sham 
hypothermia than the other groups; this is a similar finding to both whole liver and 
to  cytosol,  although  the  APE  obtained  was  approximately  10-fold  lower  than 
cytosol or whole liver, suggesting either that glycine does not equilibrate quickly 
between cytosol and mitochondria or that glycine is being produced endogenously 
with the mitochondria, via reversal of the glycine cleavage system. Unfortunately, 
mitochondrial  GSH  was  not  detectable  is  several  of  the  samples,  so  data  on 
GSHAPE  and  GSHAPE/glycineAPE  is  based  on  just  a  few  animals.  I  calculated 
GSHAPE/glycineAPE  for  mitochondria  using  both  mitochondrial  glycineAPE  and 
cytosolic  glycineAPE.  Using  mitochondrial  glycineAPE  as  the  precursor, 
GSHAPE/glycineAPE values greatly in excess of 1 were obtained, because of the very 
low glycineAPE values of mitochondria. This does not make biological sense, as the   179 
product  cannot  have  a  higher  enrichment  than  the  precursor.  In  fact,  as 
mitochondrial GSH is almost certainly synthesed entirely in the cytoplasm and then 
imported into the mitochondria (Fernandez-Checa et al. 1998;Griffith & Meister 
1985). I therefore also calculated GSHAPE/glycineAPE using the cytosolic glycineAPE 
value,  as  this  is  probably  the  true  precursor  pool.  The  results  obtained  were 
considerably  lower  and  consistent  with  those  obtained  for  whole  liver  and  for 
hepatic  cytosol.  There  were,  however,  no  significant  differences  between  the 
groups. This may be due to the small number of mitochondrial samples in which it 
was possible to successfully measure GSH. 
GlycineAPE  in  ileum  was  significantly  higher  in  the  normothermic  I/R 
group than the other groups. This may reflect a decrease in endogenous glycine 
production in the liver during normothermic I/R. Interestingly, glycine has been 
shown to have cytoprotective effects on the intestine during intestinal I/R injury 
(Jacob et al. 2003;Kallakuri et al. 2003;Lee et al. 2001;Lee et al. 2002;Mangino, 
Kotadia, & Mangino 1996). Thus it is plausible that the increase in glycineAPE in 
the I/R normothermia group could be due to a decreased glycine production rate 
during  I/R.  However,  in  their  studies  on  the  protective  effect  of  glycine  on 
intestinal I/R injury at normothermia, Lee et al. did not detect any differences in 
intestinal glycine concentration (Lee, McCauley, Kong, & Hall 2002). 
The ratio of GSHAPE to glycineAPE in the ileum resulted in a very different 
profile  from  that  in  the  liver  and  in  erythrocytes.  GSHAPE/glycineAPE  in 
normothermic  I/R  was  significantly  lower  compared  to  all  the  other  groups, 
suggesting that ileum GSH synthesis is impaired by normothermic I/R. This could 
contribute to the marked decrease in intestinal GSH concentration which has been   180 
previously  observed  in  intestinal  I/R  injury  (Bhaskar  et  al.  1995;Gibson  et  al.  
1993;Stefanutti et al. 2005). Usually, loss of GSH under conditions of oxidative 
stress is thought to be either (i) oxidation of GSH to oxidized GSH, followed by its 
loss from cells (Rahman et al. 1995;Srivastava & Beutler 1969) or (ii) loss of GSH 
by  reaction  with  hypochlorous  acid  (Pullar,  Vissers,  &  Winterbourn  2001)  or 
degradation to cystine (Bhaskar, Mathan, & Balasubramanian 1995). My results are 
novel in that they suggest a possible further mechanism by which intestinal GSH 
concentration is  decreased:  i.e. slower GSH synthesis.  The reason  for  impaired 
GSH synthesis in the ileum during I/R injury is unknown. This could be due to (i) a 
decrease in supply of precursors (glycine, glutamate, cysteine or  -glu-cys); (ii) 
inhibition of the activity of glutamyl cysteine ligase or GSH synthetase by reactive 
oxygen  or  nitrogen  species.  However,  as  I  have  shown  that  GSH  synthesis  is 
increased  in  erythrocytes,  it  appears  to  be  unlikely  that  the  enzymes  of  GSH 
synthesis  are  inhibited  by  reactive  oxygen  and  nitrogen  species,  although  it  is 
possible  that  the  degree  of  oxidative  stress  is  much  greater  in  ileum  than  in 
erythrocytes  during  I/R  and  the  two  enzymes  could  be  inhibited.  Alternatively, 
glycine, glutamate, cysteine or -glu-cys concentration could be limiting for GSH 
synthesis in the ileum during I/R. To clarify these issues would require careful 
measurement  of  the  concentration  of  GSH,  glycine,  cysteine,  and  -glu-cys, 
together with measurement of the activity of -glutamyl cysteine ligase and GSH 
synthetase. 
Hypothermia,  on  the  other  hand,  appeared  to  relatively  preserve  GSH 
synthesis, as GSHAPE/glycineAPE was significantly higher in hypothermic I/R ileum 
than  normothermic  I/R  ileum,  and  was  not  significantly  different  from  either   181 
normothermic or hypothermic sham animals. The reason for this preservation of 
GSH synthesis is unknown. As the synthesis of GSH from glycine, cysteine and 
glutamate  is  enzymatic,  one  would  expect  that  the  activity  of  the  enzymes  -
glutamyl cysteine ligase and GSH synthetase would be decreased by hypothermia. 
I was not able to find any literature on the temperature dependence of either of 
these enzymes, but it appears unlikely that the activity of either of these enzymes is 
increased by lowering the temperature from 37°C to 30-32ºC, although there are 
some mammalian enzymes which are stimulated at lower temperatures, e.g. during 
hibernation  (Andrews  2007).  Although  the  body  temperature  of  hibernating 
animals  is  much  lower  than  the  hypothermia  induced  in  my  experiments,  it  is 
interesting to note that the intestinal total GSH pool is larger in hibernating animals 
than active animals (Carey, Rhoads, & Aw 2003) and that hibernating animals are 
markedly resistant to intestinal I/R injury (Kurtz et al. 2006).  
Again,  clarification of the mechanism by which hypothermia preserves 
GSH synthesis in the intestine during I/R should involve careful measurement of 
the  concentration  of  GSH,  glycine,  cysteine,  and  -glu-cys,  together  with 
measurement of the activity of -glutamyl cysteine ligase and GSH synthetase at 
different temperatures.    182 
5.6   Conclusion 
 
In this study, I have shown that: 
(i) erythrocyte GSH synthesis is stimulated by normothermic intestinal I/R, 
probably  due  to  relieving  product  inhibition  of  γ-glutamyl  cysteine  ligase. 
Hypothermic I/R animals had a similar rate of GSH synthesis to sham animals. 
(ii)  in  the  liver,  the  results  of  GSH  synthesis  are  difficult  to  interpret, 
because the ratio GSHAPE/glycineAPE  is greater than 1, suggesting that there may be 
compartmentation of glycine/GSH metabolism and that whole liver glycine is not 
the true precursor for whole liver GSH. 
(iii)  intestinal  GSH  synthesis  is  markedly  decreased  by  normothermic 
intestinal I/R, and this may contribute to the low GSH concentrations observed in 
the intestine following I/R injury. Interestingly, hypothermia during I/R appeared 
to prevent the impairment in GSH synthesis, which is in keeping with previous 
observations that hypothermia causes preservation of ileal GSH levels during I/R. 
However, the mechanisms of these alterations are not known and require further 
investigation along the directions indicated above.  
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Chapter 6 
 
General Discussion 
and 
Further work 
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During sepsis and critical illness, a systemic inflammatory response can 
significantly produce reactive oxygen and nitrogen species, which can damage host 
tissues. Usually, several different antioxidant defences protect host cells from these 
reactive species. One of the important antioxidant defences is GSH, a tripeptide 
synthesised from the precursor amino acids cysteine, glutamate and glycine. The 
aim of this study was to measure GSH synthesis in vivo, using deuterated glycine 
as a tracer, and to use this method to measure GSH synthesis in vivo in both animal 
studies and in humans 
In order to do this, it was necessary to develop a method to measure GSH 
synthesis using stable isotope precursors. Previous methods for measuring GSH 
synthesis have used radioactive precursors (not suitable for use in human patients), 
or  have  separated  GSH  by  liquid  chromatography,  hydrolysed  to  its  precursor 
amino acids, and analysed isotopic enrichment by GC-MS. This would therefore 
require large volumes of blood samples, and at least two separate aliquots of blood, 
one for measurement of precursor enrichment, the other for purification of GSH 
and subsequent enrichment measurement. I chose to try to develop a method with 
the characteristics: 
(i) isotopic enrichment of the precursor amino acid and GSH should be 
possible  from  a  single  aliquot  of  blood  sample,  preferably  in  a  single 
chromatographic separation 
(ii)  enrichment  should  be  measurable  from  both  deuterated  and 
13C-
labelled amino acid precursors, to allow wide applicability 
(iii) low levels of enrichment should be measurable, so that low rates of 
isotopic tracer infusion are able to be used.   185 
In order to develop a method with these characteristics, I chose to develop 
a method which was based on GC-IRMS. GC-IRMS is capable of obtaining highly 
accurate  and  specific  isotopic  ratios,  provided  that  adequate  chromatographic 
separation  is  obtained  before  conversion  of  target  analyte  to 
13CO2/
12CO2  or 
2H2/
1H2.  However,  care  must  be  taken  during  derivatisation  not  to  introduce 
materials  which  are  incompatible  with  IRMS.  Hence,  silylated  or  fluorinated 
derivatives,  commonly used in GC-MS, were not used as they may chemically 
react with parts of the GC-IRMS. Glycine and GSH were effectively derivatised by 
n-propyl  chloroformate  and  methanolic  hydrochloric  acid.  This  yielded  esters 
which were compatible with both GC-IRMS and GC-MS. The newly developed 
method can be used to analyse both glycine and GSH as a tracer and a tracee in a 
single  chromatogram,  which  means  more  exact  estimate  isotopic  traceability. 
However, the method which I developed had the disadvantage that as I could not 
identify a suitable internal standard for GSH, I was unable to quantify GSH in the 
same GC-IRMS analysis as enrichment was measured. As I was limited by the 
blood volume available, in the further studies I undertook using this method, only 
fractional synthesis rates rather than absolute synthesis rates could be measured. In 
order to establish general suitability of the method, I constructed calibration curves 
using 
13C-GSH/
12C-GSH.  A  very  good  linear  relationship  between 
theoretical/calculated  enrichment  was  obtained,  showing  that  the  method  was 
suitable for use with 
13C-labelled tracers. However, 
2H-GSH is not commercially 
available, so in order to construct calibration curves for 
2H-GSH/
1H-GSH, I first 
had  so  generate 
2H-GSH  by  incubating  erythrocytes  with 
2H-glycine.  This  was 
successful,  so  I  was  able  to  construct  calibration  curves  for 
2H-GSH/
1H-GSH.   186 
These  curves  generally  showed  a  good  linear  relationship,  except  at  deuterium 
enrichments close to natural abundance. This showed that my method was also 
suitable for measurement of GSH synthesis from deuterated amino acids precursors. 
As GC-IRMS is inherently less sensitive in deuterium mode than in carbon 
mode, in order to obtain enough signal to reliably measure GSH in erythrocyte 
samples from human infants, it was not sufficient to inject 2μl in splitless mode on 
a split/splitless injector. I therefore developed a technique of large volume injection, 
using  a  programmable  temperature  vaporization  (PTV)  injector,  which  allowed 
injection of up to 12μl. Using this method, I was able to measure both glycine and 
GSH enrichment in a single 50μl blood sample, thus my method was suitable for 
the measurement of GSH synthesis in infants in children, where repeated blood 
samples must, by necessity, be very small. 
  
Sepsis is the most common cause of MODS in the paediatric population. 
Despite recent advances in the care of critically ill children, sepsis and MODS 
remain a major source of morbidity and mortality in paediatric patients (Edited by: 
Deitch, Vincent, Windsor, & Editors 2002). Until now there has been no definitive 
treatment  of  MODS  patients,  therefore,  control  of  infections,  conventional 
treatments and TPN support is necessary. Antioxidant defences play a key role in 
critical  illness  as  they  can  protect  tissues  and  cells  from  reactive  oxygen  and 
nitrogen species which are induced from a systemic inflammatory response. GSH 
is  a  very  important  intracellular  antioxidant  during  sepsis,  however,  details  of 
synthesis and metabolism of GSH in particularly children and infants are still not 
clear. I hypothesised that GSH synthesis could be impaired by sepsis in infants in   187 
children, owing to decreased supply of precursor amino acids (e.g. cysteine and 
glutamine/glutamate). However, the fractional synthesis rate of GSH was similar in 
critically-ill  controls and septic patients. This could have been due to  the wide 
variation in calculated FSR, or could also have been due to the fact that the controls 
which  were  studied  were  critically  ill,  and  may  therefore  have  also  had  an 
impairment in GSH synthesis. In order to study this further, it would be useful to 
study  a  further  group  of  infants  and  children,  with  a  lesser  degree  of  illness. 
However,  this  is  difficult  to  undertake,  as  it  is  not  ethical  to  expose  relatively 
healthy  children  to  two  venepunctures  (one  for  isotope  administration,  one  for 
sampling) and an 8-hour infusion. In addition, it would have potentially also been 
beneficial to measure GSH synthesis in more critically ill and septic patients, as 
this might have showed a significant difference. It is also possible that if the GSH 
concentration had been measured, there may have been a difference in GSH pool 
size and/or absolute synthesis rate between the two groups. 
Glutamine,  as  a  precursor  for  GSH,  has  been  suggested  to  become 
conditionally essential during sepsis, so, using my newly-developed method for 
GSH  synthesis,  I  undertook  a  study  to  determine  whether  glutamine 
supplementation would increase GSH synthesis in septic infants and children. Free 
glutamine is not usually added to parenteral nutrition, for reasons of stability, as it 
forms  either  free  glutamate,  or  pyroglutamic  acid.  With  the  advent  of  stable 
glutamine dipeptides, it is possible to add glutamine into parenteral nutrition as 
either alanyl-glutamine or as glycyl-glutamine. However, in this study, a stand-
alone infusion of either alanyl-glutamine or Vaminolact (isonitrogenous placebo) 
was used,  allowing the study to be initiated quickly in a wide range of septic   188 
patients, rather than being restricted only to those receiving TPN. GSH synthesis 
was measured on two occasions during the intervention with glutamine or placebo. 
Thus, I was able to test whether glutamine was able to increase erythrocyte GSH 
synthesis under two conditions: (i) initiation of glutamine/placebo infusion and (ii) 
after 20 hours of glutamine/placebo infusion. The results showed that glutamine 
supplementation did not significantly enhance erythrocyte GSH synthesis in septic 
paediatric  patients  in  comparison  to  placebo.  In  addition,  it  would  appear  that 
cysteine may not be rate-limiting for GSH synthesis under the conditions studied, 
as the placebo arm would have received more cysteine than the glutamine arm 
(cysteine is a component of Vaminolact). Although these results showed that there 
was no significant effect of glutamine on GSH synthesis during sepsis, glutamine 
could  have other benefits  such as  modulation of the inflammatory response, or 
could have improved GSH synthesis in other organs, such as the intestine, muscle 
of liver, which it is not possible to ethically sample in children. 
 
In order to study GSH synthesis in tissues other than whole blood, it was 
necessary to undertake studies in an animal model. I chose to use the rat model of 
intestinal ischaemia-reperfusion (I/R), which easily induces systemic inflammatory 
response syndrome (SIRS)  and multiple organ dysfunction syndrome.  Intestinal 
GSH has been shown to be important in this model, so I aimed to measure GSH 
synthesis from deuterated glycine infusion in whole blood, intestine and liver. I did 
these  studies  under  normothermic  conditions,  and  during  hypothermia,  as 
hypothermia has previously been shown the have beneficial effects on intestinal 
GSH levels but it was not known whether these effects were due to an effect on   189 
GSH synthesis. To summarise the data from these experiments, in erythrocytes, 
intestinal I/R injury increased to the rate of GSH synthesis – possibly as a result of 
reactive oxygen and nitrogen species causing a depletion in GSH concentration, 
thus relieving the product inhibition of the enzymes of GSH synthesis. In liver, 
there was  an apparent increase in  GSH synthesis compared to the hypothermic 
sham group, but not to other groups. This is difficult to understand, and further 
experiments would be necessary to further explore this effect.  
The rate of GSH synthesis in whole liver was significantly higher in the 
normothermia I/R group compared to hypothermia sham group, but that there was 
no differences  between  the other groups. This  isolated difference is  difficult  to 
interpret, as there was no difference with the corresponding normothermic sham 
group.  It  is  possible  that  there  were  differences  in  the  production  of  reactive 
oxygen and nitrogen species between the groups, but this difference was only of 
sufficient  magnitude  to  cause  an  difference  in  GSH  synthesis  rate  between 
normothermic  I/R  and  hypothermic  sham.  However,  this  would  need  further 
experiments  to  verify.  This  finding  is  also  complicated  by  the  finding  that  the 
enrichment in GSH appeared to by higher than that of glycine, which makes the 
liver data difficult to interpret. In the intestine, GSH synthesis was significantly 
decreased by normothermic I/R, which could contribute to the marked decrease in 
GSH concentration observed by other workers. This could be due to inhibition of 
the  enzymes  of  GSH  synthesis  by  reactive  oxygen  and  nitrogen  species. 
Interestingly, hypothermia led to a significant improvement in the rate of GSH 
synthesis, suggesting that the enzymes of GSH synthesis are relatively preserved   190 
by  hypothermia,  allowing  GSH  synthesis  to  continue,  even  though  the  body 
temperature is lower (30 - 32ºC).  
 
In conclusion, the newly developed method in my study was used for an 
assay of patient samples and several tissue samples from the animal model. The 
preparation of samples and the analytical procedure in this method was simple and 
straight forward. The derivatised samples obtained were relatively stable and gave 
good quality results. From the results of my studies, GSH synthesis shows a rather 
complex relationship with sepsis and systemic inflammation. Although therapies 
such as glutamine supplementation and hypothermia could have benefits on GSH 
synthesis, further work is necessary, both in humans and animals, to understand 
whether they could have a useful clinical role. 
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Further work_________________________         _________ 
   
In my study, I was unable to analyse the concentration of blood GSH in 
patient samples because of lack of volume. Therefore, absolute synthesis rate was 
not  measured.  Future  work  should  be  aimed  to  further  develop  the  method  by 
finding an appropriate internal standard so that concentration of blood GSH can be 
analysed in the same sample as the enrichment. This would allow calculation of the 
absolute  synthesis  rate  of  GSH  from  the  GSH  concentration  and  enrichment. 
Although I had tried to find an appropriate internal standard for measurement of 
GSH concentration in this study, this was limited to commercially available di- and 
tri- peptides. Organic synthesis of other di- and tri-peptides would potentially allow 
a suitable internal standard to be developed. 
  In the patient studies, glutamine supplementation was used to try to enhance 
the GSH synthesis rate. Further studies in these patient groups could also be aimed 
to  try cysteine supplementation,  either directly  or as  N-acetylcysteine, to try to 
enhance GSH synthesis. In further studies, it would be interesting to measure γ-
glutamylcysteine ligase activity, and γ-glutamylcysteine concentration to obtain an 
overview of the control of GSH synthesis in sepsis.  
  The  preliminary  data  from  my  animal  experiments  on  ischaemia-
reperfusion  injury  suggested  some  very  interesting  changes  in  GSH  synthesis. 
These  data  could  be  greatly  expanded.  For  instance,  it  would  be  important  to 
measure the activity of the enzymes γ-glutamylcysteine ligase and GSH synthetase, 
and also the mitochondrial import of GSH in this model. In addition, the model that 
I used was limited by being a short-term model, in which steady state for glycine   192 
isotopic enrichment could not be reached, as the clinical status of the rats changed 
too rapidly. These experiments could be repeated in other animal models of sepsis/ 
inflammation,  such  as  the  caecal  ligation  and  puncture  model,  where  animals 
typically survive for at least 24h. It would be possible to measure GSH synthesis 
after peritonitis is established, but infusion of labelled glycine could be continued 
for long enough to obtain a true steady state, thus allowing measurement of a true 
fractional synthetic rate. In addition, it would be of great interest to extend these 
studies to infant rats.   193 
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Appendix   195 
Materials & Procedures 
 
1.  Mechanics 
 
GC-MS:  
Agilent 6890 Series Gas Chromatograph coupled to an Agilent 5973 Series 
Mass Spectrometer 
GC-IRMS:  
Thermo Finnigan
TM GC Combustion III and Thermo Finnigan
TM DELTA
Plus 
XP with ISODAT software 
GC Column:  
10m, ZB-50 column (ID 0.25mm × film thickness 0.25μm)  
Phenomenex, Macclesfield, Cheshire, UK 
PTV inlet: Programmable temperature vaporization inlet (Gerstel CIS4) on the 
Agilent 6890 GC  
Liner:  Siltek-deactivated  baffled  inlet  liner  plugged  with  Siltek-deactivated 
glass wool  
both Thames Restek, Saunderton, Bucks, UK 
 
2.   Chemicals and Procedures  
 
L-glycine: Sigma-Aldrich, Poole, Dorset, UK 
Reduced glutathione: Sigma-Aldrich, Poole, Dorset, UK   196 
13C2-glycine: Sigma-Aldrich, Poole, Dorset, UK 
Gly
13C(C2)-
15N-glutathione: Cambridge Isotope Laboratories, Inc. 
D2-glycine: Cambridge Isotope Laboratories, Inc. 
D2-glycine saline ampoule (11.55 mg/ml): packed in ampoules by Department 
of  Pharmacy  at  Northwick  Park  Hospital  in  Harrow  and  Department  of 
Pharmacy at the Royal Victoria Infirmary in Newcastle. 
Water: Analytical (HPLC) grade water (MiliQ water) 
 
Reduction; 200 μl of TCEP buffer added 50 - 200 μl of erythrocytes, and 
mixed up for 15 min at room temperature.  
TCEP buffer (pH 7.5):  
7.5 mM TCEP (tris-(2-carboxyethyl)-phosphine)  
0.2 M KH2PO4  (potassium dihydrogen orthophosphate)  
5 mM EDTA (ethylendiaminetetraacetic acid)  
These chemicals: Sigma-Aldrich, Poole, Dorset, UK 
 
Protein precipitation; 200 μl of 10% (v/v) SSA (sulphosalicylic acid) added 
into the reduction sample and mixed vigorously. The sample was centrifuged 
at 1200g for 13 min at 4°C. 
SSA (sulphosalicylic acid): Sigma-Aldrich, Poole, Dorset, UK 
 
Derivatization;  200  μl  of  the  supernatant  was  made  to  pH  >  10  with  2M 
NaOH  (sodium  hydrochloride).  50  μl  of  n-PCF  (n-Propyl  chloroformate) 
added the sample and mixed for 5 min at room temperature. The sample was   197 
acidified (<pH 2) with 1M HCl (hydrochloric acid) and saturated with 0.5g of 
NaCl (sodium chloride). The sample was extracted twice with 3 ml diethyl 
ether and the combined organic phase was dried under N2 (nitrogen gas) at 
60°C. The sample was methylated with 200 μl of 1M methanolic HCl. The 
samples was heated to 80°C for 10 min, and the evaporated under N2. The 
sample was resolved in 100 μl ethyl acetate and transferred to an autosampler 
vial. 
1M methanolic HCl; 340 μl of 6M HCl added into 10 ml methanol. 
2M NaOH (sodium hydrochloride) 
n-PCF (n-Propyl chloroformate) 
1M HCl (hydrochloric acid) 
NaCl (sodium chloride) 
Ethyl acetate 
Methanol 
These chemicals: Sigma-Aldrich, Poole, Dorset, UK 
Diethyl ether (peroxide free): VWR, Lutterworth, Leics., UK 
 
All  other  chemicals  and  solvents  were  analytical  grade  or  other  from  Sigma-
Aldrich, Poole, Dorset, or VWR, Lutterworth, Leics., UK. 
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